

09-29-00

Box Sec / A

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b> <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>	Attorney Docket No.	G0307/7017 (JRV)
	First Named Inventor or Application Identifier	
	Stocker et al.	
	Express Mail Label No.	EL711220885US
Date of Deposit	September 28, 2000	

<b>APPLICATION ELEMENTS</b> <i>See MPEP chapter 600 concerning utility patent application contents</i>	<b>ADDRESS TO:</b> Box Patent Application Commissioner for Patents Washington, DC 20231
1. <input type="checkbox"/> Fee Transmittal Form <i>(Submit an original, and a duplicate for fee processing)</i>  2. <input checked="" type="checkbox"/> Specification [Total pages 57] 50 - pages description 1 - pages abstract 6 - pages claims                      46 - Total claims  3. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total sheets ] <input type="checkbox"/> Informal <input type="checkbox"/> Formal [Total drawings ]  4. <input type="checkbox"/> Oath or Declaration [Total pages ] a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.53(d)) <i>(for continuation/divisional with Box 17 completed)</i> [Note Box 5 below] i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).  5. <input type="checkbox"/> Incorporation by Reference <i>(usable if Box 4b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	6. <input type="checkbox"/> Microfiche Computer Program (Appendix)  7. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input checked="" type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above
<b>ACCOMPANYING APPLICATION PARTS</b>	
8. <input type="checkbox"/> Assignment Papers/cover sheet & documents(s)  9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <i>(when there is an assignee)</i> <input type="checkbox"/> Power of Attorney  10. <input type="checkbox"/> English Translation of Document <i>(if applicable)</i>  11. <input type="checkbox"/> Information Disclosure Statement PTO-1449 <input type="checkbox"/> Copies of IDS Citations  12. <input type="checkbox"/> Preliminary Amendment  13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i>  14. <input type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, Status still proper and desired  15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i>	
16. Other:	
17. If a <b>CONTINUING APPLICATION</b> , check appropriate box and supply the requisite information:  <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No.:  <input type="checkbox"/> Cancel in this application original claims of the prior application before calculating the filing fee.  <input type="checkbox"/> Amend the specification by inserting before the first line the sentence:  This application is a <input type="checkbox"/> continuation <input type="checkbox"/> divisional of application serial no. , filed , entitled , and now .	

**18. CORRESPONDENCE ADDRESS**

Correspondence address below

<b>ATTORNEY'S NAME</b>	John R. Van Amsterdam, Reg. No. 40,212				
<b>NAME</b>	Wolf, Greenfield & Sacks, P.C.				
<b>ADDRESS</b>	600 Atlantic Avenue				
<b>CITY</b>	Boston	<b>STATE</b>	MA	<b>ZIP</b>	02210
<b>COUNTRY</b>	USA	<b>TELEPHONE</b>	(617) 720-3500	<b>FAX</b>	(617) 720-2441

**19. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

<b>NAME</b>	John R. Van Amsterdam, Reg. No. 40,212
<b>SIGNATURE</b>	<i>John R. Van Amsterdam</i>
<b>DATE</b>	SEPTEMBER 28, 2000

## **P-GLYCOPROTEINS AND USES THEREOF**

### **Related Applications**

This application claims priority under 35 U.S.C. §119 from U.S. provisional patent  
5 application 60/156,510, filed September 28, 1999.

### **Field of the Invention**

The invention pertains to P-glycoproteins of dog (*Canis familiaris*).

### **Background of the Invention**

10 P-glycoprotein (PGP; also known as multidrug transporter, MDR1) is a member of the ABC transporter superfamily and is expressed in the human intestine, liver and other tissues. This enzyme serves as an efflux pump exporting small molecules across the cell membrane. It has been known for several years that high level expression of PGP is a mechanism for  
15 tumor resistance to cancer chemotherapy. Intestinal expression of PGP may affect the oral bioavailability of drug molecules that are substrates for this transporter. PGP can efficiently efflux drugs back into the intestinal lumen and thus reduce the amount of drug that enters into circulation.

20 The measurement of interaction with PGP can provide a better understanding of the reasons why particular drugs demonstrate low or high bioavailability. Interaction with PGP can be studied using either direct assays of drug transport in polarized cell systems or with indirect assays such as drug-stimulated ATPase activity and inhibition of the transport of fluorescent substrates.

25 Therefore there is a need for additional PGP polypeptides, preferably which are closely related to the human PGP, for use in the foregoing drug assays.

### **Summary of the Invention**

30 Nucleic acids encoding P-glycoprotein of dog (*Canis familiaris*) have now been identified, isolated, cloned and sequenced. This PGP is closely related (has a high degree of identity) to the human PGP. The invention provides isolated nucleic acid molecules, unique fragments of those molecules, expression vectors containing the foregoing, and host cells transfected with those molecules. The invention also provides isolated polypeptides and

inhibitors of the foregoing nucleic acids and polypeptides which reduce drug transport. The PGP nucleic acids and polypeptides are useful in assays for evaluating bioavailability of drugs, as well as for the optimization or discovery of drugs. In addition, the foregoing can be used in the diagnosis or treatment of conditions characterized by PGP activity and can be used in methods in which it is therapeutically useful to increase or decrease PGP activity.

According to one aspect of the invention, an isolated nucleic acid molecule is provided which is selected from the group consisting of (a) nucleic acid molecules that code for the amino acid sequence of SEQ ID NO:2, (b) allelic variants of (a), wherein the allelic variants exclude SEQ ID NO:3 and SEQ ID NO:5, and (c) complements of (a) or (b).

Preferred allelic variants include nucleic acid molecules that encode an amino acid sequence selected from the group consisting of SEQ ID NO:23, SEQ ID NO:25 and SEQ ID NO:27, particularly nucleotide sequences selected from the group consisting of SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26. In preferred embodiments the isolated nucleic acid molecule codes for SEQ ID NO:2, or comprises the nucleotide sequence of SEQ ID NO:1. In particularly preferred embodiments, the nucleic acid molecules comprise or consist of the coding region of the aforementioned nucleotide sequences.

According to other aspects of the invention, isolated P-glycoprotein polypeptides or fragments thereof are provided. The polypeptides include at least one amino acid of a dog P-glycoprotein selected from the group consisting of amino acids 25, 192, 197, 212, 288, 329, 532, 696, 1273 and 1355 of SEQ ID NO:2; amino acid 25 of SEQ ID NO:23; and amino acids 25 and 1148 of SEQ ID NO:25. Other isolated P-glycoprotein polypeptides or fragments thereof include at least one amino acid of a dog P-glycoprotein selected from the group consisting of amino acids 3, 6, 8, 10, 12, 14-26, 36, 38, 48, 52, 56, 64, 74, 78, 84-92, 94, 96, 98, 99, 101, 103, 104, 106, 108, 112, 115, 147, 187, 197, 199, 233, 288, 321, 326, 347, 397, 450, 454, 455, 467, 472, 520, 633, 637, 643, 644, 650, 657, 658, 661, 666, 667, 674-677, 679, 685, 689, 691, 693, 694, 703, 707, 717, 731, 736, 740, 744, 745, 756, 759, 763, 853, 914, 920, 942, 943, 946, 968-970, 972, 974, 983, 1005, 1010, 1017, 1025, 1026, 1029, 1040, 1095, 1098, 1105, 1144, 1148, 1149, 1158, 1162, 1165, 1168, 1170, 1252 and 1279 of SEQ ID NO:2; and amino acid 329 of SEQ ID NO:27, wherein the P-glycoprotein is identical to a human P-glycoprotein except for the at least one amino acid of a dog P-glycoprotein. In certain embodiments, the human P-glycoprotein is selected from the group of SEQ ID NO:7 and SEQ ID NO:8. Still other isolated P-glycoprotein polypeptides or fragments thereof

5

10

15

25

30

transporter activity in a mammalian cell are provided. The methods include contacting the mammalian cell with an amount of one of the foregoing agents effective to inhibit P-glycoprotein transporter activity in the mammalian cell.

Also included in the invention are methods for increasing bioavailability of a drug in a subject. The methods include administering to a subject in need of such treatment one of the foregoing agents in an amount effective to increasing bioavailability of a drug. The inhibitor can be administered prior to administering the drug, or concurrently with the drug.

Also provided are methods for increasing P-glycoprotein transporter activity in a cell. These methods include contacting the cell with a molecule selected from the group consisting of the foregoing nucleic acid molecules, in an amount effective to increase P-glycoprotein transporter activity in the cell. The cell can be contacted under conditions whereby the P-glycoprotein is expressed.

According to yet another aspect of the invention, methods for identifying lead compounds for a pharmacological agent useful in the treatment of disease associated with P-glycoprotein transporter activity are provided. The methods include providing a cell or other membrane-encapsulated space comprising a P-glycoprotein as provided herein; contacting the cell or other membrane-encapsulated space with a candidate pharmacological agent under conditions which, in the absence of the candidate pharmacological agent, cause a first amount of P-glycoprotein transporter activity; and determining a second amount of P-glycoprotein transporter activity as a measure of the effect of the pharmacological agent on the P-glycoprotein transporter activity, wherein a second amount of P-glycoprotein transporter activity which is less than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which reduces P-glycoprotein transporter activity and wherein a second amount of P-glycoprotein transporter activity which is greater than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which increases P-glycoprotein transporter activity. The methods can further include a step of loading the cell or other membrane-encapsulated space with a detectable compound, wherein the compound is detected as a measure of the P-glycoprotein transporter activity.

Also included are methods for identifying compounds which selectively bind a P-glycoprotein. The methods include contacting a P-glycoprotein provided herein with a compound, and determining the binding of the compound to the P-glycoprotein. The methods

can further include determining the effect of the compound on the P-glycoprotein transporter activity of the P-glycoprotein or determining the effect of the compound on the ATPase activity of the P-glycoprotein.

Additional methods provided according to the invention include methods for determining ATPase activity of a P-glycoprotein. The methods include contacting a host cell as provided above, or a membrane fraction thereof, with a test drug, and measuring ATPase activity of the P-glycoprotein. In certain embodiments, the step of measuring ATPase activity is performed at least twice at different times. Also provided methods for determining transmembrane transport of a compound by a P-glycoprotein. The methods include contacting a host cell provided above, or a membrane fraction thereof, with a test drug, and measuring transport of the test drug under sink conditions in at least one direction of transport selected from the group consisting of the apical to basolateral direction and the basolateral to apical direction. In certain embodiments the step of measuring transport of the test drug is performed at least twice at different times.

These and other aspects of the invention are described in greater detail below.

#### **Brief Description of the Sequences**

SEQ ID NO:1 is the nucleotide sequence encoding dog P-glycoprotein (Genotype C).

SEQ ID NO:2 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ ID

NO:1.

SEQ ID NO:3 is the nucleotide sequence encoding a prior art dog P-glycoprotein (GenBank accession number AF045016).

SEQ ID NO:4 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ ID NO:3.

SEQ ID NO:5 is the nucleotide sequence encoding another prior art dog P-glycoprotein (GenBank accession number AF092810).

SEQ ID NO:6 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ ID NO:5.

SEQ ID NO:7 is the amino acid sequence of a prior art human P-glycoprotein, having Genbank accession number M14758.

SEQ ID NO:8 is the amino acid sequence of a second prior art human P-glycoprotein, having Genbank accession numbers AF016535 or NM\_000927.

PGP1.

SEQ ID NO:11 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

PGP1.

SEQ ID NO:14 is the nucleotide sequence of a PCR primer homologous to human

PGP1.

SEQ ID NO:16 is the nucleotide sequence of a PCR primer homologous to human

PGP1.

SEQ ID NO:18 is the nucleotide sequence of a PCR primer homologous to vector.

SEQ ID NO:20 is the nucleotide sequence of a PCR primer homologous to human

PGP1.

SEQ ID NO:22 is the nucleotide sequence encoding dog P-glycoprotein (Genotype A).

ID NO:22.

SEQ ID NO:25 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ

ID NO:24.

SEQ ID NO:27 is the amino acid sequence of a dog P-glycoprotein encoded by SEQ

ID NO:25.

SEQ ID NO:29 is the nucleotide sequence of the cDNA Adapter Primer 1 from the Marathon cDNA Amplification Kit.

SEQ ID NO:30 is the nucleotide sequence of a PCR primer homologous to dog PGP1.



SEQ ID NO:31 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

SEQ ID NO:32 is the nucleotide sequence of a PCR primer homologous to dog PGP1.

### **Detailed Description of the Invention**

5 The present invention in one aspect involves the identification of novel cDNAs encoding dog P-glycoproteins, referred to herein as dog PGP. The nucleotide sequence of a dog PGP (termed "Genotype C") is presented as SEQ ID NO:1, and the amino acid sequence of this dog PGP is presented as SEQ ID NO:2.

Three allelic variants of Genotype C dog PGP were isolated ("Genotype A",  
10 "Genotype B" and "Genotype D"). The nucleotide and amino acid sequences of Genotype A are presented as SEQ ID NOs:20 and 21, respectively. The amino acid sequence of Genotype A differs from the amino acid sequence of Genotype C at amino acid 197 (histidine → glutamine) based on a C → A change at nucleotide 607 of SEQ ID NO:2. The nucleotide and amino acid sequences of Genotype B are presented as SEQ ID NOs:22 and 23, respectively.

15 The amino acid sequence of Genotype B differs from the amino acid sequence of Genotype C at amino acid 25 (asparagine → lysine) based on a T → A change at nucleotide 91 of SEQ ID NO:2, and at amino acid 197 (histidine → glutamine) based on a C → A change at nucleotide 607 of SEQ ID NO:2. The nucleotide and amino acid sequences of Genotype D are presented as SEQ ID NOs:24 and 25, respectively. The amino acid sequence of Genotype D differs  
20 from the amino acid sequence of Genotype C at amino acid 25 (asparagine → lysine) based on a T → A change at nucleotide 91 of SEQ ID NO:2, at amino acid 197 (histidine → glutamine) based on a C → A change at nucleotide 607 of SEQ ID NO:2, at amino acid 329 (serine → threonine) based on a T → A change at nucleotide 1001 of SEQ ID NO:2, and at amino acid 1148 (methionine → valine) based on a A → G change at nucleotide 3458 of SEQ  
25 ID NO:2.

Two closely related dog PGP sequence were deposited in GenBank under accession numbers AF045016 (complete cDNA) and AF092810 (partial cDNA). Whereas much of the polypeptides presented herein is identical to the known dog PGPs, the dog PGPs of the invention (SEQ ID NOs:2, 21, 23 and 25) have several single amino acid differences from the  
30 prior art sequences, including at least one deletion. These allelic differences in the very highly conserved protein domains of the P-glycoprotein are entirely unexpected.

The invention involves in one aspect dog PGP nucleic acids and polypeptides, as well

as therapeutics relating thereto. The invention also embraces isolated functionally equivalent variants, useful analogs and fragments of the foregoing nucleic acids and polypeptides; complements of the foregoing nucleic acids; and molecules which selectively bind the foregoing nucleic acids and polypeptides.

5 The dog PGP nucleic acids and polypeptides of the invention are isolated. As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA  
10 techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or  
15 expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. An isolated nucleic acid as used herein is not a naturally occurring chromosome.

As used herein with respect to polypeptides, "isolated" means separated from its  
20 native environment and present in sufficient quantity to permit its identification or use. Isolated, when referring to a protein or polypeptide, means, for example: (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may be, but need not be, substantially pure. The term "substantially pure" means that the proteins or polypeptides are essentially free of other  
25 substances with which they may be found in nature or *in vivo* systems to an extent practical and appropriate for their intended use. Substantially pure polypeptides may be produced by techniques well known in the art. Because an isolated protein may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the protein may comprise only a small percentage by weight of the preparation. The protein is nonetheless isolated in  
30 that it has been separated from the substances with which it may be associated in living systems, i.e. isolated from other proteins.

As used herein a dog PGP nucleic acid refers to an isolated nucleic acid molecule

which codes for a dog PGP polypeptide. Such nucleic acid molecules code for dog PGP polypeptides which include the amino acid sequences of SEQ ID NO:2, 23, 25, 27 and fragments thereof. The nucleic acid molecules include the nucleotide sequences of SEQ ID NO:1, and nucleotide sequences which differ from the sequences of SEQ ID NO:1, in codon sequence due to the degeneracy of the genetic code. The dog PGP nucleic acids of the invention also include alleles (e.g., SEQ ID Nos: 22, 24, 26) of the foregoing nucleic acids (except those of previously known dog PGP alleles, e.g., SEQ ID NOS:3 and 5), and encoded polypeptides, as well as fragments of the foregoing nucleic acids and polypeptides. Such fragments can be used, for example, as probes in hybridization assays and as primers in a polymerase chain reaction (PCR). Preferred dog PGP nucleic acids include the nucleic acid sequences of SEQ ID NOs:1, 22, 24, 26 and fragments thereof. Complements of the foregoing nucleic acids also are embraced by the invention.

As used herein "dog PGP activity" refers to an ability of a PGP polypeptide to export small molecules across the cell membrane. A molecule which inhibits dog PGP activity (an antagonist) is one which inhibits export of small molecules via PGP and a molecule which increases dog PGP activity (an agonist) is one which increases export of small molecules via PGP. Changes in dog PGP activity can be measured by assays such as those disclosed herein, including efflux of fluorescent compounds from cells.

Alleles of the dog PGP nucleic acids of the invention can be identified by conventional techniques. For example, alleles of dog PGP can be isolated by hybridizing a probe which includes at least a fragment of SEQ ID NO:1 under stringent conditions with a cDNA library and selecting positive clones. Thus, an aspect of the invention is those nucleic acid sequences which code for dog PGP polypeptides and which hybridize to a nucleic acid molecule consisting of SEQ ID NO:1 under stringent conditions (except those of previously known dog PGP alleles, e.g., SEQ ID NOS:3 and 5). The term "stringent conditions" as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. More specifically, stringent conditions, as used herein, refers, for example, to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM

NaH<sub>2</sub>PO<sub>4</sub>(pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.15M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid. After hybridization, the membrane upon which the DNA is transferred is washed at 2 x SSC at room temperature and then at 0.1 - 0.5 x SSC/0.1 x SDS at temperatures up to 68°C.

There are other conditions, reagents, and so forth which can be used, which result in a similar degree of stringency. The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of alleles of dog PGP nucleic acids of the invention. The skilled artisan also is familiar with the methodology for screening cells and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid molecule and sequencing.

In screening for dog PGP nucleic acids, a Southern blot may be performed using the foregoing stringent conditions, together with a radioactive probe. After washing the membrane to which the DNA is finally transferred, the membrane can be placed against X-ray film to detect the radioactive signal.

The dog PGP nucleic acids of the invention also include degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue into an elongating dog PGP polypeptide. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code.

The invention also provides modified nucleic acid molecules which include additions, substitutions and deletions of one or more nucleotides. In preferred embodiments, these

modified nucleic acid molecules and/or the polypeptides they encode retain at least one activity or function of the unmodified nucleic acid molecule and/or the polypeptides, such as transporter activity, etc. In certain embodiments, the modified nucleic acid molecules encode modified polypeptides, preferably polypeptides having conservative amino acid substitutions as are described elsewhere herein. The modified nucleic acid molecules are structurally related to the unmodified nucleic acid molecules and in preferred embodiments are sufficiently structurally related to the unmodified nucleic acid molecules so that the modified and unmodified nucleic acid molecules hybridize under stringent conditions known to one of skill in the art.

For example, modified nucleic acid molecules which encode polypeptides having single amino acid changes can be prepared. Each of these nucleic acid molecules can have one, two or three nucleotide substitutions exclusive of nucleotide changes corresponding to the degeneracy of the genetic code as described herein. Likewise, modified nucleic acid molecules which encode polypeptides having two amino acid changes can be prepared which have, e.g., 2-6 nucleotide changes. Numerous modified nucleic acid molecules like these will be readily envisioned by one of skill in the art, including for example, substitutions of nucleotides in codons encoding amino acids 2 and 3, 2 and 4, 2 and 5, 2 and 6, and so on. In the foregoing example, each combination of two amino acids is included in the set of modified nucleic acid molecules, as well as all nucleotide substitutions which code for the amino acid substitutions. Additional nucleic acid molecules that encode polypeptides having additional substitutions (i.e., 3 or more), additions or deletions (e.g., by introduction of a stop codon or a splice site(s)) also can be prepared and are embraced by the invention as readily envisioned by one of ordinary skill in the art. Any of the foregoing nucleic acids or polypeptides can be tested by routine experimentation for retention of structural relation or activity to the nucleic acids and/or polypeptides disclosed herein.

The invention also provides isolated fragments of SEQ ID NO:1. The fragments can be used as probes in Southern blot assays to identify such nucleic acids, or can be used in amplification assays such as those employing PCR. Smaller fragments are those comprising 12, 13, 14, 15, 16, 17, 18, 20, 22, 25, 30, 40, 50, or 75 nucleotides, and every integer therebetween, and are useful e.g. as primers for nucleic acid amplification procedures. As known to those skilled in the art, larger probes such as 200, 250, 300, 400 or more nucleotides are preferred for certain uses such as Southern blots, while smaller fragments will be preferred

for uses such as PCR. Fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments. Likewise, fragments can be employed to produce non-fused fragments of the dog PGP polypeptides, useful, for example, in the preparation of antibodies, in immunoassays, and the like. The foregoing nucleic acid fragments further can be used as antisense molecules to inhibit the expression of dog PGP nucleic acids and polypeptides, particularly for therapeutic purposes as described in greater detail below.

The invention also includes functionally equivalent variants of the dog PGP, which include variant nucleic acids and polypeptides which retain one or more of the functional properties of the dog PGP. For example, variants include a fusion protein which includes the extracellular and transmembrane domains of the dog PGP which retains the ability to transport molecules. Still other functionally equivalent variants include truncations, deletions, point mutations, or additions of amino acids to the sequence of SEQ ID NO:1 which retains functions of SEQ ID NOs:2, e.g., the alleles presented herein. Functionally equivalent variants also include a dog PGP which has had a portion of the N-terminus removed or replaced by a similar domain from another P-glycoprotein (e.g. a "domain-swapping" variant). Other functionally equivalent variants will be known to one of ordinary skill in the art, as will methods for preparing such variants. The activity of a functionally equivalent variant can be determined using the methods provided herein, and in references that have described assays using P-glycoproteins of other species. Such variants are useful, *inter alia*, for evaluating bioavailability of drugs, in assays for identification of compounds which bind and/or regulate the transporter function of the dog PGP, and for determining the portions of the dog PGP which are required for transporter activity.

Variants which are non-functional also can be prepared as described above. Such variants are useful, for example, as negative controls in experiments testing transporter activity.

A dog PGP nucleic acid, in one embodiment, is operably linked to a gene expression sequence which directs the expression of the dog PGP nucleic acid within a eukaryotic or prokaryotic cell. The "gene expression sequence" is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the dog PGP nucleic acid to which it is operably linked. The gene expression sequence may, for example, be a mammalian or viral promoter, such as a

constitutive or inducible promoter. Constitutive mammalian promoters include, but are not limited to, the promoters for the following genes: hypoxanthine phosphoribosyl transferase (HPTR), adenosine deaminase, pyruvate kinase,  $\beta$ -actin promoter and other constitutive promoters. Exemplary viral promoters which function constitutively in eukaryotic cells include, for example, promoters from the simian virus, papilloma virus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus, cytomegalovirus, the long terminal repeats (LTR) of Moloney murine leukemia virus and other retroviruses, and the thymidine kinase promoter of herpes simplex virus. Other constitutive promoters are known to those of ordinary skill in the art. The promoters useful as gene expression sequences of the invention also include inducible promoters. Inducible promoters are expressed in the presence of an inducing agent. For example, the metallothionein promoter is induced to promote transcription and translation in the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.

In general, the gene expression sequence shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined dog PGP nucleic acid. The gene expression sequences optionally includes enhancer sequences or upstream activator sequences as desired.

The dog PGP nucleic acid sequence and the gene expression sequence are said to be "operably linked" when they are covalently linked in such a way as to place the transcription and/or translation of the dog PGP coding sequence under the influence or control of the gene expression sequence. If it is desired that the dog PGP sequence be translated into a functional protein, two DNA sequences are said to be operably linked if induction of a promoter in the 5' gene expression sequence results in the transcription of the dog PGP sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the dog PGP sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a gene expression sequence would be operably linked to a dog PGP nucleic acid sequence if the gene expression sequence were capable of effecting transcription of that dog PGP nucleic acid sequence such that the

resulting transcript might be translated into the desired protein or polypeptide.

The dog PGP nucleic acid molecules and the dog PGP polypeptides (including the dog PGP inhibitors described below) of the invention can be delivered to the eukaryotic or prokaryotic cell alone or in association with a vector. In its broadest sense, a "vector" is any vehicle capable of facilitating: (1) delivery of a dog PGP nucleic acid or polypeptide to a target cell, (2) uptake of a dog PGP nucleic acid or polypeptide by a target cell, or (3) expression of a dog PGP nucleic acid molecule or polypeptide in a target cell. Preferably, the vectors transport the dog PGP nucleic acid or polypeptide into the target cell with reduced degradation relative to the extent of degradation that would result in the absence of the vector. Optionally, a "targeting ligand" can be attached to the vector to selectively deliver the vector to a cell which expresses on its surface the cognate receptor (e.g. a receptor, an antigen recognized by an antibody) for the targeting ligand. In this manner, the vector (containing a dog PGP nucleic acid or a dog PGP polypeptide) can be selectively delivered to a specific cell. In general, the vectors useful in the invention are divided into two classes: biological vectors and chemical/physical vectors. Biological vectors are more useful for delivery/uptake of dog PGP nucleic acids to/by a target cell. Chemical/physical vectors are more useful for delivery/uptake of dog PGP nucleic acids or dog PGP proteins to/by a target cell.

Biological vectors include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the nucleic acid sequences of the invention, and free nucleic acid fragments which can be linked to the nucleic acid sequences of the invention. Viral vectors are a preferred type of biological vector and include, but are not limited to, nucleic acid sequences from the following viruses: retroviruses, such as Moloney murine leukemia virus; Harvey murine sarcoma virus; murine mammary tumor virus; Rous sarcoma virus; adenovirus; adeno-associated virus; SV40-type viruses; polyoma viruses; poxviruses; retroviruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; and polio virus. One can readily employ other vectors not named but known in the art.

Preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. In general, the retroviruses are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but



incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell line with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., "*Gene Transfer and Expression, A Laboratory Manual*," W.H. Freeman C.O., New York (1990) and Murry, E.J. Ed. "*Methods in Molecular Biology*," vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

Another preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus can be engineered to be replication-deficient and is capable of infecting a wide range of cell types and species. It further has advantages, such as heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages; and lack of superinfection inhibition thus allowing multiple series of transductions. Reportedly, the adeno-associated virus can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression. In addition, wild-type adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding a dog PGP polypeptide or fragment or variant thereof. That heterologous DNA (RNA) is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen), which

contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 $\alpha$ , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nuc. Acids Res.* 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol. Cell. Biol.* 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J. Clin. Invest.* 90:626-630, 1992).

In addition to the biological vectors, chemical/physical vectors may be used to deliver a dog PGP nucleic acid or polypeptide to a target cell and facilitate uptake thereby. As used herein, a "chemical/physical vector" refers to a natural or synthetic molecule, other than those derived from bacteriological or viral sources, capable of delivering the isolated dog PGP nucleic acid or polypeptide to a cell.

A preferred chemical/physical vector of the invention is a colloidal dispersion system. Colloidal dispersion systems include lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system of the invention is a liposome. Liposomes are artificial membrane vesicles which are useful as a delivery vector *in vivo* or *in vitro*. It has been shown that large unilamellar vesicles (LUV), which range in size from 0.2 - 4.0  $\mu$  can encapsulate large macromolecules. RNA, DNA, and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al., *Trends Biochem. Sci.*, v. 6, p. 77 (1981)). In order for a liposome to be an efficient nucleic acid transfer vector, one or more of the following characteristics should be present: (1) encapsulation of the nucleic acid of interest at high efficiency with retention of biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information.

Liposomes may be targeted to a particular tissue by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein. Ligands which may be useful for targeting a liposome to a particular cell will depend on the particular cell or tissue type. Additionally when the vector encapsulates a nucleic acid, the vector may be coupled to a nuclear targeting peptide, which will direct the dog PGP nucleic acid to the nucleus of the host cell.

Liposomes are commercially available from Gibco BRL, for example, as LIPOFECTIN™ and LIPOFECTACE™, which are formed of cationic lipids such as N-[1-(2, 3 dioleoyloxy)-propyl]-N, N, N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many publications.

Other exemplary compositions that can be used to facilitate uptake by a target cell of the dog PGP nucleic acids include calcium phosphate and other chemical mediators of intracellular transport, microinjection compositions, electroporation and homologous recombination compositions (e.g., for integrating a dog PGP nucleic acid into a preselected location within a target cell chromosome).

The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of the previously discussed coding sequences. Other components may be added, as desired, as long as the previously mentioned sequences, which are required, are included.

It will also be recognized that the invention embraces the use of the dog PGP cDNA sequences in expression vectors, as well as to transfect host cells and cell lines, be these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as human, pig, goat, primate, etc. They may be of a wide variety of tissue types, and include primary cells and cell lines. Specific examples include intestinal cells and liver cells. The expression vectors require that the pertinent sequence, i.e., those nucleic acids described *supra*, be operably linked to a promoter.

The invention also provides isolated dog PGP polypeptides which include the amino acid sequence of SEQ ID NO:2, and fragments thereof, encoded by the dog PGP nucleic acids described above. Dog PGP polypeptides also embrace alleles, such as SEQ ID NOs:23, 25 and 27 (except not SEQ ID NOS:3 and 5), functionally equivalent variants and analogs (those non-allelic polypeptides which vary in amino acid sequence from the disclosed dog PGP polypeptides by 1, 2, 3, 4, 5, or more amino acids) provided that such polypeptides retain dog PGP activity. Non-functional variants also are embraced by the invention; these are useful as antagonists of transporter function, as negative controls in assays, and the like. Such alleles, variants, analogs and fragments are useful, for example, alone or as fusion proteins for a variety of purposes including as a component of assays.

Fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the dog PGP polypeptide, in particular as a transporter of various molecules. Other functional capabilities which can be retained in a fragment of a dog PGP polypeptide include interaction with antibodies and interaction with other polypeptides (such as would be found in a protein complex). Those skilled in the art are well versed in methods for selecting fragments which retain a functional capability of the dog PGP. Confirmation of the functional capability of the fragment can be carried out by synthesis of the fragment and testing of the capability according to standard methods. For example, to test the transporter activity of a dog PGP fragment, one inserts or expresses the fragment in a cell in which molecular transport can be measured. Such methods, which are standard in the art, are described further herein.

The invention embraces variants of the dog PGP polypeptides described above. As used herein, a "variant" of a dog PGP polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a dog PGP polypeptide. Modifications which create a dog PGP variant can be made to a dog PGP polypeptide for a variety of reasons, including 1) to reduce or eliminate an activity of a dog PGP polypeptide, such as transport; 2) to enhance a property of a dog PGP polypeptide, such as protein stability in an expression system or the stability of protein-protein binding; 3) to provide a novel activity or property to a dog PGP polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety; or 4) to establish that an amino acid substitution does or does not affect molecular transport activity. Modifications to a dog PGP polypeptide are typically made to the nucleic acid which encodes the dog PGP polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids or non-amino acid moieties. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the dog PGP amino acid sequence. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus "design" a variant dog PGP according to known methods. One example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87, 1997, whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary only a portion of the polypeptide sequence. By applying the computational methods of

Dahiyat and Mayo, specific variants of a dog PGP polypeptide can be proposed and tested to determine whether the variant retains a desired conformation.

5 Variants include dog PGP polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a dog PGP polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

10 Mutations of a nucleic acid which encode a dog PGP polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide.

15 Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with a desired property. Further mutations can be made to variants (or to non-variant dog PGP polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a dog PGP gene or cDNA clone to enhance expression of the polypeptide.

20 The activity of variants of dog PGP polypeptides can be tested by cloning the gene encoding the variant dog PGP polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the variant dog PGP polypeptide, and testing for a functional capability of the dog PGP polypeptides as disclosed herein. For example, the variant dog PGP polypeptide can be tested for ability to provide molecular transport (e.g., efflux), as set forth below in the examples. Preparation of other variant polypeptides may favor testing of other activities, as will be known to one of ordinary skill in the art.

30 The skilled artisan will also realize that conservative amino acid substitutions may be made in dog PGP polypeptides to provide functionally equivalent variants of the foregoing polypeptides, i.e., variants which retain the functional capabilities of the dog PGP

polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size characteristics of the polypeptide in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary functionally equivalent variants of the dog PGP polypeptides include conservative amino acid substitutions of SEQ ID NO:2 or SEQ ID NO:4. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

Conservative amino-acid substitutions in the amino acid sequence of dog PGP polypeptide to produce functionally equivalent variants of dog PGP typically are made by alteration of the nucleic acid sequence encoding dog PGP polypeptides (e.g., SEQ ID NO:1). Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc. Nat. Acad. Sci. U.S.A.* 82: 488-492, 1985), or by chemical synthesis of a gene encoding a dog PGP polypeptide. The activity of functionally equivalent fragments of dog PGP polypeptides can be tested by cloning the gene encoding the altered dog PGP polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered dog PGP polypeptide, and testing for the ability of the dog PGP polypeptide to mediate transmembrane transport of compounds. Peptides which are chemically synthesized can be tested directly for function.

A variety of methodologies well-known to the skilled practitioner can be utilized to obtain isolated dog PGP molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation of mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce

polypeptide. Those skilled in the art also can readily follow known methods for isolating dog PGP polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

The invention as described herein has a number of uses, some of which are described elsewhere herein. For example, the invention permits isolation of the dog PGP polypeptide molecules by e.g., expression of a recombinant nucleic acid to produce large quantities of polypeptide which may be isolated using standard protocols. As another example, the isolation of the dog PGP gene makes it possible for dog PGP to be used in methods for assaying of molecular transport, such as drug bioavailability studies. These methods involve determining transport of a drug by a first species' PGP (e.g., dog) in comparison to transport of the drug by other species' PGP (e.g. human) as a method for determining or predicting the bioavailability of the drug. Thus the results of whole animal studies on the metabolism of a drug can be evaluated in view of the relative rates or amounts of P-glycoprotein transport of the drug. For example, if a drug administered to a dog has good oral bioavailability and low transport by dog PGP, one can predict that the oral bioavailability of the drug in humans will be good if the transport by human PGP is also low. Conversely, if the transport of the drug by human PGP is high, then the bioavailability of the drug would be predicted to be low.

The invention also embraces agents which bind selectively to the dog PGP nucleic acid molecules or polypeptides as well as agents which bind to variants and fragments of the polypeptides and nucleic acids as described herein. The agents include polypeptides which bind to dog PGP, and antisense nucleic acids, both of which are described in greater detail below. The agents can inhibit or increase dog PGP activity (antagonists and agonists, respectively).

Some of the agents are inhibitors. A dog PGP inhibitor is an agent that inhibits dog PGP mediated transport of molecules across a cell membrane. Efflux assays can be performed to screen and/or determine whether a dog PGP inhibitor has the ability to inhibit dog PGP activity, and whether the inhibition is selective. An exemplary assay of efflux is described below in the Examples.

In one embodiment the dog PGP inhibitor is an antisense oligonucleotide that selectively binds to a dog PGP nucleic acid molecule, to reduce the expression of dog PGP (or other species' PGPs) in a cell. This is desirable in virtually any medical condition wherein a

reduction of PGP transporter activity is desirable, e.g., to increase retention of cytotoxic agents in a cell.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene or transcript. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon SEQ ID NO:1, or upon allelic (except SEQ ID NOS:3 and 5) or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 10 and, more preferably, at least 15 consecutive bases which are complementary to the target, although in certain cases modified oligonucleotides as short as 7 bases in length have been used successfully as antisense oligonucleotides (Wagner et al., *Nature Biotechnol.* 14:840-844, 1996). Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 14(5):439-457, 1994) and at which polypeptides are not expected to bind. Thus, the present invention also provides for antisense



oligonucleotides which are complementary to allelic (except SEQ ID NOS:3 and 5) or homologous cDNAs and genomic DNAs corresponding to a dog PGP nucleic acid containing SEQ ID NO:1.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamides, carboxymethyl esters and peptides.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding dog PGP polypeptides, together with pharmaceutically acceptable carriers.

Agents which bind dog PGP also include binding peptides and other molecules which bind to the dog PGP polypeptide and complexes containing the dog PGP polypeptide. When the binding molecules are inhibitors, the molecules bind to and inhibit the activity of dog PGP. To determine whether a dog PGP binding agent binds to dog PGP any known binding assay may be employed. For example, the binding agent may be immobilized on a surface and then contacted with a labeled dog PGP polypeptide. The amount of dog PGP which interacts with the dog PGP binding agent or the amount which does not bind to the dog PGP binding agent may then be quantitated to determine whether the dog PGP binding agent binds to dog PGP.

The dog PGP binding agents include molecules of numerous size and type that bind selectively or preferentially to dog PGP polypeptides, and complexes of both dog PGP polypeptides and their binding partners. These molecules may be derived from a variety of sources. For example, dog PGP binding agents can be provided by screening degenerate peptide libraries which can be readily prepared in solution, in immobilized form or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. m13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent, for example, a completely degenerate or biased array.

One then can select phage-bearing inserts which bind to the dog PGP polypeptide. This process can be repeated through several cycles of reselection of phage that bind to the dog PGP polypeptide. Repeated rounds lead to enrichment of phage bearing particular sequences.

DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to the dog PGP polypeptide can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Yeast two-hybrid screening methods also may be used to identify polypeptides that bind to the dog PGP polypeptides. Thus, the dog PGP polypeptides of the invention, or a fragment thereof, can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding

partners of the dog PGP polypeptides of the invention. Such molecules can be used, as described, for screening assays, for purification protocols, for interfering directly with the functioning of dog PGP and for other purposes that will be apparent to those of ordinary skill in the art.

Therefore the invention generally provides efficient methods of identifying pharmacological agents or lead compounds for agents useful in the treatment of conditions associated with aberrant PGP activity and the compounds and agents so identified. Generally, the screening methods involve assaying for compounds which inhibit or enhance transport of molecules through dog PGP. Such methods are adaptable to automated, high throughput screening of compounds. Examples of such methods are described in US patent 5,429,921.

A variety of assays for pharmacological agents are provided, including, labeled *in vitro* protein binding assays, efflux assays using detectable molecules, etc. For example, protein binding screens are used to rapidly examine the binding of candidate pharmacological agents to a dog PGP. The candidate pharmacological agents can be derived from, for example, combinatorial peptide libraries. Convenient reagents for such assays are known in the art. An exemplary cell-based assay of efflux involves contacting a cell having a dog PGP with a candidate pharmacological agent under conditions whereby the efflux of a detectably labeled molecule can occur. Specific conditions are well known in the art and are described, for example, in Sharom et al., *Biochem. Pharmacol.* 58:571-586, 1999, and references cited therein. A reduction in the efflux in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent reduces the efflux activity of dog PGP. An increase in the efflux in the presence of the candidate pharmacological agent indicates that the candidate pharmacological agent increases the efflux activity of dog PGP.

Dog PGP used in the methods of the invention can be added to an assay mixture as an isolated polypeptide (where binding of a candidate pharmaceutical agent is to be measured) or as a cell or other membrane-encapsulated space which includes a dog PGP polypeptide. In the latter assay configuration, the cell or other membrane-encapsulated space can contain the dog PGP as a preloaded polypeptide or as a nucleic acid (e.g. a cell transfected with an expression vector containing a dog PGP). In the assays described herein, the dog PGP polypeptide can be produced recombinantly, or isolated from biological extracts, but preferably is synthesized *in vitro*. Dog PGP polypeptides encompass chimeric proteins comprising a fusion of a dog PGP polypeptide with another polypeptide, e.g., a polypeptide

capable of providing or enhancing protein-protein binding, or enhancing stability of the dog PGP polypeptide under assay conditions. A polypeptide fused to a dog PGP polypeptide or fragment thereof may also provide means of readily detecting the fusion protein, e.g., by immunological recognition or by fluorescent labeling.

5       The assay mixture also comprises a candidate pharmacological agent. Typically, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a different response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration of agent or at a concentration of agent below the limits of assay detection. Candidate agents encompass numerous chemical classes,  
10       although typically they are organic compounds. Preferably, the candidate pharmacological agents are small organic compounds, i.e., those having a molecular weight of more than 50 yet less than about 2500. Candidate agents comprise functional chemical groups necessary for structural interactions with polypeptides, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups and  
15       more preferably at least three of the functional chemical groups. The candidate agents can comprise cyclic carbon or heterocyclic structure and/or aromatic or polyaromatic structures substituted with one or more of the above-identified functional groups. Candidate agents also can be biomolecules such as peptides, saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the  
20       like. Where the agent is a nucleic acid, the agent typically is a DNA or RNA molecule, although modified nucleic acids having non-natural bonds or subunits are also contemplated.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including  
25       expression of randomized oligonucleotides, synthetic organic combinatorial libraries, phage display libraries of random peptides, and the like. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural and synthetically produced libraries and compounds can be readily modified through conventional chemical, physical, and biochemical means. Further,  
30       known pharmacological agents may be subjected to directed or random chemical modifications such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs of the agents.

Therefore, a source of candidate agents are libraries of molecules based on known P-glycoprotein inhibitors, in which the structure of the inhibitor is changed at one or more positions of the molecule to contain more or fewer chemical moieties or different chemical moieties. The structural changes made to the molecules in creating the libraries of analog inhibitors can be directed, random, or a combination of both directed and random substitutions and/or additions. One of ordinary skill in the art in the preparation of combinatorial libraries can readily prepare such libraries based on existing P-glycoprotein inhibitors.

A variety of other reagents also can be included in the mixture. These include reagents such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to facilitate optimal protein-protein and/or protein-nucleic acid binding. Such a reagent may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease inhibitors, nuclease inhibitors, antimicrobial agents, and the like may also be used.

The mixture of the foregoing assay materials is incubated under conditions whereby, but for the presence of the candidate pharmacological agent, the dog PGP mediates the efflux of a control amount of a compound such as a drug. For determining the binding of a candidate pharmaceutical agent to a dog PGP, the mixture is incubated under conditions which permit binding. The order of addition of components, incubation temperature, time of incubation, and other parameters of the assay may be readily determined. Such experimentation merely involves optimization of the assay parameters, not the fundamental composition of the assay. Incubation temperatures typically are between 4°C and 40°C. Incubation times preferably are minimized to facilitate rapid, high throughput screening, and typically are between 1 minute and 10 hours.

After incubation, the level of efflux or the level of specific binding between the dog PGP polypeptide and the candidate pharmaceutical agent is detected by any convenient method available to the user. For cell free binding type assays, a separation step is often used to separate bound from unbound components. The separation step may be accomplished in a variety of ways. Conveniently, at least one of the components is immobilized on a solid substrate, from which the unbound components may be easily separated. The solid substrate can be made of a wide variety of materials and in a wide variety of shapes, e.g., microtiter plate, microbead, dipstick, resin particle, etc. The substrate preferably is chosen to maximize

signal to noise ratios, primarily to minimize background binding, as well as for ease of separation and cost.

Separation may be effected for example, by removing a bead or dipstick from a reservoir, emptying or diluting a reservoir such as a microtiter plate well, rinsing a bead, particle, chromatographic column or filter with a wash solution or solvent. The separation step preferably includes multiple rinses or washes. For example, when the solid substrate is a microtiter plate, the wells may be washed several times with a washing solution, which typically includes those components of the incubation mixture that do not participate in specific bindings such as salts, buffer, detergent, non-specific protein, etc. Where the solid substrate is a magnetic bead, the beads may be washed one or more times with a washing solution and isolated using a magnet.

Detection may be effected in any convenient way for cell-based assays such as a transmembrane transport assay. The transport of a directly or indirectly detectable product, e.g., a fluorescent molecule such as calcein AM or rhodamine 123, is preferred. For cell free binding assays, one of the components usually comprises, or is coupled to, a detectable label. A wide variety of labels can be used, such as those that provide direct detection (e.g., radioactivity, luminescence, optical or electron density, etc). or indirect detection (e.g., epitope tag such as the FLAG epitope, enzyme tag such as horseradish peroxidase, etc.). The label may be bound to a dog PGP polypeptide or the candidate pharmacological agent.

A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the solid substrate or subsequent to separation from the solid substrate. Labels may be directly detected through optical or electron density, radioactive emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, streptavidin-biotin conjugates, etc. Methods for detecting the labels are well known in the art.

The dog PGP binding agent may also be an antibody or a functionally active antibody fragment. Antibodies are well known to those of ordinary skill in the science of immunology. As used herein, the term "antibody" means not only intact antibody molecules but also fragments of antibody molecules retaining dog PGP binding ability. Such fragments are also well known in the art and are regularly employed both *in vitro* and *in vivo*. In particular, as used herein, the term "antibody" means not only intact immunoglobulin molecules but also the well-known active fragments  $F(ab')_2$ , and Fab.  $F(ab')_2$ , and Fab fragments which lack the

Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl et al., *J. Nucl. Med.* 24:316-325 (1983)).

Monoclonal antibodies may be made by any of the methods known in the art utilizing dog PGP, or a fragment thereof, as an immunogen. Alternatively the antibody may be a polyclonal antibody specific for dog PGP which inhibits dog PGP activity. The preparation and use of polyclonal antibodies is also known to one of ordinary skill in the art.

Significantly, as is well known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W.R. (1986) *The Experimental Foundations of Modern Immunology* Wiley & Sons, Inc., New York; Roitt, I. (1991) *Essential Immunology*, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')<sub>2</sub> fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

In general, intact antibodies are said to contain "Fc" and "Fab" regions. The Fc regions are involved in complement activation and are not involved in antigen binding. An

antibody from which the Fc' region has been enzymatically cleaved, or which has been produced without the Fc' region, designated an "F(ab')<sub>2</sub>" fragment, retains both of the antigen binding sites of the intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an "Fab" fragment, retains one of the antigen binding sites of the intact antibody. Fab' fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain, denoted "Fd." The Fd fragments are the major determinants of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity). Isolated Fd fragments retain the ability to specifically bind to antigen epitopes.

The sequences of the antigen-binding Fab' portion of the anti-dog PGP monoclonal antibodies identified as being useful according to the invention in the assays provided above, as well as the relevant FR and CDR regions, can be determined using amino acid sequencing methods that are routine in the art. It is well established that non-CDR regions of a mammalian antibody may be replaced with corresponding regions of non-specific or hetero-specific antibodies while retaining the epitope specificity of the original antibody. This technique is useful for the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. Techniques to humanize antibodies are particularly useful when non-human animal (e.g., murine) antibodies which inhibit dog PGP activity are identified. These non-human animal antibodies can be humanized for use in the treatment of a human subject in the methods according to the invention. Examples of methods for humanizing a murine antibody are provided in U.S. patents 4,816,567, 5,225,539, 5,585,089, 5,693,762 and 5,859,205. Other antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')<sub>2</sub> and Fab fragments of an anti-dog PGP monoclonal antibody; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions of an anti-dog PGP antibody have been replaced by homologous human or non-human sequences; chimeric F(ab')<sub>2</sub> fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions of an anti-dog PGP antibody have been replaced by homologous human or non-human sequences; and chimeric Fab fragment antibodies in which



the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences.

According to the invention dog PGP inhibitors also include "dominant negative" polypeptides derived from SEQ ID NOs:2. A dominant negative polypeptide is an inactive variant of a polypeptide, which, by interacting with the cellular machinery, displaces an active polypeptide from its interaction with the cellular machinery or competes with the active polypeptide, thereby reducing the effect of the active polypeptide. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand.

The end result of the expression of a dominant negative dog PGP polypeptide of the invention in a cell is a reduction in PGP activity such as molecular transport. One of ordinary skill in the art can assess the potential for a dominant negative variant of a dog PGP polypeptide, and using standard mutagenesis techniques to create one or more dominant negative variant polypeptides. For example, given the teachings contained herein of a dog PGP polypeptide, one of ordinary skill in the art can modify the sequence of the dog PGP polypeptide by site-specific mutagenesis, scanning mutagenesis, partial gene deletion or truncation, and the like. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in dog PGP activity and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a dog PGP polypeptide will be apparent to one of ordinary skill in the art.

Each of the compositions of the invention is useful for a variety of therapeutic and non-therapeutic purposes. For example, the dog PGP nucleic acids of the invention are useful as oligonucleotide probes. Such oligonucleotide probes can be used herein to identify genomic or cDNA library clones possessing an identical or substantially similar nucleic acid sequence. A suitable oligonucleotide or set of oligonucleotides, which is capable of hybridizing under stringent hybridization conditions to the desired sequence, a variant or fragment thereof, or an anti-sense complement of such an oligonucleotide or set of oligonucleotides, can be synthesized by means well known in the art (see, for example, *Synthesis and Application of DNA and RNA*, S.A. Narang, ed., 1987, Academic Press, San Diego, CA) and employed as a probe to identify and isolate the desired sequence, variant or

fragment thereof by techniques known in the art. Techniques of nucleic acid hybridization and clone identification are disclosed by Sambrook, et al., *Molecular Cloning, A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press, Plainview, NY (1989). To facilitate the detection of a desired nucleic acid sequence, or variant or fragment thereof, whether for cloning purposes or for the mere detection of the presence of the sequence, the above-described probes may be labeled with a detectable group. Such a detectable group may be any material having a detectable physical or chemical property. Such materials have been well-developed in the field of nucleic acid hybridization and, in general, many labels useful in such methods can be applied to the present invention. Particularly useful are radioactive labels. Any radioactive label may be employed which provides for an adequate signal and has a sufficient half-life. If single stranded, the oligonucleotide may be radioactively labeled using kinase reactions. Alternatively, oligonucleotides are also useful as nucleic acid hybridization probes when labeled with a non-radioactive marker such as biotin, an enzyme or a fluorescent group. See, for example, Leary, J.J., et al., *Proc. Natl. Acad. Sci. (USA)* 80:4045 (1983); Renz, M. et al., *Nucl. Acids Res.* 12:3435 (1984); and Renz, M., *EMBO J.* 6:817 (1983).

Additionally, complements of the dog PGP nucleic acids can be useful as antisense oligonucleotides, e.g., by delivering the antisense oligonucleotide to an animal to induce a dog PGP "knockout" phenotype. The administration of antisense RNA probes to block gene expression is discussed in Lichtenstein, C., *Nature* 333:801-802 (1988).

Alternatively, the dog PGP nucleic acid of the invention can be used to prepare a non-human transgenic animal. A "transgenic animal" is an animal having cells that contain DNA which has been artificially inserted into a cell, which DNA becomes part of the genome of the animal which develops from that cell. Preferred transgenic animals are primates, mice, rats, cows, pigs, horses, goats, sheep, dogs and cats. Animals suitable for transgenic experiments can be obtained from standard commercial sources such as Charles River (Wilmington, MA), Taconic (Germantown, NY), Harlan Sprague Dawley (Indianapolis, IN), etc. Transgenic animals having a particular property associated with a particular disease can be used to study the affects of a variety of drugs and treatment methods on the disease, and thus serve as genetic models for the study of a number of human diseases. The invention, therefore, contemplates the use of dog PGP knockout and transgenic animals as models for the study of disorders involving tranport of molecules across cell membranes. A variety of methods

known to one of ordinary skill in the art are available for the production of transgenic animals associated with this invention.

Inactivation or replacement of the endogenous PGP/MDR1 gene can be achieved by a homologous recombination system using embryonic stem cells. The resultant transgenic non-human mammals having a PGP<sup>-/-</sup> knockout phenotype may be made transgenic for the dog PGP and used as a model for screening compounds as modulators (agonists or antagonists/inhibitors) of the dog PGP. In this manner, such therapeutic drugs can be identified.

Additionally, a normal or mutant version of dog PGP can be inserted into the germ line to produce transgenic animals which constitutively or inducibly express the normal or mutant form of dog PGP. These animals are useful in studies to define the role and function of dog PGP in cells.

The compositions of the invention are also useful for therapeutic purposes. Accordingly the invention encompasses a method for inhibiting dog PGP activity in a mammalian cell. The invention further provides methods for reducing or increasing dog PGP activity in a cell. In one embodiment, the method involves contacting the mammalian cell with an amount of a dog PGP nucleic acid or polypeptide effective to inhibit molecular transport out of the mammalian cell. Such methods are useful *in vitro* for the purpose of, for example, elucidating the mechanisms involved in drug resistance and reduced drug bioavailability.

The invention also encompasses a method for increasing PGP expression in a cell or subject. The amount of dog PGP can be increased in such cell or subject by contacting the cell with, or administering to the subject, a PGP nucleic acid or a PGP polypeptide of the invention to the subject in an amount effective to increase transmembrane transport in the cell or the subject. An increase in PGP activity can be measured by the assays described herein, e.g., assays of transmembrane transport.

The preparations of the invention are administered in effective amounts. An effective amount is that amount of a pharmaceutical preparation that alone, or together with further doses, produces the desired response. Such amounts will depend, of course, on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the

knowledge and expertise of the health practitioner. It is preferred generally that a maximum dose be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.

Generally, doses of active compounds would be from about 0.01 mg/kg per day to 1000 mg/kg per day. It is expected that doses ranging from 50-500 mg/kg will be suitable and in one or several administrations per day. Lower doses will result from other forms of administration, such as intravenous administration. In the event that a response in a subject is insufficient at the initial doses applied, higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. Multiple doses per day are contemplated to achieve appropriate systemic levels of compound, although fewer doses typically will be given when compounds are prepared as slow release or sustained release medications.

When administered, the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptably compositions. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like. Also, pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.

The dog PGP inhibitors or dog PGP nucleic acids and polypeptides useful according to the invention may be combined, optionally, with a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled

with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.

The pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; and phosphoric acid in a salt.

The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.

A variety of administration routes are available. The particular mode selected will depend, of course, upon the particular compound selected, the severity of the condition being treated and the dosage required for therapeutic efficacy. The methods of the invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such modes of administration include oral, rectal, topical, nasal, intradermal, or parenteral routes. The term "parenteral" includes subcutaneous, intravenous, intrathecal, intramuscular, or infusion. Intravenous or intramuscular routes are not particularly suitable for long-term therapy and prophylaxis.

The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

Compositions suitable for oral administration may be presented as discrete units, such as capsules, tablets, lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquids or non-aqueous liquids such as a syrup, elixir or an emulsion.

Compositions suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the dog PGP inhibitor or dog PGP nucleic acids and polypeptides, which is preferably isotonic with the blood of the recipient. This aqueous preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be

employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier  
5 formulation suitable for oral, subcutaneous, intravenous, intrathecal, intramuscular, etc. administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA.

Other delivery systems can include time-release, delayed release or sustained release delivery systems such as the biological/chemical vectors is discussed above. Such systems  
10 can avoid repeated administrations of the active compound, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. Use of a long-term sustained release implant may be desirable. Long-term release, as used herein, means that the implant is constructed and arranged to deliver therapeutic levels of the active ingredient for at least 30 days, and  
15 preferably 60 days. Long-term sustained release implants are well-known to those of ordinary skill in the art and include some of the release systems described above. The invention will be more fully understood by reference to the following examples. These examples, however, are merely intended to illustrate the embodiments of the invention and are not to be construed to limit the scope of the invention.

### Examples

#### **Example 1: Isolation of dog P-glycoprotein**

cDNA libraries were prepared using dog (*Canis familiaris*) mRNA according to  
25 standard procedures. The libraries were screened for P-glycoprotein clones using a human P-glycoprotein DNA probe. Clones were isolated, purified and sequenced in accordance with standard procedures, as described below.

Liver and lung tissue was excised from Beagle dog tissue samples and flash frozen in liquid nitrogen.

30 A 890bp fragment of dog PGP1 was PCR'd out of a lambda gt11 vector cDNA library custom made by Stratagene. PCR was done using reagents from Clontech. Primers were custom designed, one specific for sequence homologous to human PGP1, the other

homologous to dog PGP2.

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
Dp1216F	5'-gaa ctg tga ttg cgt ttg gag gac-3'	24mer	9	human PGP1
Dp2133R	5'-ttc agg gcc gcc tgt acc tct g-3'	22mer	10	dog PGP2

PCR was performed with a Perkin Elmer 9700 thermocycler. PCR was done at 94°C for 2 minutes, followed by 40 cycles of 94°C for 30 seconds, 40°C for 20 seconds and 72°C for 2 minutes and 30 seconds, and then incubated at 72°C for 3 minutes. The PCR product was run on a 1% agarose gel, and stained with EtBr. The DNA band at 917bp was cut out, and purified using the QIAquick Gel Extraction kit from Qiagen Inc.

The DNA was then ligated to the vector pCR2.1 using the Original TA Cloning kit from Invitrogen. INValphaF<sup>+</sup> cells were transformed with the ligation retain, a colony was selected, grown up in 100mL of L broth with ampicillin. DNA purification was done using the Plasmid Midi purification kit from Qiagen. The insert was sequenced using an ABI 377 sequencer. This sequence corresponds to an 890bp fragment of dog PGP, from base 816 to base 1706 in the open reading frame.

Five other fragments were isolated, cloned and sequenced using the same method as stated above, with any differences in procedure stated below.

RNA extraction from dog lung tissue was performed using Nucliobond RNA Maxi Prep. purification kit from Clontech. cDNA was synthesized from the RNA preparation using Superscript Preamplification System for First Strand cDNA Synthesis from Life Technologies.

Fragment 1: cDNA source-dog lung cDNA library prep.

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
Dm1766F	5'-ccc cac aga tgg cat ggt ctg t-3'	22mer	11	dog PGP1
Dp2769R	5'-cgc ttg gtg agg atc tct cca gc-3'	23mer	12	human PGP1

This corresponds to a 981bp fragment of dog PGP from base 1364 to base 2345 in the open reading frame.

Fragment 2: cDNA source dog - lung cDNA library prep.

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
Dm2037F	5'-aga aac aga gaa tgg cca ttg ctc-3'	24mer	13	dog PGP1

Dp3793R 5'-gct gca gtc aaa cag gat ggg ct-3' 23mer 14 human PGP1  
This corresponds to a 1728bp fragment of dog PGP from base 1635 to base 3362 in the open reading frame.

5 Fragment 3: cDNA source dog - lung cDNA prep

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
Dm3411F	5'-agt tca ttt gct cct gac tat gcc-3'	24mer	15	dog PGP1
Dp4214R	5'-gat gcc ttt ctg ggc cag cag c-3'	22mer	16	human PGP1

This corresponds to a 779bp fragment of dog PGP from base 3004 to base 3783 in the open reading frame.

An RNA preparation from dog liver tissue was performed using the same method as used previously. cDNA was made from it using the SMART RACE cDNA Amplification Kit from Clontech using SMART II oligonucleotide. PCR conditions were changed to 94°C for 5 minutes, followed by 5 cycles of 94°C for 30 seconds and 72°C for 2 minutes. Five cycles of 94°C for 30 seconds, 70°C for 45 seconds and 72°C for 2 minutes were performed next. The final 30 cycles were at 94°C for 30 seconds, 68°C for 45 seconds and 72°C for 2 minutes. The PCR was concluded with 72°C for 7 minutes.

20 Fragment 4: cDNA source - dog liver cDNA (SMART RACE) prep.

<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
Dm3612FL	5'-gag gtg aag aag ggc cag acg ctg gcc ctc-3'	30mer	17	dog PGP1
RACE	5'-cta ata cga ctc act ata ggg caa gca gfg gta aca acg cag agt -3'	18		vector

This corresponds to a 3' end fragment of dog PGP from base 3212 to base 4264 in the open reading frame.

An RNA preparation from dog liver tissue was performed using the same method as used previously. cDNA was made from it using the SMART RACE cDNA Amplification Kit from Clontech using the gene specific Primer DM1680RL 5'-cgc agc cac tgt tcc caa cca ggc cca ct-3', 29mer, SEQ ID NO:19, dog PGP1.

Fragment 5: cDNA source - dog liver cDNA (SMART RACE with internal primer) prep.



<u>Primer name</u>	<u>sequence</u>	<u>size</u>	<u>SEQ NO:</u>	<u>homology</u>
Dp409F	5'-gga gcg cga ggt cgg gat gga tc- 3'	23mer	20	human PGP1
Dm1355RL	5'-gga gag gac caa gga ggt ccc ata cca gaa a-3'	31mer	21	dog PGP1

This corresponds to an ATG fragment of dog PGP from base -15 to base 945 in the open reading frame.

#### Assembly of Clones

1Kb fragment (890bp) and 981bp fragment

DNA preps were made of each fragment. Both fragments were cut with NcoI restriction enzyme. The 1Kb fragment was also cut with EcoRI. The 981bp fragment was also cut with BamHI. Each fragment was purified, ligated together, then the ends were cut, the cut molecule was gel purified and ligated into pUC19 cut with EcoRI and BamHI.

1Kb fragment (890bp)/981bp fragment and 1728bp fragment

These fragments were assembled as above except that both fragments were cut with BamHI and the 1728bp fragment was also cut with XbaI.

1Kb fragment (890bp)/981bp fragment/1728bp fragment and ATG fragment  
3'end and 779bp fragment

1Kb fragment (890bp)/981bp fragment/1728bp fragment ATG fragment and  
3'end/779bp fragment

All of these fragments were assembled as above except that, in some cases, the fragments were cut with different restriction enzymes according to their nucleotide sequences.

The nucleotide sequence of a dog P-glycoprotein is presented as SEQ ID NO:1. The coding sequence consists of nucleotides 17-3859, producing a polypeptide of 1281 amino acids (SEQ ID NO:2).

#### Example 2: Activity of dog P-glycoprotein

##### *Materials and Methods*

Dog PGP cDNA (SEQ ID NO:1) is introduced into a clonal population of LLC-PK1 cells in a vector that confers resistance to hygromycin B. LLC-PK1 cells are obtained from

the American Type Culture Collections and are propagated in Medium 199 supplemented to 7% with fetal bovine serum. LLC-PK1 cells are recloned prior to transfection in order to assure homogeneity of the cell population. Briefly, dog PGP cDNA is incorporated into the p222CMV vector. This vector is derived from the p220.2 episomal vector system based on the OriP sequences for Epstein Barr virus and the EBNA-1 gene product (Sugden et al., *Mol. Cell Biol.* 5:410-413, 1985; Yates et al., *Nature (Lond.)* 313: 812-815, 1985). The PGP cDNA is under the control of the cytomegalovirus (CMV) immediate early promoter. The vector confers resistance to hygromycin B. Cells (in 0.4 mL) and DNA (10 to 20 µg) were transfected by electroporation using a BTX Electro cell manipulator model 600 using a 2 mm gap cell, 100V, 2500 µF capacitance and 72 ohm resistance. After electroporation, the cells are plated in multiwell plates (48 well, Corning Costar) at 10% of confluence. One to two days after transfection hygromycin B is introduced at a final concentration of 400 to 600 µg/ml. Cells are refed every 2 to 4 days and are propagated in 400 to 600 µg/ml hygromycin B for 6 to 8 days at which point the bulk of the wild type cells are detached. The hygromycin B is reduced to 100 µg/ml and maintained in this concentration of hygromycin B. After 14 to 18 days the wells are inspected and wells containing single colonies are trypsinized and scaled up to bulk cultures. Expression of PGP is measured by the polarization of vinblastine (0.1 µM) transport in Transwells™.

LLC-PK1 cell based transport studies are conducted in 24 well Transwells™ (Corning Costar, Catalog number 3415). Transwells™ are prepared by the addition of 0.6 mL media to the basolateral space and 0.1 mL media to the apical space. Cells are seeded at  $4 \times 10^4$  cells per insert (typically in 0.05 mL to 0.15 mL), refed with fresh media every 2 to 4 days and used for transport studies 4 to 8 days post seeding. Transport assays are conducted in Hank's balanced saline (HBSS) buffered with 10 mM HEPES (pH 7 to 7.2). Cell monolayers are rinsed with HBSS prior to use in transport assays. Transport is measured under sink conditions in both the apical to basolateral (A to B) and basolateral to apical (B to A) directions. At least duplicate monolayers are used per determination. At the desired time points, samples are withdrawn from the receiver chamber (apical or basolateral chambers). Quantitation of the amount of compound transported is by liquid scintillation counting (vinblastine) or HPLC with UV or mass spectrometric detection.

Dog PGP cDNA is expressed in insect cells using a baculovirus vector. Membranes are prepared according to the method of (Sarkadi et al., *J. Biol. Chem.* 267: 4854-4858, 1992)

and stored at -80°C until use. ATPase assays are conducted in 96 well microtiter plates. The assays are conducted using a modification of the methods of (Sarkadi et al., 1992 and Druekes et al., *Anal. Biochem.* 230: 173-177, 1995).

A detailed method for each well of a 96 well plate is contained below:

5 A 0.06 ml reaction mixture containing 40 µg membranes, 20 µM Verapamil (positive control) or test drug, and 3-5 mM MgATP, in buffer containing 50 mM Tris-MES, 2 mM EGTA, 50 mM KCl, 2 mM dithiothreitol, and 5 mM sodium azide, is incubated at 37°C for 20 min. An identical reaction mixture containing 100 µM sodium orthovanadate is assayed in parallel. Orthovanadate inhibits PGP by trapping MgADP in the nucleotide binding site. Thus,  
10 ATPase activity measured in the presence of orthovanadate represents non-PGP ATPase activity and can be subtracted from the activity generated without orthovanadate to yield vanadate-sensitive ATPase activity. The reaction is stopped by the addition of 30 µl of 10 % SDS + Antifoam A. Two additional reaction mixtures (+ and - orthovanadate) but without MgATP, are also prepared and incubated with the others, and then supplemented with SDS  
15 and MgATP, to represent time = 0 min of reaction. The incubations are followed with addition of 200 µl of 35 mM ammonium molybdate in 15 mM zinc acetate:10 % ascorbic acid (1:4) and incubated for an additional 20 min at 37°C. The liberation of inorganic phosphate is detected by its absorbance at 800 nm and quantitated by comparing the absorbance to a phosphate standard curve.

20 Ligand binding assays and assays for measuring inhibition of fluorescent dye uptake are preformed as described by Sharom et al. (*Biochem. Pharmacol.* 58:571-586, 1999).

### *I. Stable PGP Expression in LLC-PK1 Cells.*

Functional expression of dog PGP is measured by the polarization of transport of  
25 vinblastine. Control cells typically demonstrate a B to A / A to B ratio of between 1 and 3. PGP transfected cells demonstrate a much higher ratio. The expression of cDNA-derived dog is stable.

### *II. Activation of ATPase Activity in PGP Membranes.*

30 The stimulation of ATPase assay provides a rapid measure of the concentration dependence of any interaction of a drug with PGP. The liberated inorganic phosphate is measured by a simple spectrophotometric assay performed in a microtiter plate format. The

testing of multiple drug concentrations allows estimation of the affinity of the drug for PGP and whether saturation of the response was observed.

### *III. Drug Transport Across Cell Monolayers.*

The ATPase assay does not directly measure drug transport. In order to examine the concordance between activation of ATPase and actual transport, the rates of transport of the drugs are measured in control LLC-PK1 and dog PGP cell monolayers. For each drug concentration, four measurements are made:

A:	A to B	Control cells
B:	B to A	Control cells
C:	A to B	PGP cells
D:	B to A	PGP cells

The polarization of transport is calculated in control cells (B/A) and PGP cells (D/C). The intrinsic activity (IA) of PGP is calculated as the sum of the amount PGP facilitated B to A transport in PGP cells relative to control cells (D minus B) and the amount that PGP impeded A to B transport in PGP cells relative to control cells (A minus C). The intrinsic clearance of PGP is calculated from a plot of the concentration dependence data by either calculating the slope of the line under non-saturating conditions or from the calculated apparent  $K_m$  and  $V_{max}$  values when saturation is observed. Intrinsic clearance is expressed as  $mL/m^2/min$ .

The ATPase data provides useful concentration response data. For example, the apparent  $K_m$  values for some compounds are in good agreement between the ATPase and transport systems. However, other drugs activate ATPase activity but transport by PGP is not detectable. At the least, ATPase assay can identify a concentration range below which the response to transport by PGP was linear with respect to drug concentration. This should allow simplification of the experimental design for measuring the intrinsic clearance of PGP, an important consideration if large numbers of compounds are to be tested.

### *IV. Bioavailability*

Bioavailability studies are performed by performing one or more of the assays described above with two or more different PGP types. The different PGP types can by different species (e.g., dog and human, cynomolgous monkey and human, dog and

cynomolgous monkey, etc.) or can be different alleles of the same species. The results of these assays are compared to determine or estimate the bioavailability of a drug in individuals of the different species or in individuals that express different PGP alleles. The results of one determination also may be compared to a previously determined value of, e.g., ATPase or transport, as an historical control.

### *Protocols and Procedures*

#### Isolation of RNA

Frozen beagle liver tissue was ground up using a mortar and pestle. Pulverized tissue (300 mg) was transferred to a dounce homogenizer. TRIzol Reagent (3mL; Cat. # 15596 from Life Technologies) was added and the tissue was homogenized then incubated for 15 minutes at room temperature. Aliquots (1mL) of the solution were transferred to three microfuge tubes and 200  $\mu$ L of chloroform were added to each tube. Each tube was vortexed at a high setting for 15 seconds, then incubated at room temperature for 3 minutes before being centrifuged at 10 000 g for 15 minutes at 4°C. The upper "aqueous" phase was transferred to a new microfuge tube while the remaining lower and inter phases were discarded. 500  $\mu$ L of Isopropanol was added to each of the new tubes and mixed by inverting the tube several times. Each tube was then incubated at room temperature for 10 minutes before being centrifuged at 10 000 g for 10 more minutes at 4°C. A small white pellet was observed and the supernatant was discarded. 1mL of 75% ethanol was added to each tube. The tubes were vortexed briefly then centrifuged at 10 000 g for 10 minutes at 4°C. The supernatant was discarded and the pellet dried for 5 minutes at room temperature. 50  $\mu$ L of DEPC treated sterile deionized water was added to each tube. Each pellet was resuspended and the contents of each tube were pooled.

Optical density of the resuspended pellet was analyzed using a Hitachi U3010 spectrophotometer to determine the quantity of RNA that was isolated. The RNA was then diluted using DEPC treated sterile deionized water to a concentration of 0.55  $\mu$ g/ $\mu$ L. 2 mL of this RNA was split evenly into 2 microfuge tubes. Next, 100  $\mu$ L of 5 M NaCl was added to each tube. Both tubes were heated to 65°C for 15 minutes, then put on ice for 5 minutes. 500  $\mu$ L of Oligo (dT) Cellulose Suspension from the MessageMaker mRNA Isolation System (Cat. # 10551-018 from Life Technologies) were added to both tubes. The tubes were then incubated at 37°C for 10 minutes. The contents of the tubes were transferred to the Filter

Syringe provided with the MessageMaker mRNA Isolation System. After expelling the liquid contents, the pellet in the syringe was washed using Wash Buffer 1 and Wash Buffer 2 according to the manufacturer's instructions. The RNA pellet in the syringe was resuspended in 1 mL of DEPC treated sterile deionized water (65°C), followed by the addition of 2.5 µL of 50 µg/mL glycogen and 100 µL of 7.5M ammonium acetate and mixing by inversion. The contents of the tube were then transferred to a two microfuge tubes and 1 mL of ethanol was added to each tube. The contents of both tubes were mixed by inversion, followed by incubation at -20°C overnight.

The tubes were centrifuged at 10 000 g for 30 minutes at 4°C. The supernatant was discarded and 200 µL of 75% ethanol was added to each tube. The tubes were vortexed for 10 seconds followed by centrifugation at 10 000 g for 15 minutes at 4°C. The supernatant was discarded and all remaining liquid was carefully pipetted off. The pellet was resuspended in 10 µL of DEPC treated sterile deionized water.

#### Preparation of cDNA

CDNA was prepared using the Marathon cDNA Amplification Kit (Cat. # K1802-1 from Clontech Laboratories, Inc., Palo Alto, CA) as follows. Four microliters of the resuspended mRNA were transferred to a new microfuge tube, and 1 µL of one of the following primers at 10 µM concentration was added: Dm1680RL cgc agc cac tgt tcc caa cca ggc cca ct (SEQ ID NO:19; custom designed, synthesized by Operon Technologies, Inc.) or cDNA Synthesis Primer, nnt ttt ttt ttt ttt ttt ttt ttt ttc gcc ggc gac tta aga tct t (SEQ ID NO:28), from the Marathon cDNA Amplification Kit. Tubes were incubated at 70°C for 2 minutes then placed on ice for 5 minutes. 2 µL of 5x First-Strand Buffer, 1 µL of 10mM dNTP Mix and 1 µL of 20 U/µL AMV Reverse Transcriptase were added to each tube and gently mixed. The tubes were incubated at 42°C for 1 hour, then placed on ice. 2 µL of each single stranded cDNA were used as template in PCR (see below, "PCR conditions"). 48.4 µL of DEPC treated deionized water, 16 µL of 5x Second-Strand Buffer, 1.6 µL of 10mM dNTP Mix and 4 µL of 20x Second-Strand Enzyme Cocktail were added to the remaining cDNA sample. The tube was incubated at 16°C for 1.5 hours. 2uL of 5U/uL T4 DNA Polymerase was added to the tube, which was then incubated at 16°C for an additional 45 minutes. 20x EDTA/Glycogen Mix (4 µL) was added followed by 430 µL of Buffer PN from the QIAquick Nucleotide Removal Kit (Cat. # 28304 from QIAGEN Inc., Valencia, CA). The sample was

then loaded into a QIAquick Spin Column and centrifuged at 10 000 g for 1 minute. The collection tube was emptied and 750 µL of PE Buffer (QIAGEN) were added to the QIAquick Spin Column which was again centrifuged at 10 000 g for 1 minute. The collection tube was once again emptied and the QIAquick Spin Column was centrifuged at 10 000 g for 1 minute to dry the column membrane. 50 µL of sterile deionized water heated to 50°C was added to the QIAquick Spin Column and incubated at room temperature for 1 minute before being centrifuged at 10 000 g for 1 minute into a clean microfuge tube.

To precipitate nucleic acid, 10.8 µL 7.5M ammonium acetate and 144 µL ethanol were added to the tube before it was centrifuged at 10 000 g for 20 minutes. The supernatant was removed, then 300 µL of 75% ethanol was added. The tube was vortexed and centrifuged at 10 000 g for 20 minutes. The supernatant was removed and the sample was resuspended in 12 µL of sterile deionized water. 5 µL of this cDNA were placed in a clean microfuge tube. 2 µL of 10 µM Marathon cDNA Adapter, 2 µL 5x DNA Ligation Buffer and 1 µL of 400U/µL T4 DNA Ligase, from the Marathon cDNA Amplification Kit, were added to the cDNA and mixed gently. This mixture was incubated over night at 16°C. The ligation was heat inactivated at 70°C for 5 minutes. PCR was done using this sample as a template.

#### PCR conditions

PCR was performed using reagents supplied with the Clontech Advantage 2 kit (Clontech, palo Alto, CA). Briefly, 2 µL of cDNA was placed in a 200 µL MicroAmp reaction tube (Cat. # N801-0540, PE Biosystems), then 34 µL of sterile deionized water, 5 µL of 10x Clontech Advantage 2 Polymerase Mix (Cat. # 4700-1 Clontech Laboratories, Inc.), 3 µL of 10 mM Advantage UltraPure PCR Deoxynucleotide Mix (Cat. # 8430-1 Clontech Laboratories, Inc.) and 2 µL each of a forward and reverse primer at 10mM concentration were added. Primers were either Marathon cDNA Adapter Primer 1, cca tcc taa tac gac tca ctg tag gcc (SEQ ID NO:29), from the Marathon cDNA Amplification Kit or various custom gene specific primers made by Operon Technologies Inc. Custom primers include (all listed as 5'-3'): Dm409FL: gga gcg cga ggt cgg gat gga tc (SEQ ID NO:20), Dm1455RL: gca aat gct tca atg ctt ggg gat gcc tgt cca a (SEQ ID NO:30), Dm2037F: aga aac aga gaa tcg cca ttg etc (SEQ ID NO:13), Dm3920RL: gag ctg ggt tcc ttt gtc tcc tac tct ggt gtt (SEQ ID NO:31), Dp1216F: gaa ctg tga ttg cgt ttg gag gac (SEQ ID NO:9), and Dp2587R: gca aat gct ggt tgc agg cct cc (SEQ ID NO:32).

Thermocycling was done using a Perkin Elmer 9700 at 94°C for 30 seconds followed by 2 cycles of 94°C for 5 seconds and 72°C for 4 minutes, followed by 16 cycles of 94°C for 5 seconds and 68°C for 4 minutes.

Four fragments were acquired by PCR for each Genotype. Fragment 1 was generated using primers Marathon cDNA Adapter Primer 1 and Dm1455RL. Fragment 2 was generated using primers Dp1216F and Dp2587R. Fragment 3 was generated using primers Dm2037F and Dm3920RL. Fragment 4 was generated using primers Dp3612FL and Marathon cDNA Adapter Primer 1.

#### Post PCR sample processing

Electrophoresis was performed on all PCR products using 10x Gel-loading Buffer IV (*Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, page 6.12), on a 1% agarose gel in 0.5x TBE buffer (Sambrook, et al., page B-23) containing EtBr. Fragments of gel containing the PCR products were cut out and placed in 2 mL microfuge tubes. The mass of each fragment was determined and 3 µL/mg of Buffer QX1 from QIAquick Gel Extraction Kit (Cat. # 28704 from QIAGEN Inc.) was added. Each tube was then incubated for 10 minutes at 50°C with mixture every two minutes. 1 µL/mg of isopropanol was added to each tube and mixed. The resulting solution was transferred to a QIAquick spin column from the QIAquick Gel Extraction Kit. These columns were centrifuged for 1 minute at 10 000 g at room temperature. 750 µL of Buffer PE from the QIAquick Gel Extraction Kit were added to each column followed by centrifugation for 1 minute at 10 000 g at room temperature. Each column was centrifuged again for 1 minute at 10 000 g at room temperature to remove any residual buffer. 30 µL of sterile deionized water at 50°C were added to each column and incubated for 1 minute at room temperature. Each column was then placed in a microfuge tube and centrifuged for 1 minute at 10 000 g.

Next, 6 µL of purified PCR product was transferred to a clean microfuge tube and 1 µL of 10x Ligation Buffer, 2 µL of pCR 2.1 vector and 1 µL of T4 DNA Ligase (all from the Original TA Cloning Kit (Cat. # K2000-J10) Invitrogen, Carlsbad, CA) were added to the microfuge tube and mixed. The reaction was incubated overnight at 16°C.

One 50 µL vial of frozen One Shot competent cells (Invitrogen) was thawed on ice for each ligation reaction. 3.5 µL of ligation reaction mixture was added to the competent cells



and gently mixed. The cells incubated on ice for 30 minutes, followed by a 30 second "heat shock" at 42°C. After cooling on ice again, 250 µL of SOC medium (Invitrogen) was added to each vial and the vials were put directly into a 37°C water bath for 1 hour. 50 µL and 200 µL aliquots of each transformation reaction were plated on Luria-Bertani Medium (Sambrook et al., page A-1) containing 1% agarose, 1 mg/mL glucose, 50 ng/mL ampicillin and 1.6 ng/mL X-gal. The inoculated plates were then incubated at 37°C overnight. White colored colonies were selected and used to inoculate separate 100 mL cultures of L-B Medium containing 50 ng/mL ampicillin which were incubated at 37°C overnight while being stirred at 100 rpm.

Plasmid DNA was prepared using QIAGEN Midi Plasmid Kit (Cat. # 12143 from QIAGEN Inc.), according to the manufacturer's instructions, as follows. Each 100 mL culture was aliquoted into two 50 mL conical vials and centrifuged at 3 000 g for 10 minutes at 4°C. The supernatant was poured off and 4 mL of Buffer P1 were used to resuspend the pellet in one of the two vials. This suspension was transferred to the other tube and used to resuspend that pellet. Buffer P2 (4 mL) was added, mixed and the suspension was incubated at room temperature for 5 minutes. Buffer P3 (4 mL) was added, mixed and the suspension was incubated at 4°C for 15 minutes. The samples were centrifuged at 3 000 g for 15 minutes at 4°C. All of the supernatant was transferred to a QIAGEN-tip 100 that had been previously treated with 4 mL of Buffer QBT. The supernatant was allowed to drain through the column. Buffer QC (10 mL) was added to the column and allowed to drain. Another 10 mL of Buffer QC was added and allowed to drain. Finally 4 mL of Buffer QF was added to the column and allowed to drain into a clean 15 mL conical vial. 2.8 mL of isopropanol was added and mixed with this solution. This was aliquoted into microfuge tubes, incubated at 4°C for 10 minutes and centrifuged at 10 000 g for 15 minutes at 4°C. The supernatant was removed, then 1 mL of 70% ethanol was added to each microfuge tube. Each tube was vortexed briefly, then centrifuged at 10 000 g for 15 minutes at 4°C. The supernatant was removed and 100 µL of sterile 1x TE buffer (Sambrook et al., page B-20) were added.

Restriction digests were performed on the purified DNA. Enzymes used to cut fragments out were: fragment 1, KpnI (Cat. # R0142S from New England Biolabs, Inc., Beverly, MA) and NsiI (Cat. # R0127S from New England Biolabs, Inc.); fragment 2, NsiI and HindIII (Cat. # R0104S from New England Biolabs, Inc.); fragment 3, HindIII and PstI (Cat. # V0279S from New England Biolabs, Inc.); and fragment 4, PstI and NotI (Cat. #

R0189S from New England Biolabs, Inc.). All restriction digests were preformed at 37°C in digestion buffers recommended by New England Biolabs.

Electrophoresis was performed on all restriction digest products using 10x gel-loading buffer IV (Sambrook et al., page 6.12), on a 1% agarose gel in 0.5x TBE buffer (Sambrook et al., page B-23) containing EtBr. Fragments of gel containing the restriction digest products were cut out and placed in 2 mL microfuge tubes. DNA fragments were extracted from the gel slices using a QIAquick Gel Extraction Kit (Cat. # 28704 from QIAGEN Inc.) according to the manufacturer's instructions. The mass of each fragment was determined and 3 µL/mg of Buffer QX1 was added. Each tube was then incubated for 10 minutes at 50°C with mixture every two minutes. One volume of isopropanol was added to each tube and mixed. The resulting solution was transferred to a QIAquick spin column and centrifuged for 1 minute at 10 000 g at room temperature. Buffer PE (750 µL) was added to each column followed by centrifugation for 1 minute at 10 000 g at room temperature. Each column was centrifuged again for 1 minute at 10 000 g at room temperature to remove any residual buffer. 30 µL of sterile deionized water at 50°C was added to each column and incubated for 1 minute at room temperature. Each column was then placed in a microfuge tube and centrifuged for 1 minute at 10 000 g.

Two microliters of each fragment was added to a microfuge tube as well as 1 µL of 10x Ligation Buffer and 1 µL of T4 DNA Ligase (Cat. # M0202S from New England Biolabs, Inc.). This reaction was incubated at 16 °C overnight. Restriction enzymes KpnI and NotI (1 µL each) were added to the reaction and incubated at 37°C for 1 hour. Electrophoresis was performed using 10x Gel-loading Buffer IV on a 1% agarose gel in 0.5x TBE buffer containing EtBr. The fragment of gel containing the assembled product was cut out and the DNA fragment was extracted using a QIAquick Gel Extraction Kit as described above.

The fragment was ligated into a vector using an Original TA Cloning Kit, as follows: 6 µL of purified DNA were transferred to a clean microfuge tube and 1 µL of 10x Ligation Buffer, 2 µL of pCR 2.1 vector (previously digested with KpnI and NotI), and 1 µL of T4 DNA Ligase were added and mixed. The reaction was incubated over night at 16°C. The ligation reaction mixture (3.5 µL) was used to transform One Shot competent cells as described above, 50 µL and 200 µL aliquots of the transformation reaction were plated on Luria-Bertani Medium containing 1% agarose, 1 mg/mL Glucose, 50 ng/mL Ampicillin and 1.6 ng/mL X-gal and grown as described above. White colored colonies were selected and

grown as described above. Plasmid DNA was isolated and purified using a QIAGEN Midi Plasmid Kit as described above. DNA was resuspended in 100 µL of sterile 1x TE buffer. This DNA was then sequenced using ABI 100 DNA sequencer (from ABI) by Tufts University Core Facility.

#### Identification of Four Genotypes of Dog P-glycoprotein

The dog P-glycoprotein identified in Example 1 is now termed genotype C. Sequencing of the DNA isolated from beagle liver as described in this example permitted the identification of three additional allelic variants of dog P-glycoprotein, termed genotypes A, B and D. the allelic differences in DNA sequence are set forth in Table 1 below.

**Table 1: Nucleotide and Amino Acid Differences Between Dog P-glycoprotein Genotypes (Allelic Variants)**

SEQ ID NO:		Genotype	Nucleotide position				Amino acid position			
DNA	Protein		91	607	1001	3458	25	197	329	1148
22	23	A	T	A	T	A	N	Q	S	M
24	25	B	A	A	T	A	K	Q	S	M
1	2	C	T	C	T	A	N	H	S	M
26	27	D	A	A	A	G	K	Q	T	V

Genotype A has a different nucleotide at base number 607 relative to SEQ ID NO:2. This is a base change from C to A in the DNA sequence which causes an amino acid change from Histidine to Glutamine at amino acid 197. Genotype B has different nucleotides at base number 91 and 607 relative to SEQ ID NO:2. The base change at position 91 is from T to A and causes an amino acid change from Asparagine to Lysine at amino acid 25. Base change at position 607 is identical to that in Genotype A. Genotype D has different nucleotides at base number 91, 607, 1001 and 3458 relative to SEQ ID NO:2. Base changes at position 91 and 607 are identical to that in Genotype B. The base change at position 1001 is from T to A and causes an amino acid change from Serine to Threonine at amino acid 329. The base change at position 3458 is from A to G and causes an amino acid change from Methionine to Valine at amino acid 1148.

A previously identified dog P-glycoprotein (SEQ ID NOs:3 and 4; GenBank Accession number AF045016), has 13 nucleotide differences from the genotype C dog P-glycoprotein nucleotide sequence (SEQ ID NO:1). There is a 3 base deletion at base 89 to

base 91 (relative to SEQ ID NO:1) leaving out AAT which causes a deletion of amino acid 25 Asparagine. There is a base change from A to G at position 590 which causes an amino acid change from Isoleucine to Valine at amino acid 192. There is a base change from C to A at position 607 which causing an amino acid change from Histidine to Glutamine at amino acid 5 197. There is a base change from G to C at position 651 which causes an amino acid change from Arginine to Proline at amino acid 212. There is a base change from G to A at position 878 which causes an amino acid change from Glycine to Arginine at amino acid 288. There is, a base change from T to A at position 1001 which causes an amino acid change from Serine to Threonine at amino acid 329. There is a base change from A to G at position 1012 10 which does not cause an amino acid change. This is a silent point mutation at Glutamine, amino acid 332. There is a base change from A to G at position 1611 which causes an amino acid change from Glutamine to Arginine at amino acid 532. There is a base change from A to T at position 2098 which does not cause an amino acid change. This is a silent point mutation at Valine, amino acid 694. There is a base change from C to T at position 2102 which causes 15 an amino acid change from Proline to Serine at amino acid 696. There is a base change from C to T at position 3808 which does not cause an amino acid change. This is a silent point mutation at Alanine, amino acid 1264. There is a base change from G to A at position 3833 which causes an amino acid change from Valine to Isoleucine at amino acid 1273. There is a base change from C to T at position 4080 which causes an amino acid change from Threonine 20 to Isoleucine at amino acid 1355.

Each of the foregoing patents, patent applications and references is hereby incorporated by reference. While the invention has been described with respect to certain embodiments, it should be appreciated that many modifications and changes may be made by 25 those of ordinary skill in the art without departing from the spirit of the invention. It is intended that such modification, changes and equivalents fall within the scope of the following claims.

What is claimed is:

**Claims**

1. An isolated nucleic acid molecule selected from the group consisting of
  - (a) nucleic acid molecules that code for the amino acid sequence of SEQ ID NO:2,
  - (b) allelic variants of (a), wherein the allelic variants exclude SEQ ID NO:3 and SEQ ID NO:5, and
  - (c) complements of (a) or (b).
2. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule codes for SEQ ID NO:2.
3. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid comprises the nucleotide sequence of SEQ ID NO:1.
4. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid comprises the coding region of SEQ ID NO:1.
5. The isolated nucleic acid molecule of claim 1, wherein the allelic variants are nucleic acid molecules that code for an amino acid sequence selected from the group consisting of SEQ ID NO:23, SEQ ID NO:25 and SEQ ID NO:27.
6. The isolated nucleic acid molecule of claim 5, wherein the allelic variant codes for SEQ ID NO:23.
7. The isolated nucleic acid molecule of claim 5, wherein the allelic variant codes for SEQ ID NO:25.
8. The isolated nucleic acid molecule of claim 5, wherein the allelic variant codes for SEQ ID NO:27.
9. The isolated nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:22, SEQ

ID NO:24 and SEQ ID NO:26.

10. The isolated nucleic acid molecule of claim 9, wherein the nucleotide sequence comprises SEQ ID NO:22.

11. The isolated nucleic acid molecule of claim 9, wherein the nucleotide sequence comprises SEQ ID NO:24.

12. The isolated nucleic acid molecule of claim 9, wherein the nucleotide sequence comprises SEQ ID NO:26.

13. The isolated nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a coding region of a nucleotide sequence selected from the group consisting of SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26.

14. An isolated P-glycoprotein polypeptide or fragment thereof which comprises at least one amino acid of a dog P-glycoprotein selected from the group consisting of amino acids 25, 192, 197, 212, 288, 329, 532, 696, 1273 and 1355 of SEQ ID NO:2; amino acid 25 of SEQ ID NO:25; and amino acids 25 and 1148 of SEQ ID NO:27.

15. An isolated P-glycoprotein polypeptide or fragment thereof which comprises at least one amino acid of a dog P-glycoprotein selected from the group consisting of amino acids 3, 6, 8, 10, 12, 14-26, 36, 38, 48, 52, 56, 64, 74, 78, 84-92, 94, 96, 98, 99, 101, 103, 104, 106, 108, 112, 115, 147, 187, 197, 199, 233, 288, 321, 326, 347, 397, 450, 454, 455, 467, 472, 520, 633, 637, 643, 644, 650, 657, 658, 661, 666, 667, 674-677, 679, 685, 689, 691, 693, 694, 703, 707, 717, 731, 736, 740, 744, 745, 756, 759, 763, 853, 914, 920, 942, 943, 946, 968-970, 972, 974, 983, 1005, 1010, 1017, 1025, 1026, 1029, 1040, 1095, 1098, 1105, 1144, 1148, 1149, 1158, 1162, 1165, 1168, 1170, 1252 and 1279 of SEQ ID NO:2; and amino acid 329 of SEQ ID NO:27, wherein the P-glycoprotein is identical to a human P-glycoprotein except for the at least one amino acid of a dog P-glycoprotein.

16. The isolated P-glycoprotein polypeptide or fragment thereof of claim 15, wherein the

human P-glycoprotein is selected from the group of SEQ ID NO:7 and SEQ ID NO:8.

17. The isolated P-glycoprotein polypeptide or fragment thereof of any of claims 14-16,  
wherein the amino acid sequence of the polypeptide or fragment thereof is an amino acid  
5 sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:23, SEQ ID  
NO:25, SEQ ID NO:27, fragments of SEQ ID NO:2, fragments of SEQ ID NO:23, fragments  
of SEQ ID NO:25 and fragments of SEQ ID NO:27.

18. An isolated nucleic acid molecule which encodes the isolated P-glycoprotein  
10 polypeptide or fragment thereof of any of claims 14-17.

19. An expression vector comprising the isolated nucleic acid molecule of claim 1  
operably linked to a promoter.

20. An expression vector comprising the isolated nucleic acid molecule of claim 18  
operably linked to a promoter.

21. A host cell transformed or transfected with the expression vector of claim 19.

22. A host cell transformed or transfected with the expression vector of claim 20.

23. An agent which selectively binds the isolated polypeptide of claim 14.

24. The method of claim 23, wherein the agent does not bind a human or dog P-  
25 glycoprotein.

25. The agent of claim 23, wherein the agent is a polypeptide.

26. The agent of claim 25, wherein the polypeptide is selected from the group consisting  
30 of monoclonal antibodies, polyclonal antibodies, Fab antibody fragments, F(ab)<sub>2</sub> antibody  
fragments and antibody fragments including a CDR3 region.

27. An agent which selectively binds the isolated nucleic acid molecule of claim 1 or claim 18.

28. The agent of claim 27, wherein the agent is an antisense nucleic acid which selectively  
5 binds to the isolated nucleic acid molecule.

29. A method for predicting the bioavailability of a compound, comprising  
measuring the transmembrane transport of a test compound by a first P-glycoprotein,  
comparing the transmembrane transport of the test compound by the first  
10 P-glycoprotein and a second P-glycoprotein to predict the bioavailability of the test  
compound, wherein the relative amount or rate of transport by the first P-glycoprotein and the  
second P-glycoprotein is predictive of bioavailability of the test compound.

30. The method of claim 29, wherein the first P-glycoprotein is selected from the group  
15 consisting of dog P-glycoproteins and primate P-glycoproteins.

31. The method of claim 29, wherein the first P-glycoprotein is the polypeptide of claims  
14-17.

32. The method of claim 29, wherein the second P-glycoprotein is a human P-  
glycoprotein.

33. A method for inhibiting P-glycoprotein transporter activity in a mammalian cell  
comprising  
25 contacting the mammalian cell with an amount of the agent of claim 27 effective to  
inhibit P-glycoprotein transporter activity in the mammalian cell.

34. A method for increasing bioavailability of a drug in a subject comprising  
administering to a subject in need of such treatment the agent of claim 27 in an amount  
30 effective to increasing bioavailability of a drug.

35. The method of claim 34, wherein the inhibitor is administered prior to administering



the drug.

36. The method of claim 34, wherein the inhibitor is administered concurrently with the drug.

37. A method for increasing P-glycoprotein transporter activity in a cell comprising contacting the cell with a molecule selected from the group consisting of the nucleic acid molecule of claim 1 and the nucleic acid molecule of claim 18, in an amount effective to increase P-glycoprotein transporter activity in the cell.

38. A method for identifying lead compounds for a pharmacological agent useful in the treatment of disease associated with P-glycoprotein transporter activity comprising providing a cell or other membrane-encapsulated space comprising a P-glycoprotein as claimed in claim 14 or 15;

contacting the cell or other membrane-encapsulated space with a candidate pharmacological agent under conditions which, in the absence of the candidate pharmacological agent, cause a first amount of P-glycoprotein transporter activity;

determining a second amount of P-glycoprotein transporter activity as a measure of the effect of the pharmacological agent on the P-glycoprotein transporter activity, wherein a second amount of P-glycoprotein transporter activity which is less than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which reduces P-glycoprotein transporter activity and wherein a second amount of P-glycoprotein transporter activity which is greater than the first amount indicates that the candidate pharmacological agent is a lead compound for a pharmacological agent which increases P-glycoprotein transporter activity.

39. The method of claim 38, further comprising the step of loading the cell or other membrane-encapsulated space with a detectable compound, wherein the compound is detected as a measure of the P-glycoprotein transporter activity.

40. A method for identifying compounds which selectively bind a P-glycoprotein comprising,

contacting the P-glycoprotein claimed in claim 14 or 15 with a compound,  
determining the binding of the compound to the P-glycoprotein.

41. The method of claim 40 further comprising determining the effect of the compound on  
5 the P-glycoprotein transporter activity of the P-glycoprotein.

42. The method of claim 40 further comprising determining the effect of the compound on  
the ATPase activity of the P-glycoprotein.

43. A method for determining ATPase activity of a P-glycoprotein comprising  
10 contacting the host cell of claim 20 or 22, or a membrane fraction thereof, with  
a test drug, and  
measuring ATPase activity of the P-glycoprotein.

44. The method of claim 43, wherein the step of measuring ATPase activity is performed  
15 at least twice at different times.

45. A method for determining transmembrane transport of a compound by a P-  
glycoprotein, comprising  
20 contacting the host cell of claim 20 or 22, or a membrane fraction thereof, with  
a test drug, and  
measuring transport of the test drug under sink conditions in at least one direction of  
transport selected from the group consisting of the apical to basolateral direction and the  
basolateral to apical direction.

46. The method of claim 45, wherein the step of measuring transport of the test drug is  
25 performed at least twice at different times.

**Abstract**

The invention pertains to dog P-glycoproteins and related P-glycoproteins which include dog-specific amino acids, as well as nucleic acids which encode those polypeptides.

- 5 The present invention also includes fragments and biologically functional variants of the dog P-glycoprotein. The invention further relates to methods of using such dog P-glycoprotein nucleic acids and polypeptides, especially in methods for determining bioavailability of drugs and for screening for inhibitors of dog PGP. Also included are dog PGP inhibitors which inhibit dog PGP activity by inhibiting the expression or function of dog PGP.

5	<110> Stocker, Penny J. Steimel-Crespi, Dorothy T. Crespi, Charles L. Rief, Timothy C Patten, Christopher J.	
10	<120> P-GLYCOPROTEINS AND USES THEREOF	
	<130> G0307/7017	
15	<150> US 60/156,510 <151> 1999-09-28	
	<160> 32	
20	<170> FastSEQ for Windows Version 3.0	
	<210> 1 <211> 4279 <212> DNA <213> Canis familiaris	
25	<220> <221> CDS <222> (17)... (3859)	
30	<400> 1 ggagcgcgag gtcggg atg gat cct gaa gga ggc cgt aag ggg agt gca gag	52
	Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu	
	1 5 10	
35	aag aac ttc tgg aaa atg ggc aaa aaa agt aaa aaa aat gag aag aaa	100
	Lys Asn Phe Trp Lys Met Gly Lys Lys Ser Lys Lys Asn Glu Lys Lys	
	15 20 25	
40	gaa aag aaa cca act gtc agc acg ttt gca atg ttt cgc tat tca aat	148
	Glu Lys Lys Pro Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn	
	30 35 40	
	tgg ctt gat agg ttg tat atg ttg gtg ggg aca atg gct gcc atc atc	196
45	Trp Leu Asp Arg Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile	
	45 50 55 60	
	cat gga gct gca ctc cct ctc atg atg ctg gtt ttt gga aac atg aca	244
50	His Gly Ala Ala Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr	
	65 70 75	
	gat agc ttt gca aat gca gga att tca aga aac aaa act ttt cca gtt	292
	Asp Ser Phe Ala Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val	
	80 85 90	
55	ata att aat gaa agt att acg aac aat aca caa cat ttc atc aac cat	340
	Ile Ile Asn Glu Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His	
	95 100 105	
60	ctg gag gag gaa atg acc acg tat gcc tat tat tac agt ggg atc ggt	388

	Leu	Glu	Glu	Glu	Met	Thr	Thr	Tyr	Ala	Tyr	Tyr	Ser	Gly	Ile	Gly	
	110						115					120				
5	gct	ggc	gtg	ctg	gtg	gct	gct	tac	atc	cag	gtt	tca	ttc	tg	g	ctg
	Ala	Gly	Val	Leu	Val	Ala	Ala	Tyr	Ile	Gln	Val	Ser	Phe	Trp	Cys	Leu
	125					130				135					140	436
10	gca	gca	gga	aga	cag	ata	ctc	aaa	att	aga	aaa	caa	ttt	ttt	cat	gct
	Ala	Ala	Gly	Arg	Gln	Ile	Leu	Lys	Ile	Arg	Lys	Gln	Phe	Phe	His	Ala
					145					150					155	484
15	atc	atg	cga	cag	gag	att	ggc	tg	ttt	gac	gtg	cat	gac	gtt	ggg	gag
	Ile	Met	Arg	Gln	Glu	Ile	Gly	Trp	Phe	Asp	Val	His	Asp	Val	Gly	Glu
				160					165					170		532
20	ctt	aac	acc	cgg	ctc	aca	gac	gat	gtc	tcc	aaa	atc	aat	gaa	gga	att
	Leu	Asn	Thr	Arg	Leu	Thr	Asp	Asp	Val	Ser	Lys	Ile	Asn	Glu	Gly	Ile
				175				180					185			580
25	ggc	gac	aaa	att	gga	atg	ttc	ttt	cac	tca	ata	gca	aca	ttt	ttc	acc
	Gly	Asp	Lys	Ile	Gly	Met	Phe	Phe	His	Ser	Ile	Ala	Thr	Phe	Phe	Thr
				190			195					200				628
30	ggt	ttt	ata	gtg	ggg	ttt	aca	cgt	ggt	tg	aag	cta	acc	ctt	gtg	att
	Gly	Phe	Ile	Val	Gly	Phe	Thr	Arg	Gly	Trp	Lys	Leu	Thr	Leu	Val	Ile
	205					210				215					220	676
35	ttg	gcc	atc	agc	cct	gtt	ctt	gga	ctt	tca	gcc	gcc	atc	tg	gca	aag
	Leu	Ala	Ile	Ser	Pro	Val	Leu	Gly	Leu	Ser	Ala	Ala	Ile	Trp	Ala	Lys
					225				230					235		724
40	ata	cta	tct	tca	ttt	act	gat	aaa	gaa	ctc	ttg	gcc	tat	gca	aaa	gct
	Ile	Leu	Ser	Ser	Phe	Thr	Asp	Lys	Glu	Leu	Leu	Ala	Tyr	Ala	Lys	Ala
				240				245						250		772
45	gga	gca	gta	gct	gaa	gaa	gtc	tta	gca	gca	atc	aga	act	gtg	att	gcc
	Gly	Ala	Val	Ala	Glu	Glu	Val	Leu	Ala	Ala	Ile	Arg	Thr	Val	Ile	Ala
				255			260						265			820
50	ttt	gga	gga	caa	aag	aaa	gaa	ctt	gaa	agg	tac	aac	aaa	aat	tta	gaa
	Phe	Gly	Gly	Gln	Lys	Lys	Glu	Leu	Glu	Arg	Tyr	Asn	Lys	Asn	Leu	Glu
		270				275						280				868
55	gaa	gct	aaa	gga	att	ggg	ata	aag	aaa	gct	atc	acg	gcc	aac	att	tct
	Glu	Ala	Lys	Gly	Ile	Gly	Ile	Lys	Lys	Ala	Ile	Thr	Ala	Asn	Ile	Ser
						290				295					300	916
60	att	ggt	gcc	gct	ttc	tta	ttg	atc	tat	gca	tca	tat	gct	ctg	gct	ttc
	Ile	Gly	Ala	Ala	Phe	Leu	Leu	Ile	Tyr	Ala	Ser	Tyr	Ala	Leu	Ala	Phe
					305				310					315		964
65	tg	tat	ggg	acc	tcc	ttg	gtc	ctc	tcc	agt	gaa	tat	tct	att	gga	caa
	Trp	Tyr	Gly	Thr	Ser	Leu	Val	Leu	Ser	Ser	Glu	Tyr	Ser	Ile	Gly	Gln
				320					325					330		1012
70	gta	ctc	act	gtc	ttc	ttt	tct	gta	tta	att	ggg	gct	ttt	agt	att	gga
	Val	Leu	Thr	Val	Phe	Phe	Ser	Val	Leu	Ile	Gly	Ala	Phe	Ser	Ile	Gly
				335				340					345			1060
75	cag	gca	tcc	cca	agc	att	gaa	gca	ttt	gca	aac	gca	aga	gga	gca	gct
																1108

00000-00000-00000-00000

	Gln	Ala	Ser	Pro	Ser	Ile	Glu	Ala	Phe	Ala	Asn	Ala	Arg	Gly	Ala	Ala	
	350						355					360					
5	tat	gaa	atc	ttc	aag	ata	att	gac	aat	aaa	cca	agc	att	gac	agc	tat	1156
	Tyr	Glu	Ile	Phe	Lys	Ile	Ile	Asp	Asn	Lys	Pro	Ser	Ile	Asp	Ser	Tyr	
	365					370					375					380	
10	tcg	aag	agt	gga	cat	aaa	cca	gat	aat	att	aag	gga	aat	ttg	gaa	ttc	1204
	Ser	Lys	Ser	Gly	His	Lys	Pro	Asp	Asn	Ile	Lys	Gly	Asn	Leu	Glu	Phe	
					385					390					395		
15	aaa	aat	gtt	cac	ttc	agt	tac	cct	tct	cga	aaa	gaa	gtt	aag	atc	tta	1252
	Lys	Asn	Val	His	Phe	Ser	Tyr	Pro	Ser	Arg	Lys	Glu	Val	Lys	Ile	Leu	
				400					405					410			
20	aag	ggt	ctc	aac	ctg	aag	gtt	cag	agt	ggg	cag	aca	gtg	gcg	ctg	gtt	1300
	Lys	Gly	Leu	Asn	Leu	Lys	Val	Gln	Ser	Gly	Gln	Thr	Val	Ala	Leu	Val	
			415					420					425				
25	ggg	aac	agt	ggc	tgc	ggg	aag	agc	acg	acc	gtg	cag	ctg	atg	cag	agg	1348
	Gly	Asn	Ser	Gly	Cys	Gly	Lys	Ser	Thr	Thr	Val	Gln	Leu	Met	Gln	Arg	
				430			435					440					
30	ctc	tat	gac	ccc	aca	gat	ggc	atg	gtc	tgt	att	gat	gga	cag	gac	att	1396
	Leu	Tyr	Asp	Pro	Thr	Asp	Gly	Met	Val	Cys	Ile	Asp	Gly	Gln	Asp	Ile	
	445					450					455					460	
35	agg	acc	ata	aat	gta	agg	cat	ctt	cgg	gaa	att	act	ggt	gtg	gtg	agt	1444
	Arg	Thr	Ile	Asn	Val	Arg	His	Leu	Arg	Glu	Ile	Thr	Gly	Val	Val	Ser	
					465					470					475		
40	cag	gag	cct	gtg	ttg	ttt	gcc	acc	acg	ata	gct	gaa	aac	att	cgc	tat	1492
	Gln	Glu	Pro	Val	Leu	Phe	Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	
				480					485					490			
45	ggc	cgc	gaa	aat	gtc	acc	atg	gat	gag	att	gag	aaa	gct	gtt	aag	gaa	1540
	Gly	Arg	Glu	Asn	Val	Thr	Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	
			495					500					505				
50	gcc	aat	gcc	tat	gat	ttt	atc	atg	aaa	cta	cct	aat	aaa	ttt	gac	act	1588
	Ala	Asn	Ala	Tyr	Asp	Phe	Ile	Met	Lys	Leu	Pro	Asn	Lys	Phe	Asp	Thr	
							515					520					
55	ctg	gtt	gga	gag	aga	ggg	gcc	cag	ctg	agt	ggt	gga	cag	aaa	cag	aga	1636
	Leu	Val	Gly	Glu	Arg	Gly	Ala	Gln	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	
						530					535					540	
60	atc	gcc	att	gct	cgg	gcc	ctg	gtt	cgc	aac	ccc	aag	att	ctt	ctg	ctg	1684
	Ile	Ala	Ile	Ala	Arg	Ala	Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Leu	
					545					550					555		
65	gat	gag	gca	acg	tca	gct	ctg	gac	act	gaa	agt	gaa	gca	gtg	gtt	cag	1732
	Asp	Glu	Ala	Thr	Ser	Ala	Leu	Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	
				560					565					570			
70	gtg	gcc	ctg	gat	aag	gcc	aga	aaa	ggc	cgg	act	acc	att	gtg	ata	gct	1780
	Val	Ala	Leu	Asp	Lys	Ala	Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	
				575				580					585				
75	cat	cgt	ttg	tct	aca	gtt	cgt	aat	gcc	gat	gtc	att	gct	ggt	ttt	gat	1828

	His Arg Leu Ser Thr Val Arg Asn Ala Asp Val Ile Ala Gly Phe Asp	
	590 595 600	
5	gat gga gtc att gtg gag aaa gga aat cat gat gaa ctc atg aaa gag Asp Gly Val Ile Val Glu Lys Gly Asn His Asp Glu Leu Met Lys Glu	1876
	605 610 615 620	
10	aag ggc att tac ttc aaa ctt gtc aca atg cag aca aga gga aat gaa Lys Gly Ile Tyr Phe Lys Leu Val Thr Met Gln Thr Arg Gly Asn Glu	1924
	625 630 635	
15	att gag tta gaa aat gcc act ggt gaa tcc aaa agt gaa agt gat gcc Ile Glu Leu Glu Asn Ala Thr Gly Glu Ser Lys Ser Glu Ile Lys Ser Asp Ala	1972
	640 645 650	
	ttg gaa atg tct cca aaa gat tca ggg tcc agt tta ata aaa aga aga Leu Glu Met Ser Pro Lys Asp Ser Gly Ser Ser Leu Lys Arg Arg	2020
	655 660 665	
20	tca act cgc agg agt ata cat gca cca caa ggc caa gac aga aag ctt Ser Thr Arg Arg Ser Ile His Ala Pro Gln Gly Gln Asp Arg Lys Leu	2068
	670 675 680	
25	ggg aca aaa gag gac ttg aat gag aat gta cct cca gtt tcc ttc tgg Gly Thr Lys Glu Asp Leu Asn Glu Asn Val Pro Pro Val Ser Phe Trp	2116
	685 690 695 700	
30	agg att ctg aag ctg aac tca act gaa tgg cct tat ttt gtg gtt ggt Arg Ile Leu Lys Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly	2164
	705 710 715	
35	ata ttt tgt gct att ata aac gga ggc ctg caa cca gca ttt tca ata Ile Phe Cys Ala Ile Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile	2212
	720 725 730	
	ata ttt tca agg att ata ggg atc ttt acc cga gat gag gat cct gaa Ile Phe Ser Arg Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu	2260
	735 740 745	
40	aca aaa cga cag aat agt aac atg ttt tct gta ttg ttt cta gtc ctt Thr Lys Arg Gln Asn Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu	2308
	750 755 760	
45	gga att att tct ttt att aca ttt ttc ctg cag ggc ttc aca ttt ggc Gly Ile Ile Ser Phe Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly	2356
	765 770 775 780	
50	aaa gct ggg gag atc ctg act aag cgg ctt cga tac atg gtt ttc aga Lys Ala Gly Glu Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg	2404
	785 790 795	
55	tcc atg ctg aga cag gat gtc agc tgg ttt gat gac cct aaa aac acc Ser Met Leu Arg Gln Asp Val Ser Trp Phe Asp Asp Pro Lys Asn Thr	2452
	800 805 810	
	act gga gca ttg aca acc agg ctt gcc aat gat gcg gct caa gtt aaa Thr Gly Ala Leu Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys	2500
	815 820 825	
60	ggg gct ata ggt tcc agg ctt gct gtc att acc cag aat ata gca aat	2548

096727235.092000

	Gly Ala Ile Gly Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn	
	830 835 840	
5	ctt ggg aca ggc att att ata tcc tta atc tat ggt tgg caa tta aca Leu Gly Thr Gly Ile Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr	2596
	845 850 855 860	
10	ctt tta ctc tta gca att gta ccc atc att gca ata gca gga gtt gtt Leu Leu Leu Leu Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val	2644
	865 870 875	
15	gaa atg aaa atg ttg tct gga caa gca ctg aaa gat aag aaa gag cta Glu Met Lys Met Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu	2692
	880 885 890	
	gaa gga gct ggg aag att gct aca gaa gcc atc gaa aac ttc cga act Glu Gly Ala Gly Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr	2740
	895 900 905	
20	gtt gtt tct ttg act cgg gag cag aag ttt gaa tac atg tat gca cag Val Val Ser Leu Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln	2788
	910 915 920	
25	agt ttg caa gta cca tac aga aac tct ttg agg aaa gca cac atc ttc Ser Leu Gln Val Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe	2836
	925 930 935 940	
30	ggg gtc tca ttt tct atc acc cag gca atg atg tat ttt tcc tat gct Gly Val Ser Phe Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala	2884
	945 950 955	
35	ggc tgt ttc cgg ttt ggt gcc tac ttg gtg gca aat gag ttc atg aac Gly Cys Phe Arg Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn	2932
	960 965 970	
	ttt cag gat gtt ctt ttg gta ttc tca gct att gtc ttt ggt gcc atg Phe Gln Asp Val Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met	2980
	975 980 985	
40	gca gtg ggg cag gtc agt tca ttt gct cct gac tat gcc aaa gcc aaa Ala Val Gly Gln Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys	3028
	990 995 1000	
45	gta tca gca gcc cac gtc atc atg atc att gaa aaa agc cct ctg att Val Ser Ala Ala His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile	3076
	1005 1010 1015 1020	
50	gac agc tac agc cct cac ggc ctc aag cca aat acg ttg gaa gga aat Asp Ser Tyr Ser Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn	3124
	1025 1030 1035	
	gtg aca ttt aat gag gtc gtg ttc aac tat ccc act cga cca gac atc Val Thr Phe Asn Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile	3172
	1040 1045 1050	
55	ccc gtg ctc cag ggg ctg agc ctc gag gtg aag aag ggc cag acg ctg Pro Val Leu Gln Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu	3220
	1055 1060 1065	
60	gcc ctc gta ggt agc agt ggc tgt ggg aag agc aca gtt gtt cag ctc	3268

00672736.092800



	Ala	Leu	Val	Gly	Ser	Ser	Gly	Cys	Gly	Lys	Ser	Thr	Val	Val	Gln	Leu	
	1070						1075				1080						
5	cta	gag	cgc	ttc	tat	gac	ccc	ttg	gct	ggt	tca	gtg	cta	att	gat	ggc	3316
	Leu	Arg	Glu	Phe	Tyr	Asp	Pro	Leu	Ala	Gly	Ser	Val	Leu	Ile	Asp	Gly	
	1085					1090					1095				1100		
	aaa	gag	ata	aag	cac	ctg	aat	gtc	cag	tgg	ctc	cga	gca	cac	ctg	ggc	3364
	Lys	Glu	Ile	Lys	His	Leu	Asn	Val	Gln	Trp	Leu	Arg	Ala	His	Leu	Gly	
10					1105					1110					1115		
	atc	gtg	tct	cag	gag	atc	ctg	ttt	gac	tgc	agc	att	gcc	gag	aac		3412
	Ile	Val	Ser	Gln	Glu	Pro	Ile	Leu	Phe	Asp	Cys	Ser	Ile	Ala	Glu	Asn	
					1120					1125				1130			
15	att	gcc	tat	gga	gac	aac	agc	cgg	gtc	gta	tca	cat	gaa	gag	att	atg	3460
	Ile	Ala	Tyr	Gly	Asp	Asn	Ser	Arg	Val	Val	Ser	His	Glu	Glu	Ile	Met	
					1135			1140					1145				
20	cag	gca	gcc	aag	gag	gcc	aac	ata	cac	cac	ttc	atc	gag	aca	ctc	oct	3508
	Gln	Ala	Ala	Lys	Glu	Ala	Asn	Ile	His	His	Phe	Ile	Glu	Thr	Leu	Pro	
						1150		1155				1160					
25	gag	aaa	tac	aac	acc	aga	gta	gga	gac	aaa	gga	acc	cag	ctc	tct	ggt	3556
	Glu	Lys	Tyr	Asn	Thr	Arg	Val	Gly	Asp	Lys	Gly	Thr	Gln	Leu	Ser	Gly	
						1165		1170			1175				1180		
	ggc	cag	aaa	cag	cgc	att	gcc	ata	gct	cgc	gct	ctt	ggt	aga	cag	cct	3604
	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	Ala	Arg	Ala	Leu	Val	Arg	Gln	Pro	
30					1185					1190				1195			
	cat	att	ttg	ctt	ttg	gat	gaa	gct	aca	tca	gct	ctg	gat	aca	gaa	agt	3652
	His	Ile	Leu	Leu	Leu	Asp	Glu	Ala	Thr	Ser	Ala	Leu	Asp	Thr	Glu	Ser	
					1200				1205				1210				
35	gaa	aag	gtt	gtc	caa	gaa	gcc	ctg	gac	aaa	gcc	aga	gaa	ggc	cgc	acc	3700
	Glu	Lys	Val	Val	Gln	Glu	Ala	Leu	Asp	Lys	Ala	Arg	Glu	Gly	Arg	Thr	
					1215			1220				1225					
40	tgc	att	gtg	atc	gcc	cac	cgc	ttg	tcc	acc	atc	cag	aat	gca	gat	tta	3748
	Cys	Ile	Val	Ile	Ala	His	Arg	Leu	Ser	Thr	Ile	Gln	Asn	Ala	Asp	Leu	
					1230			1235				1240					
45	ata	gtg	gtg	ttt	cag	aat	ggc	aaa	gtc	aag	gag	cat	ggc	aca	cat	caa	3796
	Ile	Val	Val	Phe	Gln	Asn	Gly	Lys	Val	Lys	Glu	His	Gly	Thr	His	Gln	
					1245		1250			1255					1260		
	cag	ctg	ctg	gcc	cag	aaa	ggc	atc	tat	ttt	tcc	atg	gtc	agt	gtc	cag	3844
	Gln	Leu	Leu	Ala	Gln	Lys	Gly	Ile	Tyr	Phe	Ser	Met	Val	Ser	Val	Gln	
50					1265					1270				1275			
	gct	gga	gca	aag	cgc	tagtgaactg	tgggccatag	agctgtttaa	tattttttaa								3899
	Ala	Gly	Ala	Lys	Arg												
					1280												
55	tatttgtgtt	aaaacatggc	atttaaatcaa	agttaaaag	tgagcactta	ctggaaaaac											3959
	tatgtagaac	tacctgttta	acatttctgt	ctgcgaactga	agatcatctc	accaagttca											4019
	gagctctcag	attttataat	taaaaggaacc	aaaagaaaca	ttactgtgat	gaataaataa											4079
	ctggtgttta	ttgcattata	aaattataga	gtaattcaaa	gtagattttg	ttaataaatt											4139
60	qtataatttt	tgtttatatt	ttattttgaa	cttactgctt	tgctgaaaga	ttatagaagt											4199

ggtaaaagt actgaatgtt tgaataaagt gctagctata ataaaactaa acttttatat 4259  
 caaaaaaaaa aaaaaaaaaa

5 <210> 2  
 <211> 1281  
 <212> PRT  
 <213> Canis familiaris

<400> 2

10 Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu Lys Asn Phe Trp  
 1 5 10 15  
 Lys Met Gly Lys Lys Ser Lys Lys Asn Glu Lys Lys Glu Lys Lys Pro  
 20 25 30

15 Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn Trp Leu Asp Arg  
 35 40 45  
 Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile His Gly Ala Ala  
 50 55 60  
 Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe Ala  
 65 70 75 80

20 Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val Ile Ile Asn Glu  
 85 90 95  
 Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His Leu Glu Glu Glu  
 100 105 110  
 Met Thr Thr Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu  
 115 120 125

25 Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg  
 130 135 140  
 Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln  
 145 150 155 160

30 Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg  
 165 170 175  
 Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile Gly Asp Lys Ile  
 180 185 190  
 Gly Met Phe Phe His Ser Ile Ala Thr Phe Phe Thr Gly Phe Ile Val  
 195 200 205

35 Gly Phe Thr Arg Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile Ser  
 210 215 220  
 Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys Ile Leu Ser Ser  
 225 230 235 240

40 Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Gly Ala Val Ala  
 245 250 255  
 Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly Gln  
 260 265 270  
 Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys Gly  
 275 280 285

45 Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser Ile Gly Ala Ala  
 290 295 300  
 Phe Leu Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr  
 305 310 315 320

50 Ser Leu Val Leu Ser Ser Glu Tyr Ser Ile Gly Gln Val Leu Thr Val  
 325 330 335  
 Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly Gln Ala Ser Pro  
 340 345 350  
 Ser Ile Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala Tyr Glu Ile Phe  
 355 360 365

55 Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr Ser Lys Ser Gly  
 370 375 380  
 His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe Lys Asn Val His  
 385 390 395 400

60 Phe Ser Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu Lys Gly Leu Asn

09672725-096800

[illegible]

885 890 895  
 Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser Leu  
 900 905 910  
 Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln Ser Leu Gln Val  
 915 920 925  
 5 Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe Gly Val Ser Phe  
 930 935 940  
 Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe Arg  
 945 950 955 960  
 10 Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn Phe Gln Asp Val  
 965 970 975  
 Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met Ala Val Gly Gln  
 980 985 990  
 15 Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys Val Ser Ala Ala  
 995 1000 1005  
 His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile Asp Ser Tyr Ser  
 1010 1015 1020  
 Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Asn  
 1025 1030 1035 104  
 20 Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln  
 1045 1050 1055  
 Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly  
 1060 1065 1070  
 Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe  
 1075 1080 1085  
 25 Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly Lys Glu Ile Lys  
 1090 1095 1100  
 His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln  
 1105 1110 1115 1120  
 30 Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly  
 1125 1130 1135  
 Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Met Gln Ala Ala Lys  
 1140 1145 1150  
 35 Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro Glu Lys Tyr Asn  
 1155 1160 1165  
 Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln  
 1170 1175 1180  
 Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu  
 1185 1190 1195 1200  
 40 Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val  
 1205 1210 1215  
 Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile  
 1220 1225 1230  
 Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe  
 1235 1240 1245  
 45 Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala  
 1250 1255 1260  
 Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Ala Lys  
 1265 1270 1275 1280  
 50 Arg

<210> 3  
 <211> 4317  
 <212> DNA  
 <213> Canis familiaris

<220>  
 <221> CDS  
 60 <222> (70)... (3912)

003225-09300

	<400> 3																		
	ctaagtccgga gtatcttctt cccaattctc ctcttcggtg gaggttcgca aggaagccc																		60
5	gaggtgacg atg gat cct gaa gga ggc cgt aag ggg agt gca gag aag aac																		111
	Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu Lys Asn																		
	1 5 10																		
	ttc tgg aaa atg ggc aaa aaa agt aaa aaa gag aag aaa gaa aag aaa																		159
10	Phe Trp Lys Met Gly Lys Lys Ser Lys Lys Glu Lys Lys Glu Lys Lys																		
	15 20 25 30																		
	cca act gtc agc acg ttt gca atg ttt cgc tat tca aat tgg ctt gat																		207
	Pro Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn Trp Leu Asp																		
15	35 40 45																		
	agg ttg tat atg ttg gtg ggg aca atg gct gcc atc atc cat gga gct																		255
	Arg Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile His Gly Ala																		
	50 55 60																		
20	gca ctc cct ctc atg atg ctg gtt ttt gga aac atg aca gat agc ttt																		303
	Ala Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe																		
	65 70 75																		
25	gca aat gca gga att tca aga aac aaa act ttt cca gtt ata att aat																		351
	Ala Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val Ile Ile Asn																		
	80 85 90																		
	gaa agt att acg aac aat aca caa cat ttc atc aac cat ctg gag gag																		399
30	Glu Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His Leu Glu Glu																		
	95 100 105 110																		
	gaa atg acc acg tat gcc tat tat tac agt ggg atc ggt gct gcc gtg																		447
	Glu Met Thr Thr Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val																		
35	115 120 125																		
	ctg gtg gct gct tac atc cag gtt tca ttc tgg tgc ctg gca gca gga																		495
	Leu Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly																		
	130 135 140																		
40	aga cag ata ctc aaa att aga aaa caa ttt cat got atc atg cga																		543
	Arg Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg																		
	145 150 155																		
45	cag gag att ggc tgg ttt gac gtg cat gac gtt ggg gag ctt aac acc																		591
	Gln Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr																		
	160 165 170																		
	cgg ctc aca gac gat gtc tcc aaa atc aat gaa gga att ggc gac aaa																		639
50	Arg Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile Gly Asp Lys																		
	175 180 185 190																		
	gtt gga atg ttc ttt caa tca ata gca aca ttt ttc acc ggt ttt ata																		687
	Val Gly Met Phe Phe Gln Ser Ile Ala Thr Phe Phe Thr Gly Phe Ile																		
55	195 200 205																		
	gtg ggg ttt aca cct ggt tgg aag cta acc ctt gtg att ttg gcc atc																		735
	Val Gly Phe Thr Pro Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile																		
	210 215 220																		
60	agc cct gtt ctt gga ctt tca gcc gcc atc tgg gca aag ata cta tct																		783

	Ser	Pro	Val	Leu	Gly	Leu	Ser	Ala	Ala	Ile	Trp	Ala	Lys	Ile	Leu	Ser	
	225							230					235				
5	tca	ttt	act	gat	aaa	gaa	ctc	ttg	gcc	tat	gca	aaa	gct	gga	gca	gta	831
	Ser	Phe	Thr	Asp	Lys	Glu	Leu	Leu	Ala	Tyr	Ala	Lys	Ala	Gly	Ala	Val	
	240						245					250					
10	gct	gaa	gaa	gtc	tta	gca	gca	atc	aga	act	gtg	att	gcc	ttt	gga	gga	879
	Ala	Glu	Glu	Val	Leu	Ala	Ala	Ile	Arg	Thr	Val	Ile	Ala	Phe	Gly	Gly	
	255					260					265				270		
15	caa	aag	aaa	gaa	ctt	gaa	agg	tac	aac	aaa	aat	tta	gaa	gaa	gct	aaa	927
	Gln	Lys	Lys	Glu	Leu	Glu	Arg	Tyr	Asn	Lys	Asn	Leu	Glu	Glu	Ala	Lys	
					275					280					285		
	aga	att	ggg	ata	aag	aaa	gct	atc	acg	gcc	aac	att	tct	att	ggt	gcc	975
	Arg	Ile	Gly	Ile	Lys	Lys	Ala	Ile	Thr	Ala	Asn	Ile	Ser	Ile	Gly	Ala	
					290				295					300			
20	gct	ttc	tta	ttg	atc	tat	gca	tca	tat	gct	ctg	gct	ttc	tgg	tat	ggg	1023
	Ala	Phe	Leu	Leu	Ile	Tyr	Ala	Ser	Tyr	Ala	Leu	Ala	Phe	Trp	Tyr	Gly	
					305			310						315			
25	acc	tcc	ttg	gtc	ctc	tcc	agt	gaa	tat	act	att	gga	cag	gta	ctc	act	1071
	Thr	Ser	Leu	Val	Leu	Ser	Ser	Glu	Tyr	Thr	Ile	Gly	Gln	Val	Leu	Thr	
		320					325					330					
30	gtc	ttc	ttt	tct	gta	tta	att	ggg	gct	ttt	agt	att	gga	cag	gca	tcc	1119
	Val	Phe	Phe	Ser	Val	Leu	Ile	Gly	Ala	Phe	Ser	Ile	Gly	Gln	Ala	Ser	
	335					340					345					350	
35	cca	agc	att	gaa	gca	ttt	gca	aac	gca	aga	gga	gca	gct	tat	gaa	atc	1167
	Pro	Ser	Ile	Glu	Ala	Phe	Ala	Asn	Ala	Arg	Gly	Ala	Ala	Tyr	Glu	Ile	
					355					360					365		
	ttc	aag	ata	att	gac	aat	aaa	cca	agc	att	gac	agc	tat	tgc	aag	agt	1215
	Phe	Lys	Ile	Ile	Asp	Asn	Lys	Pro	Ser	Ile	Asp	Ser	Tyr	Ser	Lys	Ser	
					370				375					380			
40	gga	cat	aaa	cca	gat	aat	att	aag	gga	aat	ttg	gaa	ttc	aaa	aat	gtt	1263
	Gly	His	Lys	Pro	Asp	Asn	Ile	Lys	Gly	Asn	Leu	Glu	Phe	Lys	Asn	Val	
					385			390					395				
45	cac	ttc	agt	tac	cct	tct	cga	aaa	gaa	gtt	aag	atc	tta	aag	ggt	ctc	1311
	His	Phe	Ser	Tyr	Pro	Ser	Arg	Lys	Glu	Val	Lys	Ile	Leu	Lys	Gly	Leu	
		400					405					410					
50	aac	ctg	aag	gtt	cag	agt	ggg	cag	aca	gtg	gcg	ctg	gtt	ggg	aac	agt	1359
	Asn	Leu	Lys	Val	Gln	Ser	Gly	Gln	Thr	Val	Ala	Leu	Val	Gly	Asn	Ser	
	415					420					425				430		
55	ggc	tgc	ggg	aag	agc	acc	gtg	cag	ctg	atg	cag	agg	ctc	tat	gac		1407
	Gly	Cys	Gly	Lys	Ser	Thr	Thr	Val	Gln	Leu	Met	Gln	Arg	Leu	Tyr	Asp	
					435				440					445			
	ccc	aca	gat	ggc	atg	gtc	tgt	att	gat	gga	cag	gac	att	agg	acc	ata	1455
	Pro	Thr	Asp	Gly	Met	Val	Cys	Ile	Asp	Gly	Gln	Asp	Ile	Arg	Thr	Ile	
					450				455					460			
60	aat	gta	agg	cat	ctt	cgg	gaa	att	act	ggt	gtg	gtg	agt	cag	gag	cct	1503

00672725-002800

	Asn	Val	Arg	His	Leu	Arg	Glu	Ile	Thr	Gly	Val	Val	Ser	Gln	Glu	Pro	
			465					470					475				
5	gtg	ttg	ttt	gcc	acc	acg	ata	gct	gaa	aac	att	cgc	tat	ggc	cgc	gaa	1551
	Val	Leu	Phe	Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	Gly	Arg	Glu	
		480					485					490					
10	aat	gtc	acc	atg	gat	gag	att	gag	aaa	gct	gtt	aag	gaa	gcc	aat	gcc	1599
	Asn	Val	Thr	Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	Ala	Asn	Ala	
	495					500					505				510		
15	tat	gat	ttt	atc	atg	aaa	cta	cct	aat	aaa	ttt	gac	act	ctg	gtt	gga	1647
	Tyr	Asp	Phe	Ile	Met	Lys	Leu	Pro	Asn	Lys	Phe	Asp	Thr	Leu	Val	Gly	
					515					520					525		
20	gag	aga	ggg	gcc	cgg	ctg	agt	ggt	gga	cag	aaa	cag	aga	atc	gcc	att	1695
	Glu	Arg	Gly	Ala	Arg	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	
				530					535					540			
25	gct	cgg	gcc	ctg	gtt	cgc	aac	ccc	aag	att	ctt	ctg	ctg	gat	gag	gca	1743
	Ala	Arg	Ala	Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Leu	Asp	Glu	Ala	
			545					550					555				
30	acg	tca	gct	ctg	gac	act	gaa	agt	gaa	gca	gtg	gtt	cag	gtg	gcc	ctg	1791
	Thr	Ser	Ala	Leu	Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	Val	Ala	Leu	
			560				565					570					
35	gat	aag	gcc	aga	aaa	ggc	cgg	act	acc	att	gtg	ata	gct	cat	cgt	ttg	1839
	Asp	Lys	Ala	Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	His	Arg	Leu	
	575					580					585					590	
40	tct	aca	gtt	cgt	aat	gcc	gat	gtc	att	gct	ggt	ttt	gat	gat	gga	gtc	1887
	Ser	Thr	Val	Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	Asp	Gly	Val	
					595					600					605		
45	att	gtg	gag	aaa	gga	aat	cat	gat	gaa	ctc	atg	aaa	gag	aag	ggc	att	1935
	Ile	Val	Glu	Lys	Gly	Asn	His	Asp	Glu	Leu	Met	Lys	Glu	Lys	Gly	Ile	
				610					615					620			
50	tac	tto	aaa	ctt	gtc	aca	atg	cag	aca	aga	gga	aat	gaa	att	gag	tta	1983
	Tyr	Phe	Lys	Leu	Val	Thr	Met	Gln	Thr	Arg	Gly	Asn	Glu	Ile	Glu	Leu	
			625					630					635				
55	gaa	aat	gcc	act	ggt	gaa	tcc	aaa	agt	gaa	agt	gat	gcc	ttg	gaa	atg	2031
	Glu	Asn	Ala	Thr	Gly	Glu	Ser	Lys	Ser	Glu	Ser	Asp	Ala	Leu	Glu	Met	
			640				645					650					
60	tct	cca	aaa	gat	tca	ggg	tcc	agt	tta	ata	aaa	aga	aga	tca	act	cgc	2079
	Ser	Pro	Lys	Asp	Ser	Gly	Ser	Ser	Leu	Ile	Lys	Arg	Arg	Ser	Thr	Arg	
	655					660					665					670	
65	agg	agt	ata	cat	gca	cca	ggc	caa	gac	aga	aag	ctt	ggt	aca	aaa		2127
	Arg	Ser	Ile	His	Ala	Pro	Gln	Gly	Gln	Asp	Arg	Lys	Leu	Gly	Thr	Lys	
					675				680					685			
70	gag	gac	ttg	aat	gag	aat	gtt	cct	tca	gtt	tcc	ttc	tgg	agg	att	ctg	2175
	Glu	Asp	Leu	Asn	Glu	Asn	Val	Pro	Ser	Val	Ser	Phe	Trp	Arg	Ile	Leu	
				690					695					700			
75	aag	ctg	aac	tca	act	gaa	tgg	cct	tat	ttt	gtg	gtt	ggt	ata	ttt	tgt	2223

09672725-092800

	Lys	Leu	Asn	Ser	Thr	Glu	Trp	Pro	Tyr	Phe	Val	Val	Gly	Ile	Phe	Cys	
			705					710					715				
5	gct	att	ata	aac	gga	ggc	ctg	caa	cca	gca	ttt	tca	ata	ata	ttt	tca	2271
	Ala	Ile	Ile	Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ser	Ile	Ile	Phe	Ser	
		720					725					730					
10	agg	att	ata	ggg	atc	ttt	acc	cga	gat	gag	gat	cct	gaa	aca	aaa	cga	2319
	Arg	Ile	Ile	Gly	Ile	Phe	Thr	Arg	Asp	Glu	Asp	Pro	Glu	Thr	Lys	Arg	
		735			740					745					750		
15	cag	aat	agt	aac	atg	ttt	tct	gta	ttg	ttt	cta	gtc	ctt	gga	att	att	2367
	Gln	Asn	Ser	Asn	Met	Phe	Ser	Val	Leu	Phe	Leu	Val	Leu	Gly	Ile	Ile	
					755					760					765		
	tct	ttt	att	aca	ttt	ttc	ctc	cag	ggc	ttc	aca	ttt	ggc	aaa	gct	ggg	2415
	Ser	Phe	Ile	Thr	Phe	Phe	Leu	Gln	Gly	Phe	Thr	Phe	Gly	Lys	Ala	Gly	
				770					775					780			
20	gag	atc	ctc	act	aag	cgg	ctt	cga	tac	atg	gtt	ttc	aga	tcc	atg	ctg	2463
	Glu	Ile	Leu	Thr	Lys	Arg	Leu	Arg	Tyr	Met	Val	Phe	Arg	Ser	Met	Leu	
				785				790					795				
25	aga	cag	gat	gtc	agc	tgg	ttt	gat	gac	cct	aaa	aac	acc	act	gga	gca	2511
	Arg	Gln	Asp	Val	Ser	Trp	Phe	Asp	Asp	Pro	Lys	Asn	Thr	Thr	Gly	Ala	
		800					805					810					
30	ttg	aca	acc	agg	ctt	gcc	aat	gat	gcg	gct	caa	gtt	aaa	ggg	gct	ata	2559
	Leu	Thr	Thr	Arg	Leu	Ala	Asn	Asp	Ala	Ala	Gln	Val	Lys	Gly	Ala	Ile	
		815				820					825				830		
35	ggt	tcc	agg	ctt	gct	gtc	att	acc	cag	aat	ata	gca	aat	ctt	ggg	aca	2607
	Gly	Ser	Arg	Leu	Ala	Val	Ile	Thr	Gln	Asn	Ile	Ala	Asn	Leu	Gly	Thr	
					835					840					845		
	ggc	att	att	ata	tcc	tta	atc	tat	ggt	tgg	caa	tta	aca	ctt	tta	ctc	2655
	Gly	Ile	Ile	Ile	Ser	Leu	Ile	Tyr	Gly	Trp	Gln	Leu	Thr	Leu	Leu	Ser	
				850					855					860			
40	tta	gca	att	gta	ccc	atc	att	gca	ata	gca	gga	gtt	gtt	gaa	atg	aaa	2703
	Leu	Ala	Ile	Val	Pro	Ile	Ile	Ala	Ile	Ala	Gly	Val	Val	Glu	Met	Lys	
				865				870						875			
45	atg	ttg	tct	gga	caa	gca	ctg	aaa	gat	aag	aaa	gag	cta	gaa	gga	gct	2751
	Met	Leu	Ser	Gly	Gln	Ala	Leu	Lys	Asp	Lys	Lys	Glu	Leu	Glu	Gly	Ala	
		880					885					890					
50	ggg	aag	att	gct	aca	gaa	gcc	atc	gaa	aac	ttc	cga	act	gtt	gtt	tct	2799
	Gly	Lys	Ile	Ala	Thr	Glu	Ala	Ile	Glu	Asn	Phe	Arg	Thr	Val	Val	Ser	
		895				900					905				910		
55	ttg	act	cgg	gag	cag	aag	ttt	gaa	tac	atg	tat	gca	cag	agt	ttg	caa	2847
	Leu	Thr	Arg	Glu	Gln	Lys	Phe	Glu	Tyr	Met	Tyr	Ala	Gln	Ser	Leu	Gln	
					915					920					925		
	gta	cca	tac	aga	aac	tct	ttg	agg	aaa	gca	cac	atc	ttc	ggg	gtc	tca	2895
	Val	Pro	Tyr	Arg	Asn	Ser	Leu	Arg	Lys	Ala	His	Ile	Phe	Gly	Val	Ser	
				930					935					940			
60	ttt	tct	atc	acc	cag	gca	atg	atg	tat	ttt	tcc	tat	gct	ggc	tgt	ttc	2943

00072725-002800



	Phe	Ser	Ile	Thr	Gln	Ala	Met	Met	Tyr	Phe	Ser	Tyr	Ala	Gly	Cys	Phe	
				945					950					955			
5	cgg	ttt	ggt	gcc	tac	ttg	gtg	gca	aat	gag	ttc	atg	aac	ttt	cag	gat	2991
	Arg	Phe	Gly	Ala	Tyr	Leu	Val	Ala	Asn	Glu	Phe	Met	Asn	Phe	Gln	Asp	
		960					965					970					
	gtt	ctt	ttg	gta	ttc	tca	gct	att	gtc	ttt	ggt	gcc	atg	gca	gtg	ggg	3039
10	Val	Leu	Leu	Val	Phe	Ser	Ala	Ile	Val	Phe	Gly	Ala	Met	Ala	Val	Gly	
		975				980				985					990		
	cag	gtc	agt	tca	ttt	gct	cct	gac	tat	gcc	aaa	gcc	aaa	gta	tca	gca	3087
	Gln	Val	Ser	Ser	Phe	Ala	Pro	Asp	Tyr	Ala	Lys	Ala	Lys	Val	Ser	Ala	
					995				1000					1005			
15	gcc	cac	gtc	atc	atg	atc	att	gaa	aaa	agc	cct	ctg	att	gac	agc	tac	3135
	Ala	His	Val	Ile	Met	Ile	Ile	Glu	Lys	Ser	Pro	Leu	Ile	Asp	Ser	Tyr	
			1010					1015					1020				
20	agc	cct	cac	ggc	ctc	aag	cca	aat	acg	ttg	gaa	gga	aat	gtg	aca	ttt	3183
	Ser	Pro	His	Gly	Leu	Lys	Pro	Asn	Thr	Leu	Glu	Gly	Asn	Val	Thr	Phe	
			1025				1030					1035					
25	aat	gag	gtc	gtg	ttc	aac	tat	ccc	act	cga	cca	gac	atc	ccc	gtg	ctc	3231
	Asn	Glu	Val	Val	Phe	Asn	Tyr	Pro	Thr	Arg	Pro	Asp	Ile	Pro	Val	Leu	
		1040				1045				1050							
	cag	ggg	ctg	agc	ctc	gag	gtg	aag	aag	ggc	cag	acg	ctg	gcc	ctc	gta	3279
30	Gln	Gly	Leu	Ser	Leu	Glu	Val	Lys	Lys	Gly	Gln	Thr	Leu	Ala	Leu	Val	
		1055				1060				1065					1070		
	ggt	agc	agt	ggc	tgt	ggg	aag	agc	aca	gtt	gtt	cag	ctc	cta	gag	cgc	3327
	Gly	Ser	Ser	Gly	Cys	Gly	Lys	Ser	Thr	Val	Val	Gln	Leu	Leu	Glu	Arg	
				1075					1080				1085				
35	ttc	tat	gac	ccc	ttg	gct	ggt	tca	gtg	cta	att	gat	ggc	aaa	gag	ata	3375
	Phe	Tyr	Asp	Pro	Leu	Ala	Gly	Ser	Val	Leu	Ile	Asp	Gly	Lys	Glu	Ile	
			1090					1095					1100				
40	aag	cac	ctg	aat	gtc	cag	tgg	ctc	cga	gca	cac	ctg	ggc	atc	gtg	tct	3423
	Lys	His	Leu	Asn	Val	Gln	Trp	Leu	Arg	Ala	His	Leu	Gly	Ile	Val	Ser	
			1105				1110					1115					
45	cag	gag	ccc	atc	ctg	ttt	gac	tgc	agc	att	gcc	gag	aac	att	gcc	tat	3471
	Gln	Glu	Pro	Ile	Leu	Phe	Asp	Cys	Ser	Ile	Ala	Glu	Asn	Ile	Ala	Tyr	
		1120				1125				1130							
	gga	gac	aac	agc	cgg	gtc	gta	tca	cat	gaa	gag	att	atg	cag	gca	gcc	3519
50	Gly	Asp	Asn	Ser	Arg	Val	Val	Ser	His	Glu	Glu	Ile	Met	Gln	Ala	Ala	
		1135				1140				1145					1150		
	aag	gag	gcc	aac	ata	cac	cac	ttc	atc	gag	aca	ctc	cct	gag	aaa	tac	3567
	Lys	Glu	Ala	Asn	Ile	His	His	Phe	Ile	Glu	Thr	Leu	Pro	Glu	Lys	Tyr	
			1155					1160					1165				
55	aac	acc	aga	gta	gga	gac	aaa	gga	acc	cag	ctc	tct	ggt	ggc	cag	aaa	3615
	Asn	Thr	Arg	Val	Gly	Asp	Lys	Gly	Thr	Gln	Leu	Ser	Gly	Gly	Gln	Lys	
			1170					1175					1180				
60	cag	cgc	att	gcc	ata	gct	cgc	gct	ctt	gtt	aga	cag	cct	cat	att	ttg	3663

Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln Glu

5	145	Ile	Gly	Trp	Phe	Asp	150	Val	His	Asp	Val	Gly	155	Glu	Leu	Asn	Thr	Arg	160	Leu
					165	Ser	Lys	Ile	Asn	Glu	Gly	170	Ile	Gly	Asp	Lys	Val	Gly		
	Thr	Asp	Asp	Val	180						185					190				
	Met	Phe	Phe	Gln	Ser	Ile	Ala	Thr	Phe	Phe	Thr	Gly	Phe	Ile	Val	Gly				
10				195					200						205					
	Phe	Thr	Pro	Gly	Trp	Lys	Leu	Thr	Leu	Val	Ile	Leu	Ala	Ile	Ser	Pro				
		210					215					220								
	Val	Leu	Gly	Leu	Ser	Ala	Ala	Ile	Trp	Ala	Lys	Ile	Leu	Ser	Ser	Phe				
15	225					230						235							240	
	Thr	Asp	Lys	Glu	Leu	Leu	Ala	Tyr	Ala	Lys	Ala	Gly	Ala	Val	Ala	Glu			255	
					245					250						255				
	Glu	Val	Leu	Ala	Ala	Ile	Arg	Thr	Val	Ile	Ala	Phe	Gly	Gly	Gln	Lys				
20				260						265					270					
	Lys	Glu	Leu	Glu	Arg	Tyr	Asn	Lys	Asn	Leu	Glu	Glu	Ala	Lys	Arg	Ile				
		275					280						285							
	Gly	Ile	Lys	Lys	Ala	Ile	Thr	Ala	Asn	Ile	Ser	Ile	Gly	Ala	Ala	Phe				
25				290				295					300							
	Leu	Leu	Ile	Tyr	Ala	Ser	Tyr	Ala	Leu	Ala	Phe	Trp	Tyr	Gly	Thr	Ser				
		305					310					315								
	Leu	Val	Leu	Ser	Ser	Glu	Tyr	Thr	Ile	Gly	Gln	Val	Leu	Thr	Val	Phe				
30				325								330							335	
	Phe	Ser	Val	Leu	Ile	Gly	Ala	Phe	Ser	Ile	Gly	Gln	Ala	Ser	Pro	Ser				
				340						345					350					
	Ile	Glu	Ala	Phe	Ala	Asn	Ala	Arg	Gly	Ala	Ala	Tyr	Glu	Ile	Phe	Lys				
35				355						360					365					
	Ile	Ile	Asp	Asn	Lys	Pro	Ser	Ile	Asp	Ser	Tyr	Ser	Lys	Ser	Gly	His				
		370					375					380								
	Lys	Pro	Asp	Asn	Ile	Lys	Gly	Asn	Leu	Glu	Phe	Lys	Asn	Val	His	Phe				
40				405				410				415								
	Ser	Tyr	Pro	Ser	Arg	Lys	Glu	Val	Lys	Ile	Leu	Lys	Gly	Leu	Asn	Leu				
				420						425					430					
	Lys	Val	Gln	Ser	Gly	Gln	Thr	Val	Ala	Leu	Val	Gly	Asn	Ser	Gly	Cys				
45				435				440						445						
	Gly	Lys	Ser	Thr	Thr	Val	Gln	Leu	Met	Gln	Arg	Leu	Tyr	Asp	Pro	Thr				
				450					455				460							
	Asp	Gly	Met	Val	Cys	Ile	Asp	Gly	Gln	Asp	Ile	Arg	Thr	Ile	Asn	Val				
50				465				470					475							
	Arg	His	Leu	Arg	Glu	Ile	Thr	Gly	Val	Val	Ser	Gln	Glu	Pro	Val	Leu				
				485							490				495					
	Phe	Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	Gly	Arg	Glu	Asn	Val				
55				500						505					510					
	Thr	Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	Ala	Asn	Ala	Tyr	Asp				
				515					520					525						
	Phe	Ile	Met	Lys	Leu	Pro	Asn	Lys	Phe	Asp	Thr	Leu	Val	Gly	Glu	Arg				
60				530						535				540						
	Gly	Ala	Arg	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	Ala	Arg				
				545				550					555							
	Ala	Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Leu	Asp	Glu	Ala	Thr	Ser				
55				565						570					575					
	Ala	Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	His	Arg	Leu	Ser	Thr				
				580					585					590						
	Val	Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	Asp	Gly	Val	Ile	Val				
60				595					600					605						
	Glu	Lys	Gly	Asn	His	Asp	Glu	Leu	Met	Lys	Glu	Lys	Gly	Ile	Tyr	Phe				
				610				615					620							
	Lys	Leu	Val	Thr	Met	Gln	Thr	Arg	Gly	Asn	Glu	Ile	Glu	Leu	Glu	Asn				

625 630 635 640  
 Ala Thr Gly Glu Ser Lys Ser Glu Ser Asp Ala Leu Glu Met Ser Pro  
 Lys Asp Ser Gly Ser Ser Leu Ile Lys Arg Arg Ser Thr Arg Arg Ser  
 5 Ile His Ala Pro Gln Gly Gln Asp Arg Lys Leu Gly Thr Lys Glu Asp  
 Leu Asn Glu Asn Val Pro Ser Val Ser Phe Trp Arg Ile Leu Lys Leu  
 10 Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly Ile Phe Cys Ala Ile  
 Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile Ile Phe Ser Arg Ile  
 15 Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu Thr Lys Arg Gln Asn  
 Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu Gly Ile Ile Ser Phe  
 Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly Glu Ile  
 20 Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu Arg Gln  
 Asp Val Ser Trp Phe Asp Asp Pro Lys Asn Thr Thr Gly Ala Leu Thr  
 Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile Gly Ser  
 25 Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr Gly Ile  
 Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr Leu Leu Leu Ala  
 30 Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val Glu Met Lys Met Leu  
 Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala Gly Lys  
 35 Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser Leu Thr  
 Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln Ser Leu Gln Val Pro  
 Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe Gly Val Ser Phe Ser  
 40 Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe Arg Phe  
 Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn Phe Gln Asp Val Leu  
 Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met Ala Val Gly Gln Val  
 45 Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys Val Ser Ala Ala His  
 Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile Asp Ser Tyr Ser Pro  
 50 His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Asn Glu  
 Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln Gly  
 Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly Ser  
 55 Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe Tyr  
 Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly Lys Glu Ile Lys His  
 60 Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln Glu

00672725-091000

60

	agg agt ata cat gca cca caa ggc caa gac aga aag ctt ggt aca aaa	384
	Arg Ser Ile His Ala Pro Gln Gly Gln Asp Arg Lys Leu Gly Thr Lys	
	115 120 125	
5	gag gac ttg aat gag aat gta cct cca gtt tcc ttc tgg agg att ctg	432
	Glu Asp Leu Asn Glu Asn Val Pro Pro Val Ser Phe Trp Arg Ile Leu	
	130 135 140	
10	aag ctg aac tca act gaa tgg cct tat ttt gtg gtt ggt ata ttt tgt	480
	Lys Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly Ile Phe Cys	
	145 150 155 160	
15	gct att ata aac gga ggc ctg cag cca gca ttt tca ata ata ttt tca	528
	Ala Ile Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile Ile Phe Ser	
	165 170 175	
	agg att ata ggg atc ttt acc cga gat gag gat cct gaa aca aaa cga	576
	Arg Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu Thr Lys Arg	
	180 185 190	
20	cag att agt aac atg ttt tct gta ttg ttt cta gtc ctt gga att att	624
	Gln Ile Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu Gly Ile Ile	
	195 200 205	
25	tct ttt att aca ttt ttc ctt cag ggt ttc aca ttt ggc aaa gct gga	672
	Ser Phe Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly	
	210 215 220	
30	gag atc ctc act aag cgg ctt cga tac atg gtt ttc aga tcc atg ctg	720
	Glu Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu	
	225 230 235 240	
35	aga cag gat gtc agc tgg ttt gat gac ctt aaa aac acc act gga gca	768
	Arg Gln Asp Val Ser Trp Phe Asp Asp Leu Lys Asn Thr Thr Gly Ala	
	245 250 255	
	ttg acc acc agg ctt gcc aat gat gct gct caa gtt aaa ggg gct ata	816
	Leu Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile	
	260 265 270	
40	ggt tcc agg ctt gct gtc att acc cag aat ata gca aat ctt ggg aca	864
	Gly Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr	
	275 280 285	
45	ggc att att ata tcc tta atc tat ggt tgg caa tta aca ctt tta ctc	912
	Gly Ile Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr Leu Leu Leu	
	290 295 300	
50	tta gca att gta ccc atc att gca ata gca gga gtt gtt gaa atg aaa	960
	Leu Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val Glu Met Lys	
	305 310 315 320	
55	atg ttg tct gga caa gca ctg aaa gat aag aaa gag cta gaa gga gct	1008
	Met Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala	
	325 330 335	
	ggg aag att gct aca gaa gcc atc gaa aac ttc cga act gtt gtt tct	1056
	Gly Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser	
	340 345 350	
60		

00672736.062600

ttg act cag gag cag aag ttt gaa cac atg tat gca cag agt ttg cag 1104  
 Leu Thr Gln Glu Gln Lys Phe Glu His Met Tyr Ala Gln Ser Leu Gln  
 355 360 365

5 gta 1107

<210> 6

<211> 368

<212> PRT

10 <213> Canis familiaris

<400> 6

Thr Ser Ala Leu Asp Thr Glu Ser Glu Ala Val Val Gln Val Ala Leu  
 1 5 10 15  
 15 Asp Lys Ala Arg Lys Gly Arg Thr Thr Ile Val Ile Ala His Arg Leu  
 20 25 30  
 Ser Thr Val Arg Asn Ala Asp Val Ile Ala Gly Phe Asp Asp Gly Val  
 35 40 45  
 20 Ile Val Glu Lys Gly Asn His Asp Glu Leu Met Lys Glu Lys Gly Ile  
 50 55 60  
 Tyr Phe Lys Leu Val Thr Met Gln Thr Arg Gly Asn Glu Ile Asp Leu  
 65 70 75 80  
 Glu Asn Ala Thr Gly Glu Ser Lys Ser Glu Ser Asp Ala Leu Glu Met  
 85 90 95  
 25 Ser Pro Lys Asp Ser Gly Ser Ser Leu Ile Lys Arg Arg Ser Thr Arg  
 100 105 110  
 Arg Ser Ile His Ala Pro Gln Gly Gln Asp Arg Lys Leu Gly Thr Lys  
 115 120 125  
 30 Glu Asp Leu Asn Glu Asn Val Pro Pro Val Ser Phe Trp Arg Ile Leu  
 130 135 140  
 Lys Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly Ile Phe Cys  
 145 150 155 160  
 Ala Ile Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile Ile Phe Ser  
 165 170 175  
 35 Arg Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu Thr Lys Arg  
 180 185 190  
 Gln Ile Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu Gly Ile Ile  
 195 200 205  
 Ser Phe Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly  
 210 215 220  
 40 Glu Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu  
 225 230 235 240  
 Arg Gln Asp Val Ser Trp Phe Asp Asp Leu Lys Asn Thr Thr Gly Ala  
 245 250 255  
 45 Leu Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile  
 260 265 270  
 Gly Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr  
 275 280 285  
 50 Gly Ile Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr Leu Leu Leu  
 290 295 300  
 Leu Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val Glu Met Lys  
 305 310 315 320  
 Met Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala  
 325 330 335  
 55 Gly Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser  
 340 345 350  
 Leu Thr Gln Glu Gln Lys Phe Glu His Met Tyr Ala Gln Ser Leu Gln  
 355 360 365

60 <210> 7

5	<400> 7																
	Met	Asp	Leu	Glu	Gly	Asp	Arg	Asn	Gly	Gly	Ala	Lys	Lys	Lys	Asn	Phe	
	1				5				10						15		
	Phe	Lys	Leu	Asn	Asn	Lys	Ser	Glu	Lys	Asp	Lys	Lys	Glu	Lys	Lys	Pro	
				20					25					30			
10	Thr	Val	Ser	Val	Phe	Ser	Met	Phe	Arg	Tyr	Ser	Asn	Trp	Leu	Asp	Lys	
			35					40					45				
	Leu	Tyr	Met	Val	Val	Gly	Thr	Leu	Ala	Ala	Ile	Ile	His	Gly	Ala	Gly	
		50					55					60					
15	Leu	Pro	Leu	Met	Met	Leu	Val	Phe	Gly	Glu	Met	Thr	Asp	Ile	Phe	Ala	
	65					70					75				80		
	Asn	Ala	Gly	Asn	Leu	Glu	Asp	Leu	Met	Ser	Asn	Ile	Thr	Asn	Arg	Ser	
				85						90				95			
	Asp	Ile	Asn	Asp	Trp	Gly	Phe	Phe	Met	Asn	Leu	Glu	Glu	Asp	Met	Thr	
				100					105					110			
20	Arg	Tyr	Ala	Tyr	Tyr	Tyr	Ser	Gly	Ile	Gly	Ala	Gly	Val	Leu	Val	Ala	
			115					120					125				
	Ala	Tyr	Ile	Gln	Val	Ser	Phe	Trp	Cys	Leu	Ala	Ala	Gly	Arg	Gln	Ile	
		130					135					140					
25	His	Lys	Ile	Arg	Lys	Gln	Phe	Phe	His	Ala	Ile	Met	Arg	Gln	Glu	Ile	
	145					150					155				160		
	Gly	Trp	Phe	Asp	Val	His	Asp	Val	Gly	Glu	Leu	Asn	Thr	Arg	Leu	Thr	
				165						170				175			
	Asp	Asp	Val	Ser	Lys	Ile	Asn	Glu	Val	Ile	Gly	Asp	Lys	Ile	Gly	Met	
				180					185					190			
30	Phe	Phe	Gln	Ser	Met	Ala	Thr	Phe	Phe	Thr	Gly	Phe	Ile	Val	Gly	Phe	
		195						200					205				
	Thr	Arg	Gly	Trp	Lys	Leu	Thr	Leu	Val	Ile	Leu	Ala	Ile	Ser	Pro	Val	
		210					215					220					
35	Leu	Gly	Leu	Ser	Ala	Ala	Val	Trp	Ala	Lys	Ile	Leu	Ser	Ser	Phe	Thr	
	225				230						235				240		
	Asp	Lys	Glu	Leu	Leu	Ala	Tyr	Ala	Lys	Ala	Gly	Ala	Val	Ala	Glu	Glu	
				245						250				255			
	Val	Leu	Ala	Ala	Ile	Arg	Thr	Val	Ile	Ala	Phe	Gly	Gly	Gln	Lys	Lys	
			260						265					270			
40	Glu	Leu	Glu	Arg	Tyr	Asn	Lys	Asn	Leu	Glu	Glu	Ala	Lys	Arg	Ile	Gly	
			275					280					285				
	Ile	Lys	Lys	Ala	Ile	Thr	Ala	Asn	Ile	Ser	Ile	Gly	Ala	Ala	Phe	Leu	
		290					295					300					
45	Leu	Ile	Tyr	Ala	Ser	Tyr	Ala	Leu	Ala	Phe	Trp	Tyr	Gly	Thr	Thr	Leu	
	305					310					315				320		
	Val	Leu	Ser	Gly	Glu	Tyr	Ser	Ile	Gly	Gln	Val	Leu	Thr	Val	Phe	Phe	
				325						330				335	</		



	Gly	Met	Val	Ser	Val	Asp	Gly	Gln	Asp	Ile	Arg	Thr	Ile	Asn	Val	Arg
	Phe	Leu	Arg	Glu	Ile	Ile	Gly	Val	Val	Ser	Gln	Glu	Pro	Val	Leu	Phe
5	Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	Gly	Arg	Glu	Asn	Val	Thr
	Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	Ala	Asn	Ala	Tyr	Asp	Phe
10	Ile	Met	Lys	Leu	Pro	His	Lys	Phe	Asp	Thr	Leu	Val	Gly	Glu	Arg	Gly
	Ala	Gln	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	Ala	Arg	Ala
15	Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Leu	Asp	Glu	Ala	Thr	Ser	Ala
	Leu	Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	Val	Ala	Leu	Asp	Lys	Ala
20	Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	His	Arg	Leu	Ser	Thr	Val
	Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	Asp	Gly	Val	Ile	Val	Glu
25	Leu	Val	Thr	Met	Gln	Thr	Ala	Gly	Asn	Glu	Val	Glu	Leu	Gln	Asn	Ala
	Ala	Asp	Glu	Ser	Lys	Ser	Glu	Ile	Asp	Ala	Leu	Glu	Met	Ser	Ser	Asn
30	Asp	Ser	Arg	Ser	Ser	Leu	Ile	Arg	Lys	Arg	Ser	Thr	Arg	Arg	Ser	Val
	Arg	Gly	Ser	Gln	Ala	Gln	Asp	Arg	Lys	Leu	Ser	Thr	Lys	Glu	Ala	Leu
35	Leu	Thr	Glu	Trp	Pro	Tyr	Phe	Val	Val	Gly	Val	Phe	Cys	Ala	Ile	Ile
	Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ala	Ile	Ile	Phe	Ser	Lys	Ile	Ile
40	Gly	Val	Phe	Thr	Arg	Ile	Asp	Asp	Pro	Glu	Thr	Lys	Arg	Gln	Asn	Ser
	Asn	Leu	Phe	Ser	Leu	Leu	Phe	Leu	Ala	Leu	Gly	Ile	Ile	Ser	Phe	Ile
45	Thr	Phe	Phe	Leu	Gln	Gly	Phe	Thr	Phe	Gly	Lys	Ala	Gly	Glu	Ile	Asp
	Thr	Lys	Arg	Leu	Arg	Tyr	Met	Val	Phe	Arg	Ser	Met	Leu	Arg	Gln	Asp
50	Val	Ser	Trp	Phe	Asp	Asp	Pro	Lys	Asn	Thr	Thr	Gly	Ala	Leu	Thr	Thr
	Arg	Leu	Ala	Asn	Asp	Ala	Ala	Gln	Val	Lys	Gly	Ala	Ile	Gly	Ser	Arg
55	Leu	Ala	Val	Ile	Thr	Gln	Asn	Ile	Ala	Asn	Leu	Gly	Thr	Gly	Ile	Ile
	Ile	Ser	Phe	Ile	Tyr	Gly	Trp	Gln	Leu	Thr	Leu	Leu	Leu	Leu	Ala	Ile
	Val	Pro	Ile	Ile	Ala	Ile	Ala	Gly	Val	Val	Glu	Met	Lys	Met	Leu	Ser
	Gly	Gln	Ala	Leu	Lys	Asp	Lys	Lys	Glu	Leu	Glu	Gly	Ala	Gly	Lys	Ile
	Ala	Thr	Glu	Ala	Ile	Glu	Asn	Phe	Arg	Thr	Val	Val	Ser	Leu	Thr	Gln
60	Glu	Gln	Lys	Phe	Glu	His	Met	Tyr	Ala	Gln	Ser	Leu	Gln	Val	Pro	Tyr

60

[illegible]

Val Arg Asn Pro Lys Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala Leu  
 545 550 555 560  
 Asp Thr Glu Ser Glu Ala Val Val Gln Val Ala Leu Asp Lys Ala Arg  
 565 570 575  
 5 Lys Gly Arg Thr Thr Ile Val Ile Ala His Arg Leu Ser Thr Val Arg  
 580 585 590  
 Asn Ala Asp Val Ile Ala Gly Phe Asp Asp Gly Val Ile Val Glu Lys  
 595 600 605  
 10 Gly Asn His Asp Glu Leu Met Lys Glu Lys Gly Ile Tyr Phe Lys Leu  
 610 615 620  
 Val Thr Met Gln Thr Ala Gly Asn Glu Val Glu Leu Glu Asn Ala Ala  
 625 630 635 640  
 Asp Glu Ser Lys Ser Glu Ile Asp Ala Leu Glu Met Ser Ser Asn Asp  
 645 650 655  
 15 Ser Arg Ser Ser Leu Ile Arg Lys Arg Ser Thr Arg Arg Ser Val Arg  
 660 665 670  
 Gly Ser Gln Ala Gln Asp Arg Lys Leu Ser Thr Lys Glu Ala Leu Asp  
 675 680 685  
 20 Glu Ser Ile Pro Pro Val Ser Phe Trp Arg Ile Met Lys Leu Asn Leu  
 690 695 700  
 Thr Glu Trp Pro Tyr Phe Val Val Gly Val Phe Cys Ala Ile Ile Asn  
 705 710 715 720  
 Gly Gly Leu Gln Pro Ala Phe Ala Ile Ile Phe Ser Lys Ile Ile Gly  
 725 730 735  
 25 Val Phe Thr Arg Ile Asp Asp Pro Glu Thr Lys Arg Gln Asn Ser Asn  
 740 745 750  
 Leu Phe Ser Leu Leu Phe Leu Ala Leu Gly Ile Ile Ser Phe Ile Thr  
 755 760 765  
 30 Phe Phe Leu Gln Gly Phe Thr Phe Gly Lys Ala Gly Glu Ile Leu Thr  
 770 775 780  
 Lys Arg Leu Arg Tyr Met Val Phe Arg Ser Met Leu Arg Gln Asp Val  
 785 790 795 800  
 Ser Trp Phe Asp Asp Pro Lys Asn Thr Thr Gly Ala Leu Thr Thr Arg  
 805 810 815  
 35 Leu Ala Asn Asp Ala Ala Gln Val Lys Gly Ala Ile Gly Ser Arg Leu  
 820 825 830  
 Ala Val Ile Thr Gln Asn Ile Ala Asn Leu Gly Thr Gly Ile Ile Ile  
 835 840 845  
 40 Ser Phe Ile Tyr Gly Trp Gln Leu Thr Leu Leu Leu Ala Ile Val  
 850 855 860  
 Pro Ile Ile Ala Ile Ala Gly Val Val Glu Met Lys Met Leu Ser Gly  
 865 870 875 880  
 Gln Ala Leu Lys Asp Lys Lys Glu Leu Glu Gly Ala Gly Lys Ile Ala  
 885 890 895  
 45 Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser Leu Thr Gln Glu  
 900 905 910  
 Gln Lys Phe Glu His Met Tyr Ala Gln Ser Leu Gln Val Pro Tyr Arg  
 915 920 925  
 50 Asn Ser Leu Arg Lys Ala His Ile Phe Gly Ile Thr Phe Ser Phe Thr  
 930 935 940  
 Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe Arg Phe Gly Ala  
 945 950 955 960  
 Tyr Leu Val Ala His Lys Leu Met Ser Phe Glu Asp Val Leu Leu Val  
 965 970 975  
 55 Phe Ser Ala Val Val Phe Gly Ala Met Ala Val Gly Gln Val Ser Ser  
 980 985 990  
 Phe Ala Pro Asp Tyr Ala Lys Ala Lys Ile Ser Ala Ala His Ile Ile  
 995 1000 1005  
 60 Met Ile Ile Glu Lys Thr Pro Leu Ile Asp Ser Tyr Ser Thr Glu Gly  
 1010 1015 1020

00672725-092800

Leu Met Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Gly Glu Val Val  
 1025 1030 1035 1040  
 Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln Gly Leu Ser  
 1045 1050 1055  
 5 Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly Ser Ser Gly  
 1060 1065 1070  
 Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe Tyr Asp Pro  
 1075 1080 1085  
 Leu Ala Gly Lys Val Leu Leu Asp Gly Lys Glu Ile Lys Arg Leu Asn  
 1090 1095 1100  
 10 Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln Glu Pro Ile  
 1105 1110 1115 1120  
 Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly Asp Asn Ser  
 1125 1130 1135  
 15 Arg Val Val Ser Gln Glu Glu Ile Val Arg Ala Ala Lys Glu Ala Asn  
 1140 1145 1150  
 Ile His Ala Phe Ile Glu Ser Leu Pro Asn Lys Tyr Ser Thr Lys Val  
 1155 1160 1165  
 Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln Arg Ile Ala  
 1170 1175 1180  
 20 Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu Leu Asp Glu  
 1185 1190 1195 1200  
 Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val Gln Glu Ala  
 1205 1210 1215  
 25 Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile Ala His Arg  
 1220 1225 1230  
 Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe Gln Asn Gly  
 1235 1240 1245  
 Arg Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala Gln Lys Gly  
 1250 1255 1260  
 30 Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Thr Lys Arg Gln  
 1265 1270 1275  
 35 <210> 9  
 <211> 24  
 <212> DNA  
 <213> Homo sapiens  
 <400> 9  
 40 gaactgtgat tgcgtttgga ggac 24  
 <210> 10  
 <211> 22  
 <212> DNA  
 45 <213> Canis familiaris  
 <400> 10  
 ttcagggcgc cctgtacctc tg 22  
 50 <210> 11  
 <211> 22  
 <212> DNA  
 <213> Canis familiaris  
 55 <400> 11  
 cccacacagat ggcatggtct gt 22  
 <210> 12  
 <211> 23  
 60 <212> DNA

00662726-00000

	<213> Homo sapiens	
	<400> 12	
5	cgcttggtga ggatctctcc agc	23
	<210> 13	
	<211> 24	
	<212> DNA	
10	<213> Canis familiaris	
	<400> 13	
	agaaacagag aatcgccatt gctc	24
	<210> 14	
15	<211> 23	
	<212> DNA	
	<213> Homo sapiens	
	<400> 14	
20	gctgcagtca aacaggatgg gct	23
	<210> 15	
	<211> 24	
	<212> DNA	
25	<213> Canis familiaris	
	<400> 15	
	agttcatttg ctctgacta tgcc	24
30	<210> 16	
	<211> 22	
	<212> DNA	
	<213> Homo sapiens	
35	<400> 16	
	gatgccttgc tgggccagca gc	22
	<210> 17	
40	<211> 30	
	<212> DNA	
	<213> Canis familiaris	
	<400> 17	
45	gagtggaaga agggccagac gctggccctc	30
	<210> 18	
	<211> 45	
	<212> DNA	
	<213> Artificial Sequence	
50	<220>	
	<223> Synthetic oligonucleotide	
	<400> 18	
55	ctaatacgac tcactatagg gcaagcagtg gtaacaacgc agagt	45
	<210> 19	
	<211> 29	
	<212> DNA	
60	<213> Canis familiaris	

00672725-00000

	<400> 19	
	cgcgagccact gttcccaacc agcgccact	29
5	<210> 20 <211> 23 <212> DNA <213> Homo sapiens	
10	<400> 20 ggagcgcgag gtcgggatgg atc	23
15	<210> 21 <211> 31 <212> DNA <213> Canis familiaris	
20	<400> 21 ggagaggacc aaggaggtcc cataccagaa a	31
25	<210> 22 <211> 4279 <212> DNA <213> Canis familiaris	
30	<220> <221> CDS <222> (17)... (3859)	
30	<400> 22 ggagcgcgag gtcggg atg gat cct gaa gga ggc cgt aag ggg agt gca gag Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu 1 5 10	52
35	aag aac ttc tgg aaa atg ggc aaa aaa agt aaa aaa aat gag aag aaa Lys Asn Phe Trp Lys Met Gly Lys Lys Ser Lys Lys Asn Glu Lys Lys 15 20 25	100
40	gaa aag aaa cca act gtc agc acg ttt gca atg ttt cgc tat tca aat Glu Lys Lys Pro Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn 30 35 40	148
45	tgg ctt gat agg ttg tat atg ttg gtg ggg aca atg gct gcc atc atc Trp Leu Asp Arg Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile 45 50 55 60	196
50	cat gga gct gca ctc cct ctc atg atg ctg gtt ttt gga aac atg aca His Gly Ala Ala Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr 65 70 75	244
55	gat agc ttt gca aat gca gga att tca aga aac aaa act ttt cca gtt Asp Ser Phe Ala Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val 80 85 90	292
55	ata att aat gaa agt att acg aac aat aca caa cat ttc atc aac cat Ile Ile Asn Glu Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His 95 100 105	340
60	ctg gag gag gaa atg acc acg tat gcc tat tat tac agt ggg atc ggt Leu Glu Glu Glu Met Thr Thr Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly 110 115 120 125 130 135 140	388

		110				115				120								
		gct	ggc	gtg	ctg	gtg	gct	gct	tac	atc	cag	gtt	tca	ttc	tg	tgc	ctg	436
5		Ala	Gly	Val	Leu	Val	Ala	Ala	Tyr	Ile	Gln	Val	Ser	Phe	Trp	Cys	Leu	
		125					130					135					140	
		gca	gca	gga	aga	cag	ata	ctc	aaa	att	aga	aaa	caa	ttt	ttt	cat	gct	484
		Ala	Ala	Gly	Arg	Gln	Ile	Leu	Lys	Ile	Arg	Lys	Gln	Phe	Phe	His	Ala	
10						145					150				155			
		atc	atg	cga	cag	gag	att	ggc	tg	ttt	gac	gtg	cat	gac	gtt	ggg	gag	532
		Ile	Met	Arg	Gln	Glu	Ile	Gly	Trp	Phe	Asp	Val	His	Asp	Val	gly	Glu	
						160				165					170			
15		ctt	aac	acc	cgg	ctc	aca	gac	gat	gtc	tcc	aaa	atc	aat	gaa	gga	att	580
		Leu	Asn	Thr	Arg	Leu	Thr	Asp	Asp	Val	Ser	Lys	Ile	Asn	Glu	Gly	Ile	
				175					180					185				
20		ggc	gac	aaa	att	gga	atg	ttc	ttt	caa	tca	ata	gca	aca	ttt	ttc	acc	628
		Gly	Asn	Lys	Ile	Gly	Met	Phe	Phe	Gln	Ser	Ile	Ala	Thr	Phe	Phe	Thr	
				190				195					200					
25		gg	ttt	ata	gtg	ggg	ttt	aca	cgt	gg	tg	aag	cta	acc	ctt	gtg	att	676
		Gly	Phe	Ile	Val	Gly	Phe	Thr	Arg	Gly	Trp	Lys	Leu	Thr	Leu	Val	Ile	
		205				210					215					220		
		ttg	gcc	atc	agc	cct	gtt	ctt	gga	ctt	tca	gcc	gcc	atc	tg	gca	aag	724
		Leu	Ala	Ile	Ser	Pro	Val	Leu	Gly	Leu	Ser	Ala	Ala	Ile	Trp	Ala	Lys	
						225					230				235			
30		ata	cta	tct	tca	ttt	act	gat	aaa	gaa	ctc	ttg	gcc	tat	gca	aaa	gct	772
		Ile	Leu	Ser	Ser	Phe	Thr	Asp	Lys	Glu	Leu	Leu	Ala	Tyr	Ala	Lys	Ala	
						240				245					250			
35		gga	gca	gta	gct	gaa	gaa	gtc	tta	gca	gca	atc	aga	act	gtg	att	gcc	820
		Gly	Ala	Val	Ala	Glu	Glu	Val	Leu	Ala	Ala	Ile	Arg	Thr	Val	Ile	Ala	
						255			260					265				
40		ttt	gga	gga	caa	aag	aaa	gaa	ctt	gaa	agg	tac	aac	aaa	aat	tta	gaa	868
		Phe	Gly	Gly	Gln	Lys	Lys	Glu	Leu	Glu	Arg	Tyr	Asn	Lys	Asn	Leu	Glu	
						270		275					280					
		gaa	gct	aaa	gga	att	ggg	ata	aag	aaa	gct	atc	acg	gcc	aac	att	tct	916
		Glu	Ala	Lys	Gly	Ile	Gly	Ile	Lys	Lys	Ala	Ile	Thr	Ala	Asn	Ile	Ser	
45		285					290					295				300		
		att	gg	gcc	gct	ttc	tta	ttg	atc	tat	gca	tca	tat	gct	ctg	gct	ttc	964
		Ile	Gly	Ala	Ala	Phe	Leu	Leu	Ile	Tyr	Ala	Ser	Tyr	Ala	Leu	Ala	Phe	
						305					310				315			
50		tg	tat	gg	acc	tcc	ttg	gtc	ctc	tcc	agt	gaa	tat	tct	att	gga	caa	1012
		Trp	Tyr	Gly	Thr	Ser	Leu	Val	Leu	Ser	Ser	Glu	Tyr	Ser	Ile	Gly	Gln	
						320				325					330			
55		gta	ctc	act	gtc	ttc	ttt	tct	gta	tta	att	ggg	gct	ttt	agt	att	gga	1060
		Val	Leu	Thr	Val	Phe	Phe	Ser	Val	Leu	Ile	Gly	Ala	Phe	Ser	Ile	Gly	
						335			340					345				
60		cag	gca	tcc	cca	agc	att	gaa	gca	ttt	gca	aac	gca	aga	gga	gca	gct	1108
		Gln	Ala	Ser	Pro	Ser	Ile	Glu	Ala	Phe	Ala	Asn	Ala	Arg	Gly	Ala	Ala	



	350	355	360	
5	tat gaa atc ttc aag ata att gac aat aaa cca agc att gac agc tat Tyr Glu Ile Phe Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr 365 370 375 380			1156
10	tcg aag agt gga cat aaa cca gat aat att aag gga aat ttg gaa ttc Ser Lys Ser Gly His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe 385 390 395			1204
15	aaa aat gtt cac ttc agt tac cct tct cga aaa gaa gtt aag atc tta Lys Asn Val His Phe Ser Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu 400 405 410			1252
20	aag ggt ctc aac ctg aag gtt cag agt ggg cag aca gtg gcg ctg gtt Lys Gly Leu Asn Leu Lys Val Gln Ser Gly Gln Thr Val Ala Leu Val 415 420 425			1300
25	ggg aac agt ggc tgc ggg aag agc acg acc gtg cag ctg atg cag agg Gly Asn Ser Gly Cys Gly Lys Ser Thr Thr Val Gln Leu Met Gln Arg 430 435 440			1348
30	ctc tat gac ccc aca gat ggc atg gtc tgt att gat gga cag gac att Leu Tyr Asp Pro Val Thr Asp Gly Met Val Cys Ile Asp Gly Gln Asp Ile 445 450 455 460			1396
35	agg acc ata aat gta agg cat ctt cgg gaa att act ggt gtg gtg agt Arg Thr Ile Asn Val Arg His Leu Arg Glu Ile Thr Gly Val Val Ser 465 470 475			1444
40	cag gag cct gtg ttg ttt gcc acc acg ata gct gaa aac att cgc tat Gln Glu Pro Val Leu Phe Ala Thr Thr Ile Ala Glu Asn Ile Arg Tyr 480 485 490			1492
45	ggc cgc gaa aat gtc acc atg gat gag att gag aaa gct gtt aag gaa Gly Arg Glu Asn Val Thr Met Asp Glu Ile Glu Lys Ala Val Lys Glu 495 500 505			1540
50	gcc aat gcc tat gat ttt atc atg aaa cta cct aat aaa ttt gac act Ala Asn Ala Tyr Asp Phe Ile Met Lys Leu Pro Asn Lys Phe Asp Thr 510 515 520			1588
55	ctg gtt gga gag aga ggg gcc cag ctg agt ggt gga cag aaa cag aga Leu Val Gly Glu Arg Gly Ala Gln Leu Ser Gly Gln Lys Gln Arg 525 530 535 540			1636
60	atc gcc att gct cgg gcc ctg gtt cgc aac ccc aag att ctt ctg ctg Ile Ala Ile Ala Arg Ala Leu Val Arg Asn Pro Lys Ile Leu Leu Leu 545 550 555			1684
65	gat gag gca acg tca gct ctg gac act gaa agt gaa gca gtg gtt cag Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Ala Val Val Gln 560 565 570			1732
70	gtg gcc ctg gat aag gcc aga aaa ggc cgg act acc att gtg ata gct Val Ala Leu Asp Lys Ala Arg Lys Gly Arg Thr Thr Ile Val Ile Ala 575 580 585			1780
75	cat cgt ttg tct aca gtt cgt aat gcc gat gtc att gct ggt ttt gat His Arg Leu Ser Thr Val Arg Asn Ala Asp Val Ile Ala Gly Phe Asp 590 595 600			1828

00672225-00000

	590				595				600								
5	gat Asp 605	gga Gly Val	gtc Val Ile	att Val 610	gtg Glu Lys	gag Gly 610	aaa Gly Asn	gga Asn His	aat His 615	cat Asp 615	gat Glu Leu	ctc Met 615	atg Lys 615	aaa Glu 620	gag Glu 620	1876	
	aag Lys	ggc Gly	att Ile	tac Tyr	ttc Phe 625	aaa Lys	ctt Leu	gtc Val	aca Thr	atg Met 630	cag Gln	aca Thr	aga Arg	gga Gly 635	aat Asn	gaa Glu	1924
10	att Ile	gag Glu	tta Leu	gaa Glu 640	aat Asn 640	gcc Ala	act Thr	ggt Gly	gaa Glu 645	tcc Ser	aaa Lys	agt Ser	gaa Glu 650	agt Ser	gat Asp	gcc Ala	1972
15	ttg Leu	gaa Glu	atg Met	tct Ser	cca Pro	aaa Lys	gat Asp	tca Ser	ggg Gly	tcc Ser	agt Ser	tta Leu	ata Ile 665	aaa Lys	aga Arg	aga Arg	2020
20	tca Ser	act Thr	cgc Arg	agg Arg	agt Ser	ata Ile	cat His 675	gca Ala	cca Pro	caa Gln	ggc Gly	caa Gln	gac Asp	aga Arg	aag Lys	ctt Leu	2068
25	ggt Gly 685	aca Thr	aaa Lys	gag Glu	gac Asp	ttg Leu 690	aat Asn	gag Glu	aat Asn	gta Val	cct Pro 695	cca Pro	ggt Val	tcc Ser	ttc Phe	tg Trp 700	2116
	agg Arg	att Ile	ctg Leu	aag Lys	ctg Leu	aac Asn	tca Ser	act Thr	gaa Glu	tg Trp	cct Pro	tat Tyr	ttt Phe	gtg Val	gtt Val	ggt Gly	2164
30	ata Ile	ttt Phe	tgt Cys	gct Ala	att Ile	ata Ile	aac Asn	gga Gly	ggc Gly	ctg Gln	caa Gln	cca Pro	gca Ala	ttt Phe 730	tca Ser	ata Ile	2212
35	ata Ile	ttt Phe	tca Ser	agg Arg	att Ile	ata Ile	ggg Gly	atc Ile	ttt Phe	acc Thr	cga Arg	gat Asp	gag Glu 745	gat Asp	cct Pro	gaa Glu	2260
40	aca Thr	aaa Lys	cga Arg	cag Gln	aat Asn	agt Ser	aac Ser	atg Met	ttt Phe	tct Ser	gta Val	ttg Phe 760	ttt Phe	cta Leu	gtc Val	ctt Leu	2308
45	gga Gly	att Ile	att Ile	tct Ser	ttt Phe	att Ile	aca Thr	ttt Phe	ttc Phe	ctc Leu	cag Gln 775	ggc Gly	ttc Phe	aca Thr	ttt Phe	ggc Gly 780	2356
	aaa Lys	gct Ala	ggg Gly	gag Glu	atc Ile	ctc Leu	act Thr	aag Lys	cgg Arg	ctt Leu	cga Arg	tac Tyr	atg Met	gtt Val	ttc Phe	aga Arg	2404
50	tcc Ser	atg Met	ctg Leu	aga Arg	cag Gln	gat Asp	gtc Val	agc Ser	tg Trp	ttt Phe	gat Asp	gac Asp	cct Pro	aaa Lys	aac Asn	acc Thr	2452
55	act Thr	gga Gly	gca Ala	ttg Leu	aca Thr	acc Thr	agg Arg	ctt Leu	gcc Ala	aat Asn	gat Asp	gcg Gln	gct Ala	caa Gln	gtt Val	aaa Lys	2500
60	ggg Gly	gct Ala	ata Ile	ggt Ser	tcc Arg	agg Glu	ctt Leu	gct Ala	att Val	acc Ile	cag Thr	aat Gln	aat Asn	ata Ile	gca Ala	aat Asn	2548

		830				835				840								
5		ctt	ggg	aca	ggc	att	att	ata	tcc	tta	atc	tat	ggt	tgg	caa	tta	aca	2596
		Leu	Gly	Thr	Gly	Ile	Ile	Ile	Ser	Leu	Ile	Tyr	Gly	Trp	Gln	Leu	Thr	
		845				850						855					860	
10		ctt	tta	ctc	tta	gca	att	gta	ccc	atc	att	gca	ata	gca	gga	gtt	gtt	2644
		Leu	Leu	Leu	Leu	Ala	Ile	Val	Pro	Ile	Ile	Ala	Ile	Ala	Gly	Val	Val	
						865					870						875	
15		gaa	atg	aaa	atg	ttg	tct	gga	caa	gca	ctg	aaa	gat	aag	aaa	gag	cta	2692
		Glu	Met	Lys	Met	Leu	Ser	Gly	Gln	Ala	Leu	Lys	Asp	Lys	Lys	Glu	Leu	
						880					885					890		
20		gaa	gga	gct	ggg	aag	att	gct	aca	gaa	gcc	atc	gaa	aac	ttc	cga	act	2740
		Glu	Gly	Ala	Gly	Lys	Ile	Ala	Thr	Glu	Ala	Ile	Glu	Asn	Phe	Arg	Thr	
						895					900				905			
25		ggt	gtt	tct	ttg	act	cgg	gag	cag	aag	ttt	gaa	tac	atg	tat	gca	cag	2788
		Val	Val	Ser	Leu	Thr	Arg	Gag	Gln	Lys	Phe	Glu	Tyr	Met	Tyr	Ala	Gln	
						910				915				920				
30		agt	ttg	caa	gta	cca	tac	aga	aac	tct	ttg	agg	aaa	gca	cac	atc	ttc	2836
		Ser	Leu	Gln	Val	Pro	Tyr	Arg	Asn	Ser	Leu	Arg	Lys	Ala	His	Ile	Phe	
						925				930				935			940	
35		ggg	gtc	tca	ttt	tct	atc	acc	cag	gca	atg	atg	tat	ttt	tcc	tat	gct	2884
		Gly	Val	Ser	Phe	Ser	Ile	Thr	Gln	Ala	Met	Met	Tyr	Phe	Ser	Tyr	Ala	
						945						950				955		
40		ggc	tgt	ttc	cgg	ttt	ggt	gcc	tac	ttg	gtg	gca	aat	gag	ttc	atg	aac	2932
		Gly	Cys	Phe	Arg	Phe	Gly	Ala	Tyr	Leu	Val	Ala	Asn	Glu	Phe	Met	Asn	
						960						965				970		
45		ttt	cag	gat	gtt	ctt	ttg	gta	ttc	tca	gct	att	gtc	ttt	ggt	gcc	atg	2980
		Phe	Gln	Asp	Val	Leu	Leu	Val	Phe	Ser	Ala	Ile	Val	Phe	Gly	Ala	Met	
						975					980					985		
50		gca	gtg	ggg	cag	gtc	agt	tca	ttt	gct	cct	gac	tat	gcc	aaa	gcc	aaa	3028
		Ala	Val	Gly	Gln	Val	Ser	Ser	Phe	Ala	Pro	Asp	Tyr	Ala	Lys	Ala	Lys	
						990					995				1000			
55		gta	tca	gca	gcc	cac	gtc	atc	atg	atc	att	gaa	aaa	agc	cct	ctg	att	3076
		Val	Ser	Ala	Ala	His	Val	Ile	Met	Ile	Ile	Glu	Lys	Ser	Pro	Leu	Ile	
						1005								1015			1020	
60		gac	agc	tac	agc	cct	cac	ggc	ctc	aag	cca	aat	acg	ttg	gaa	gga	aat	3124
		Asp	Ser	Tyr	Ser	Pro	His	Gly	Leu	Lys	Pro	Asn	Thr	Leu	Glu	Gly	Asn	
						1025						1030					1035	
65		gtg	aca	ttt	aat	gag	gtc	gtg	ttc	aac	tat	ccc	act	cga	cca	gac	atc	3172
		Val	Thr	Phe	Asn	Glu	Val	Val	Phe	Asn	Tyr	Pro	Thr	Arg	Pro	Asp	Ile	
						1040						1045				1050		
70		ccc	gtg	ctc	cag	ggg	ctg	agc	ctc	gag	gtg	aag	aag	ggc	cag	acg	ctg	3220
		Pro	Val	Leu	Gln	Gly	Leu	Ser	Leu	Glu	Val	Lys	Lys	Gly	Gln	Thr	Leu	
						1055					1060				1065			
75		gcc	ctc	gta	ggg	agc	agc	ggc	tgt	ggg	aag	agc	aca	ggt	gtt	cag	ctc	3268
		Ala	Leu	Val	Gly	Ser	Ser	Gly	Cys	Gly	Lys	Ser	Thr	Val	Val	Gln	Leu	

	1070	1075	1080	
5	cta gag cgc ttc tat gac ccc ttg gct ggt tca gtg cta att gat ggc Leu Glu Arg Phe Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly 1085 1090 1095 1100			3316
10	aaa gag ata aag cac ctg aat gtc cag tgg ctc cga gca cac ctg ggc Lys Glu Ile Lys His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly 1105 1110 1115			3364
15	atc gtg tct cag gag ccc atc ctg ttt gac tgc agc att gcc gag aac Ile Val Ser Gln Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn 1120 1125 1130			3412
20	att gcc tat gga gac aac agc cgg gtc gta tca cat gaa gag att atg Ile Ala Tyr Gly Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Met 1135 1140 1145			3460
25	cag gca gcc aag gag gcc aac ata cac cac ttc atc gag aca ctc cct Gln Ala Ala Lys Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro 1150 1155 1160			3508
30	gag aaa tac aac acc aga gta gga gac aaa gga acc cag ctc tct ggt Glu Lys Tyr Asn Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly 1165 1170 1175 1180			3556
35	ggc cag aaa cag cgc att gcc ata gct cgc gct ctt gtt aga cag cct Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro 1185 1190 1195			3604
40	cat att ttg ctt ttg gat gaa gct aca tca gct ctg gat aca gaa agt His Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser 1200 1205 1210			3652
45	gaa aag gtt gtc caa gaa gcc ctg gac aaa gcc aga gaa ggc cgc acc Glu Lys Val Val Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr 1215 1220 1225			3700
50	tgc att gtg atc gcc cac cgc ttg tcc acc atc cag aat gca gat tta Cys Ile Val Ile Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu 1230 1235 1240			3748
55	ata gtg gtg ttt cag aat ggc aaa gtc aag gag cat ggc aca cat caa Ile Val Val Phe Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln 1245 1250 1255 1260			3796
60	cag ctg ctg gcc cag aaa ggc atc tat ttt tcc atg gtc agt gtc cag Gln Leu Leu Ala Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln 1265 1270 1275			3844
	gct gga gca aag cgc tagtgaactg tggccatatg agctgttataa tatttttttaa Ala Gly Ala Lys Arg 1280			3899
55	tatttgtgtt aaaacatggc atttaaatcaa agttaaagg tgagcactta ctggaaaaaac tatgtagaac tacctgttta acatttcttg ctgcaactga agatcattcc accaagtcca gagcttccag attttataat taaagggaacc aaaagaaaca ttatctgatg gaataaaata ctgtgtgttaa ttgcattata aaattataga gtaattcaaa gtatgattttg ttaataaatt gtataatttt tgtttatatt ttatttgttaa cttactgctt tgctgaaaga ttatagaagt 60 ggtaaaaagt actgaaatgt tgaataaagt gctagctata ataaaactaa acttttatat			3959 4019 4079 4139 4199 4259

00672725-00000

caaaaaaaaaaaaaaaaaaaaa

<210> 23  
 <211> 1281  
 <212> PRT  
 <213> Canis familiaris

<400> 23  
 Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu Lys Asn Phe Trp  
 1 5 10  
 Lys Met Gly Lys Lys Ser Lys Lys Asn Glu Lys Lys Glu Lys Lys Pro  
 20 25 30  
 Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn Trp Leu Asp Arg  
 35 40 45  
 15 Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile His Gly Ala Ala  
 50 55 60  
 Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe Ala  
 65 70 75 80  
 20 Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val Ile Ile Asn Glu  
 85 90 95  
 Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His Leu Glu Glu Glu  
 100 105 110  
 Met Thr Thr Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu  
 115 120 125  
 25 Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg  
 130 135 140  
 Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln  
 145 150 155 160  
 Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg  
 165 170 175  
 30 Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile Gly Asp Lys Ile  
 180 185 190  
 Gly Met Phe Phe Gln Ser Ile Ala Thr Phe Phe Thr Gly Phe Ile Val  
 195 200 205  
 35 Gly Phe Thr Arg Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile Ser  
 210 215 220  
 Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys Ile Leu Ser Ser  
 225 230 235 240  
 Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Gly Ala Val Ala  
 245 250 255  
 40 Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly Gln  
 260 265 270  
 Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys Gly  
 275 280 285  
 45 Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser Ile Gly Ala Ala  
 290 295 300  
 Phe Leu Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr  
 305 310 315 320  
 Ser Leu Val Leu Ser Ser Glu Tyr Ser Ile Gly Gln Val Leu Thr Val  
 325 330 335  
 50 Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly Gln Ala Ser Pro  
 340 345 350  
 Ser Ile Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala Tyr Glu Ile Phe  
 355 360 365  
 55 Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr Ser Lys Ser Gly  
 370 375 380  
 His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe Lys Asn Val His  
 385 390 395 400  
 Phe Ser Tyr Pro Ser Arg Lys Glu Val Lys Ile Leu Lys Gly Leu Asn  
 405 410 415

00672725.00000

	Leu	Lys	Val	Gln	Ser	Gly	Gln	Thr	Val	Ala	Leu	Val	Gly	Asn	Ser	Gly
				420					425					430		
	Cys	Gly	Lys	Ser	Thr	Thr	Val	Gln	Leu	Met	Gln	Arg	Leu	Tyr	Asp	Pro
			435					440					445			
5	Thr	Asp	Gly	Met	Val	Cys	Ile	Asp	Gly	Gln	Asp	Ile	Arg	Thr	Ile	Asn
	Val	Arg	His	Leu	Arg	Glu	Ile	Thr	Gly	Val	Val	Ser	Gln	Glu	Pro	Val
	465					470					475					480
10	Leu	Phe	Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	Gly	Arg	Glu	Asn
					485					490					495	
	Val	Thr	Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	Ala	Asn	Ala	Tyr
				500					505					510		
	Asp	Phe	Ile	Met	Lys	Leu	Pro	Asn	Lys	Phe	Asp	Thr	Leu	Val	Gly	Glu
			515					520					525			
15	Arg	Gly	Ala	Gln	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	Ala
							535					540				
	Arg	Ala	Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Leu	Asp	Glu	Ala	Thr
	545					550					555					560
20	Ser	Ala	Leu	Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	Val	Ala	Leu	Asp
					565					570						575
	Lys	Ala	Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	His	Arg	Leu	Ser
				580					585					590		
	Thr	Val	Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	Asp	Gly	Val	Ile
				595				600					605			
25	Val	Glu	Lys	Gly	Asn	His	Asp	Glu	Leu	Met	Lys	Glu	Lys	Gly	Ile	Tyr
							615					620				
	Phe	Lys	Leu	Val	Thr	Met	Gln	Thr	Arg	Gly	Asn	Glu	Ile	Glu	Leu	Glu
	625					630					635					640
30	Asn	Ala	Thr	Gly	Glu	Ser	Lys	Ser	Glu	Ser	Asp	Ala	Leu	Glu	Met	Ser
					645					650					655	
	Pro	Lys	Asp	Ser	Gly	Ser	Ser	Leu	Ile	Lys	Arg	Arg	Ser	Thr	Arg	Arg
				660				665					670			
	Ser	Ile	His	Ala	Pro	Gln	Gly	Gln	Asp	Arg	Lys	Leu	Gly	Thr	Lys	Glu
				675				680					685			
35	Asp	Leu	Asn	Glu	Asn	Val	Pro	Pro	Val	Ser	Phe	Trp	Arg	Ile	Leu	Lys
							695					700				
	Leu	Asn	Ser	Thr	Glu	Trp	Pro	Tyr	Phe	Val	Val	Gly	Ile	Phe	Cys	Ala
	705					710					715					720
40	Ile	Ile	Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ser	Ile	Ile	Phe	Ser	Arg
					725					730					735	
	Ile	Ile	Gly	Ile	Phe	Thr	Arg	Asp	Glu	Asp	Pro	Glu	Thr	Lys	Arg	Gln
				740					745					750		
	Asn	Ser	Asn	Met	Phe	Ser	Val	Leu	Phe	Leu	Val	Leu	Gly	Ile	Ile	Ser
	</															

Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr Val Val Ser Leu  
 900 905 910  
 Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln Ser Leu Gln Val  
 915 920 925  
 5 Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe Gly Val Ser Phe  
 930 935 940  
 Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala Gly Cys Phe Arg  
 945 950 955 960  
 10 Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn Phe Gln Asp Val  
 965 970 975  
 Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met Ala Val Gly Gln  
 980 985 990  
 Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys Val Ser Ala Ala  
 995 1000 1005  
 15 His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile Asp Ser Tyr Ser  
 1010 1015 1020  
 Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn Val Thr Phe Asn  
 1025 1030 1035 1040  
 20 Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile Pro Val Leu Gln  
 1045 1050 1055  
 Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu Ala Leu Val Gly  
 1060 1065 1070  
 Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu Leu Glu Arg Phe  
 1075 1080 1085  
 25 Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly Lys Glu Ile Lys  
 1090 1095 1100  
 His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly Ile Val Ser Gln  
 1105 1110 1115 1120  
 30 Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn Ile Ala Tyr Gly  
 1125 1130 1135  
 Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Met Gln Ala Ala Lys  
 1140 1145 1150  
 Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro Glu Lys Tyr Asn  
 1155 1160 1165  
 35 Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly Gly Gln Lys Gln  
 1170 1175 1180  
 Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro His Ile Leu Leu  
 1185 1190 1195 1200  
 40 Leu Asp Glu Ala Thr Ser Ala Leu Asp Thr Glu Ser Glu Lys Val Val  
 1205 1210 1215  
 Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr Cys Ile Val Ile  
 1220 1225 1230  
 Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu Ile Val Val Phe  
 1235 1240 1245  
 45 Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln Gln Leu Leu Ala  
 1250 1255 1260  
 Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln Ala Gly Ala Lys  
 1265 1270 1275 1280  
 50 Arg  
  
 <210> 24  
 <211> 4279  
 <212> DNA  
 55 <213> Canis familiaris  
  
 <220>  
 <221> CDS  
 <222> (17)...(3859)  
 60

00672725-00000

	<400> 24																		
	ggagcgcgag	gtcggg	atg	gat	cct	gaa	gga	ggc	cgt	aag	ggg	agt	gca	gag				52	
				Met	Asp	Pro	Glu	Gly	Gly	Arg	Lys	Gly	Ser	Ala	Glu				
5	aag	aac	ttc	tgg	aaa	atg	ggc	aaa	aaa	agt	aaa	aaa	gag	aag	aaa			100	
	Lys	Asn	Phe	Trp	Lys	Met	Gly	Lys	Lys	Ser	Lys	Lys	Lys	Glu	Lys	Lys			
			15					20					25						
10	gaa	aag	aaa	cca	act	gtc	agc	acg	ttt	gca	atg	ttt	cgc	tat	tca	aat		148	
	Glu	Lys	Lys	Pro	Thr	Val	Ser	Thr	Phe	Ala	Met	Phe	Arg	Tyr	Ser	Asn			
			30					35					40						
15	tgg	ctt	gat	agg	ttg	tat	atg	ttg	gtg	ggg	aca	atg	gct	gcc	atc	atc		196	
	Trp	Leu	Asp	Arg	Leu	Tyr	Met	Leu	Val	Gly	Thr	Met	Ala	Ala	Ile	Ile			
			45			50					55					60			
20	cat	gga	gct	gca	ctc	cct	ctc	atg	atg	ctg	gtt	ttt	gga	aac	atg	aca		244	
	His	Gly	Ala	Ala	Leu	Pro	Leu	Met	Met	Leu	Val	Phe	Gly	Asn	Met	Thr			
					65					70					75				
25	gat	agc	ttt	gca	aat	gca	gga	att	tca	aga	aac	aaa	act	ttt	cca	gtt		292	
	Asp	Ser	Phe	Ala	Asn	Ala	Gly	Ile	Ser	Arg	Asn	Lys	Thr	Phe	Pro	Val			
				80					85					90					
30	ata	att	aat	gaa	agt	att	acg	aac	aat	aca	caa	cat	ttc	atc	aac	cat		340	
	Ile	Ile	Asn	Glu	Ser	Ile	Thr	Asn	Asn	Thr	Gln	His	Phe	Ile	Asn	His			
			95					100					105						
35	ctg	gag	gag	gaa	atg	acc	acg	tat	gcc	tat	tat	tac	agt	ggg	atc	ggt		388	
	Leu	Glu	Glu	Glu	Met	Thr	Thr	Tyr	Ala	Tyr	Tyr	Tyr	Ser	Gly	Ile	Gly			
							115					120							
40	gct	ggc	gtg	ctg	gtg	gct	gct	tac	atc	cag	gtt	tca	ttc	tgg	tgc	ctg		436	
	Ala	Gly	Val	Leu	Val	Ala	Ala	Tyr	Ile	Gln	Val	Val	Ser	Phe	Trp	Cys	Leu		
						130					135					140			
45	gca	gca	gga	aga	cag	ata	ctc	aaa	att	aga	aaa	caa	ttt	ttt	cat	gct		484	
	Ala	Ala	Gly	Arg	Gln	Ile	Leu	Lys	Ile	Arg	Lys	Gln	Phe	Phe	His	Ala			
					145					150					155				
50	atc	atg	cga	cag	gag	att	ggc	tgg	ttt	gac	gtg	cat	gac	gtt	ggg	gag		532	
	Ile	Met	Arg	Gln	Glu	Ile	Gly	Trp	Phe	Asp	Val	His	Asp	Val	Gly	Glu			
				160				165						170					
55	ctt	aac	acc	cgg	ctc	aca	gac	gat	gtc	tcc	aaa	atc	aat	gaa	gga	att		580	
	Leu	Asn	Thr	Arg	Leu	Thr	Asp	Asp	Val	Ser	Lys	Ile	Asn	Glu	Gly	Ile			
			175					180					185						
60	ggc	gac	aaa	att	gga	atg	phe	ttt	caa	tca	ata								



[illegible]

	cag Gln	gag Glu	cct Pro	gtg 480	ttg Leu	ttt Phe	gcc Ala	acc Thr	acg Thr	ata Ile	gct Ala	gaa Glu	aac Asn	att Ile	cgc Arg	tat Tyr	1492
5	ggc Gly	cgc Arg	gaa Glu	aat Asn	gtc Val	acc Thr	atg Met	gat Asp	gag Glu	att Ile	gag Glu	aaa Lys	gct Ala	gtt Val	aag Lys	gaa Glu	1540
10	gcc Ala	aat Asn	gcc Ala	tat Tyr	gat Asp	ttt Phe	atc Ile	atg Met	aaa Lys	cta Leu	cct Pro	aat Asn	aaa Lys	ttt Phe	gac Asp	act Thr	1588
15	ctg Leu	gtt Val	gga Gly	gag Glu	aga Arg	ggg Gly	gcc Ala	cag Gln	ctg Leu	agt Ser	ggt Gly	gga Gly	cag Gln	aaa Lys	cag Gln	aga Arg	1636
20	atc Ile	gcc Ala	att Ile	gct Ala	cgg Arg	gcc Ala	ctg Leu	gtt Val	cgc Arg	aac Pro	ccc Pro	aag Lys	att Ile	ctt Leu	ctg Leu	ctg Leu	1684
25	gat Asp	gag Glu	gca Ala	acg Thr	tca Ser	gct Ala	ctg Leu	gac Asp	act Thr	gaa Glu	agt Ser	gaa Glu	gca Ala	gtg Val	gtt Val	cag Gln	1732
30	gtg Val	gcc Ala	ctg Ala	gat Asp	aag Lys	gcc Ala	aga Arg	aaa Lys	ggc Gly	cgg Arg	act Thr	acc Thr	att Ile	gtg Val	ata Ile	gct Ala	1780
35	cat His	cgt Arg	ttg Leu	tct Ser	aca Thr	gtt Val	cgt Val	aat Asn	gcc Ala	gat Asp	gtc Val	att Ile	gct Ala	ggt Ile	ttt Phe	gat Asp	1828
40	gat Asp	gga Gly	gtc Val	att Ile	gtg Val	gag Glu	aaa Gln	gga Lys	aat Asn	cat His	gat Asp	gaa Glu	ctc Leu	atg Met	aaa Lys	gag Glu	1876
45	aag Lys	ggc Gly	att Ile	tac Tyr	ttc Phe	aaa Lys	ctt Leu	gtc Val	aca Thr	atg Met	caq Gln	aca Thr	aga Arg	gga Gly	aat Asn	gaa Glu	1924
50	att Ile	gag Glu	tta Leu	gaa Glu	aat Asn	gcc Ala	act Thr	ggt Gly	gaa Glu	tcc Ser	aaa Lys	agt Ser	gaa Glu	agt Ser	gat Asp	gcc Ala	1972
55	ttg Leu	gaa Glu	atg Met	tct Ser	cca Pro	aaa Lys	gat Asp	tca Ser	ggg Gly	tcc Ser	agt Ser	tta Leu	ata Ile	aaa Lys	aga Arg	aga Arg	2020
60	tca Ser	act Thr	cgc Arg	agg Arg	agt Ser	ata Ile	cat His	gca Ala	cca Pro	caa Gln	ggc Gly	caa Gln	gac Asp	aga Arg	aag Lys	ctt Leu	2068
65	ggt Gly	aca Thr	aaa Lys	gag Glu	gac Asp	ttg Leu	aat Asn	gag Glu	aat Asn	gta Val	cct Pro	cca Pro	gtt Val	tcc Ser	ttc Phe	tggt Trp	2116
70	agg Arg	att Ile	ctg Leu	aag Lys	ctg Leu	aac Asn	tca Ser	act Thr	gaa Glu	tgg Trp	cct Pro	tat Tyr	ttt Phe	gtg Val	gtt Val	ggt Gly	2164

	ata	ttt	tgt	gct	att	ata	aac	gga	ggc	ctg	caa	cca	gca	ttt	tca	ata	2212
	Ile	Phe	Cys	Ala	Ile	Ile	Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ser	Ile	
				720					725					730			
5	ata	ttt	tca	agg	att	ata	ggg	atc	ttt	acc	cga	gat	gag	gat	cct	gaa	2260
	Ile	Phe	Ser	Arg	Ile	Ile	Gly	Ile	Phe	Thr	Arg	Asp	Glu	Asp	Pro	Glu	
				735				740					745				
10	aca	aaa	cga	cag	aat	agt	aac	atg	ttt	tct	gta	ttg	ttt	cta	gtc	ctt	2308
	Thr	Lys	Arg	Gln	Asn	Ser	Asn	Met	Phe	Ser	Val	Leu	Phe	Leu	Val	Leu	
				750			755					760					
15	gga	att	att	tct	ttt	att	aca	ttt	ttc	ctc	cag	ggc	ttc	aca	ttt	ggc	2356
	Gly	Ile	Ile	Ser	Phe	Ile	Thr	Phe	Phe	Leu	Gln	Gly	Phe	Thr	Phe	Gly	
						770					775					780	
20	aaa	gct	ggg	gag	atc	ctc	act	aag	cgg	ctt	cga	tac	atg	ggt	ttc	aga	2404
	Lys	Ala	Gly	Glu	Ile	Leu	Thr	Lys	Arg	Leu	Arg	Tyr	Met	Val	Phe	Arg	
					785					790					795		
25	tcc	atg	ctg	aga	cag	gat	gtc	agc	tgg	ttt	gat	gac	cct	aaa	aac	acc	2452
	Ser	Met	Leu	Arg	Gln	Asp	Val	Ser	Trp	Phe	Asp	Asp	Pro	Lys	Asn	Thr	
				800					805					810			
30	act	gga	gca	ttg	aca	acc	agg	ctt	gcc	aat	gat	gcg	gct	caa	gtt	aaa	2500
	Thr	Gly	Ala	Leu	Thr	Thr	Arg	Leu	Ala	Asn	Asp	Ala	Ala	Gln	Val	Lys	
				815				820					825				
35	ggg	gct	ata	ggc	tcc	agg	ctt	gct	gtc	att	acc	cag	aat	ata	gca	aat	2548
	Gly	Ala	Ile	Gly	Ser	Arg	Leu	Ala	Val	Ile	Thr	Gln	Asn	Ile	Ala	Asn	
				830			835					840					
40	ctt	ggg	aca	ggc	att	att	ata	tcc	tta	atc	tat	ggt	tgg	caa	tta	aca	2596
	Leu	Gly	Thr	Gly	Ile	Ile	Ile	Ser	Leu	Ile	Tyr	Gly	Trp	Gln	Leu	Thr	
				845		850				855						860	
45	ctt	tta	ctc	tta	gca	att	gta	ccc	atc	att	gca	ata	gca	gga	gtt	gtt	2644
	Leu	Leu	Leu	Leu	Ala	Ile	Val	Pro	Ile	Ile	Ala	Ile	Ala	Gly	Val	Val	
					865				870					875			
50	gaa	atg	aaa	atg	ttg	tct	gga	caa	gca	ctg	aaa	gat	aag	aaa	gag	cta	2692
	Glu	Met	Lys	Met	Leu	Ser	Gly	Gln	Ala	Leu	Lys	Asp	Lys	Lys	Glu	Leu	
				880				885						890			
55	gaa	gga	gct	ggg	aag	att	gct	aca	gaa	gcc	atc	gaa	aac	ttc	cga	act	2740
	Glu	Gly	Ala	Gly	Lys	Ile	Ala	Thr	Glu	Ala	Ile	Glu	Asn	Phe	Arg	Thr	
				895			900					905					
60	gtt	gtt	tct	ttg	act	cgg	gag	cag	aag	ttt	gaa	tac	atg	tat	gca	cag	2788
	Val	Val	Ser	Leu	Thr	Arg	Glu	Gln	Lys	Phe	Glu	Tyr	Met	Tyr	Ala	Gln	
				910			915				920						
55	agt	ttg	caa	gta	cca	tac	aga	aac	tct	ttg	agg	aaa	gca	cac	atc	ttc	2836
	Ser	Leu	Gln	Val	Pro	Tyr	Arg	Asn	Ser	Leu	Arg	Lys	Ala	His	Ile	Phe	
						930					935					940	
60	ggg	gtc	tca	ttt	tct	atc	acc	cag	gca	atg	atg	tat	ttt	tcc	tat	gct	2884
	Gly	Val	Ser	Phe	Ser	Ile	Thr	Gln	Ala	Met	Met	Tyr	Phe	Ser	Tyr	Ala	
						945				950				955			

	ggc tgt ttc cgg ttt ggt gcc tac ttg gtg gca aat gag ttc atg aac Gly Cys Phe Arg Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn 960 965 970	2932
5	ttt cag gat gtt ctt ttg gta ttc tca gct att gtc ttt ggt gcc atg Phe Gln Asp Val Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met 975 980 985	2980
10	gca gtg ggg cag gtc agt tca ttt gct cct gac tat gcc aaa gcc aaa Ala Val Gly Gln Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys 990 995 1000	3028
15	gta tca gca gcc cac gtc atc atg atc att gaa aaa agc cct ctg att Val Ser Ala Ala His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile 1005 1010 1015 1020	3076
20	gac agc tac agc cct cac ggc ctc aaq cca aat acg ttg gaa gga aat Asp Ser Tyr Ser Pro His Gly Leu Lys Pro Asn Thr Leu Glu Gly Asn 1025 1030 1035	3124
	gtg aca ttt aat gag gtc gtg ttc aac tat ccc act cga cca gac atc Val Thr Phe Asn Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile 1040 1045 1050	3172
25	ccc gtg ctc cag ggg ctg agc ctc gag gtg aag aag ggc cag acg ctg Pro Val Leu Gln Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu 1055 1060 1065	3220
30	gcc ctc gta ggt agc agt ggc tgt ggg aag agc aca gtt gtt cag ctc Ala Leu Val Gly Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu 1070 1075 1080	3268
35	cta gag cgc ttc tat gac ccc ttg gct ggt tca gtg cta att gat ggc Leu Glu Arg Phe Tyr Asp Pro Leu Ala Gly Ser Val Leu Ile Asp Gly 1085 1090 1095 1100	3316
40	aaa gag ata aag cac ctg aat gtc cag tgg ctc cga gca cac ctg ggc Lys Glu Ile Lys His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly 1105 1110 1115	3364
	atc gtg tct cag gag ccc atc ctg ttt gac tgc agc att gcc gag aac Ile Val Ser Gln Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn 1120 1125 1130	3412
45	att gcc tat gga gac aac agc cgg gtc gta tca cat gaa gag att atg Ile Ala Tyr Gly Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Met 1135 1140 1145	3460
50	cag gca gcc aag gag gcc aac ata cac cac ttc atc gag aca ctc cct Gln Ala Ala Lys Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro 1150 1155 1160	3508
55	gag aaa tac aac acc aga gta gga gac aaa gga acc cag ctc tct ggt Glu Lys Tyr Asn Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly 1165 1170 1175 1180	3556
60	ggc cag aaa cag cgc att gcc ata gct cgc gct ctt gtt aga cag cct Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro 1185 1190 1195	3604

006727225-092800

	cat	att	ttg	ctt	ttg	gat	gaa	gct	aca	tca	gct	ctg	gat	aca	gaa	agt	3652
	His	Ile	Leu	Leu	Leu	Asp	Glu	Ala	Thr	Ser	Ala	Leu	Asp	Thr	Glu	Ser	
			1200						1205					1210			
5																	
	gaa	aag	gtt	gtc	caa	gaa	gcc	ctg	gac	aaa	gcc	aga	gaa	ggc	cgc	acc	3700
	Glu	Lys	Val	Val	Gln	Glu	Ala	Leu	Asp	Lys	Ala	Arg	Glu	Gly	Arg	Thr	
			1215					1220				1225					
10																	
	tgc	att	gtg	atc	gcc	cac	cgc	ttg	tcc	acc	atc	cag	aat	gca	gat	tta	3748
	Cys	Ile	Val	Ile	Ala	His	Arg	Leu	Ser	Thr	Ile	Gln	Asn	Ala	Asp	Leu	
			1230				1235					1240					
15																	
	ata	gtg	gtg	ttt	cag	aat	ggc	aaa	gtc	aag	gag	cat	ggc	aca	cat	caa	3796
	Ile	Val	Val	Phe	Gln	Asn	Gly	Lys	Val	Lys	Glu	His	Gly	Thr	His	Gln	
			1245				1250					1255				1260	
20																	
	cag	ctg	ctg	gcc	cag	aaa	ggc	atc	tat	ttt	tcc	atg	gtc	agt	gtc	cag	3844
	Gln	Leu	Leu	Ala	Gln	Lys	Gly	Ile	Tyr	Phe	Ser	Met	Val	Ser	Val	Gln	
				1265							1270					1275	
25																	
	gct	gga	gca	aag	cgc	tagtgaactg	tgggccatgatg	agctgttataa	tatttttttaa								3899
	Ala	Gly	Ala	Lys	Arg												
			1280														
30																	
	tattttgtgtt	aaaacatggc	atttaaatcaa	agttaaaaag	tgagcactta	ctggaaaaaac											3959
	tatgtagaac	taacctgttta	acattctctt	ctgccaactg	agatcattcc	accaagttca											4019
	gagctcttcag	attttataat	taaaaggaacc	aaaagaaaaca	ttatctgatg	gaataaaaata											4079
	ctgggtgttaa	ttgcattata	aaatatataga	gtaattccaa	gtagattttg	tttaataaatt											4139
	gtataatttt	tgtttatatt	ttatttgttaa	cttaactgctt	tgctgaaag	ttatagaagtt											4199
	ggtaaaaaagt	actgaatggt	tgaaataaagt	gctagctata	ataaaaactaa	actttttatat											4259
	caaaaaaaaaa	aaaaaaaaaaa															
35																	
	<210>	25															
	<211>	1281															
	<212>	PRT															
	<213>	Canis familiaris															
40																	
	<400>	25															
	Met	Asp	Pro	Glu	Gly	Gly	Arg	Lys	Gly	Ser	Ala	Glu	Lys	Asn	Phe	Trp	
	1				5					10					15		
	Lys	Met	Gly	Lys	Lys	Ser	Lys	Lys	Lys	Glu							

					165					170					175		
	Leu	Thr	Asp	Asp	Val	Ser	Lys	Ile	Asn	Glu	Gly	Ile	Gly	Asp	Lys	Ile	
				180					185					190			
5	Gly	Met	Phe	Phe	Gln	Ser	Ile	Ala	Thr	Phe	Phe	Thr	Gly	Phe	Ile	Val	
			195					200					205				
	Gly	Phe	Thr	Arg	Gly	Trp	Lys	Leu	Thr	Leu	Val	Ile	Leu	Ala	Ile	Ser	
		210					215					220					
	Pro	Val	Leu	Gly	Leu	Ser	Ala	Ala	Ile	Trp	Ala	Lys	Ile	Leu	Ser	Ser	
10	225					230					235					240	
	Phe	Thr	Asp	Lys	Glu	Leu	Leu	Ala	Tyr	Ala	Lys	Ala	Gly	Ala	Val	Ala	
					245										255		
	Glu	Glu	Val	Leu	Ala	Ala	Ile	Arg	Thr	Val	Ile	Ala	Phe	Gly	Gly	Gln	
				260					265					270			
15	Lys	Lys	Glu	Leu	Glu	Arg	Tyr	Asn	Lys	Asn	Leu	Glu	Glu	Ala	Lys	Gly	
			275					280					285				
	Ile	Gly	Ile	Lys	Lys	Ala	Ile	Thr	Ala	Asn	Ile	Ser	Ile	Gly	Ala	Ala	
		290					295					300					
20	Phe	Leu	Leu	Ile	Tyr	Ala	Ser	Tyr	Ala	Leu	Ala	Phe	Trp	Tyr	Gly	Thr	
	305					310					315					320	
	Ser	Leu	Val	Leu	Ser	Ser	Glu	Tyr	Ser	Ile	Gly	Gln	Val	Leu	Thr	Val	
					325					330					335		
	Phe	Phe	Ser	Val	Leu	Ile	Gly	Ala	Phe	Ser	Ile	Gly	Gln	Ala	Ser	Pro	
					340				345					350			
25	Ser	Ile	Glu	Ala	Phe	Ala	Asn	Ala	Arg	Gly	Ala	Ala	Tyr	Glu	Ile	Phe	
			355					360					365				
	Lys	Ile	Ile	Asp	Asn	Lys	Pro	Ser	Ile	Asp	Ser	Tyr	Ser	Lys	Ser	Gly	
		370					375					380					
30	His	Lys	Pro	Asp	Asn	Ile	Lys	Gly	Asn	Leu	Glu	Phe	Lys	Asn	Val	His	
	385					390					395					400	
	Phe	Ser	Tyr	Pro	Ser	Arg	Lys	Glu	Val	Lys	Ile	Leu	Lys	Gly	Leu	Asn	
					405					410					415		
	Leu	Lys	Val	Gln	Ser	Gly	Gln	Thr	Val	Ala	Leu	Val	Gly	Asn	Ser	Gly	
				420					425					430			
35	Cys	Gly	Lys	Ser	Thr	Thr	Val	Gln	Leu	Met	Gln	Arg	Leu	Tyr	Asp	Pro	
			435					440					445				
	Thr	Asp	Gly	Met	Val	Cys	Ile	Asp	Gly	Gln	Asp	Ile	Arg	Thr	Ile	Asn	
		450					455					460					
40	Val	Arg	His	Leu	Arg	Glu	Ile	Thr	Gly	Val	Val	Ser	Gln	Glu	Pro	Val	
	465					470					475					480	
	Leu	Phe	Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	Gly	Arg	Glu	Asn	
					485					490				495			
	Val	Thr	Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	Ala	Asn	Ala	Tyr	
				500					505					510			
45	Asp	Phe	Ile	Met	Lys	Leu	Pro	Asn	Lys	Phe	Asp	Thr	Leu	Val	Gly	Glu	
			515					520					525				
	Arg	Gly	Ala	Gln	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	Ala	
		530					535					540					
	Arg	Ala	Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Leu	Asp	Glu	Ala	Thr	
50	545					550					555					560	
	Ser	Ala	Leu	Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	Val	Ala	Leu	Asp	
					565					570					575		
	Lys	Ala	Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	His	Arg	Leu	Ser	
				580					585					590			
55	Thr	Val	Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	Asp	Gly	Val	Ile	
			595					600					605				
	Val	Glu	Lys	Gly	Asn	His	Asp	Glu	Leu	Met	Lys	Glu	Lys	Gly	Ile	Tyr	
				610			615					620					
	Phe	Lys	Leu	Val	Thr	Met	Gln	Thr	Arg	Gly	Asn	Glu	Ile	Glu	Leu	Glu	
		625				630					635					640	
60	Asn	Ala	Thr	Gly	Glu	Ser	Lys	Ser	Glu	Ser	Asp	Ala	Leu	Glu	Met	Ser	

[illegible]

	Asp	Asn	Ser	Arg	Val	Val	Ser	His	Glu	Glu	Ile	Met	Gln	Ala	Ala	Lys	
				1125					1130							1135	
				1140					1145							1150	
5	Glu	Ala	Asn	Ile	His	His	Phe	Ile	Glu	Thr	Leu	Pro	Glu	Lys	Tyr	Asn	
			1155					1160						1165			
	Thr	Arg	Val	Gly	Asp	Lys	Gly	Thr	Gln	Leu	Ser	Gly	Gly	Gln	Lys	Gln	
			1170				1175						1180				
	Arg	Ile	Ala	Ile	Ala	Arg	Ala	Leu	Val	Arg	Gln	Pro	His	Ile	Leu	Leu	
	1185					1190					1195				1200		
10	Leu	Asp	Glu	Ala	Thr	Ser	Ala	Leu	Asp	Thr	Glu	Ser	Glu	Lys	Val	Val	
				1205						1210					1215		
	Gln	Glu	Ala	Leu	Asp	Lys	Ala	Arg	Glu	Gly	Arg	Thr	Cys	Ile	Val	Ile	
				1220					1225					1230			
	Ala	His	Arg	Leu	Ser	Thr	Ile	Gln	Asn	Ala	Asp	Leu	Ile	Val	Val	Phe	
			1235					1240					1245				
15	Gln	Asn	Gly	Lys	Val	Lys	Glu	His	Gly	Thr	His	Gln	Gln	Leu	Leu	Ala	
		1250				1255						1260					
	Gln	Lys	Gly	Ile	Tyr	Phe	Ser	Met	Val	Ser	Val	Gln	Ala	Gly	Ala	Lys	
	1265					1270						1275				1280	
20	Arg																
	<210>	26															
	<211>	4279															
25	<212>	DNA															
	<213>	Canis familiaris															
	<220>																
	<221>	CDS															
30	<222>	(17)...(3859)															
	<400>	26															
	ggagcgcgag gtcggg atg gat cct gaa gga ggc cgt aag ggg agt gca gag																52
		Met Asp Pro Glu Gly Arg Lys Gly Ser Ala Glu															
35		1 5 10															
	aag aac ttc tgg aaa atg ggc aaa aaa agt aaa aaa aag aag aag																100
	Lys Asn Phe Trp Lys Met Gly Lys Ser Lys Lys Lys Glu Lys Lys																
		15 20 25															
40	gaa aag aaa cca act gtc agc acg ttt gca atg ttt cgc tat tca aat																148
	Glu Lys Lys Pro Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn																
		30 35 40															
45	tgg ctt gat agg ttg tat atg ttg gtg ggg aca atg gct gcc atc atc																196
	Trp Leu Asp Arg Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile																
		45 50 55 60															
	cat gga gct gca ctg cct ctg atg atg ctg gtt ttt gga aac atg aca																244
50	His Gly Ala Ala Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr			</													



	ctg gag gag gaa atg acc acg tat gcc tat tat tac agt ggg atc ggt Leu Glu Glu Glu Met Thr Tyr Ala Tyr Tyr Ser Gly Ile Gly 110 115 120	388
5	gct ggc gtg ctg gtg gct gct tac atc cag gtt tca ttc tgg tgc ctg Ala Gly Val Leu Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu 125 130 135 140	436
10	gca gca gga aga cag ata ctc aaa att aga aaa caa ttt ttt cat gct Ala Ala Gly Arg Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala 145 150 155	484
15	atc atg cga cag gag att ggc tgg ttt gac gtg cat gac gtt ggg gag Ile Met Arg Gln Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu 160 165 170	532
20	ctt aac acc cgg ctc aca gac gat gtc tcc aaa atc aat gaa gga att Leu Asn Thr Arg Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile 175 180 185	580
25	ggc gac aaa att gga atg ttc ttt caa tca ata gca aca ttt ttc acc Gly Asp Lys Ile Gly Met Phe Phe Gln Ser Ile Ala Thr Phe Phe Thr 190 195 200	628
30	ggt ttt ata gtg ggg ttt aca cgt ggt tgg aag cta acc ctt gtg att Gly Phe Ile Val Gly Phe Thr Arg Gly Trp Lys Leu Thr Leu Val Ile 205 210 215 220	676
35	ttg gcc atc agc cot gtt ctt gga ctt tca gcc gcc atc tgg gca aag Leu Ala Ile Ser Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys 225 230 235	724
40	ata cta tct tca ttt act gat aaa gaa ctc ttg gcc tat gca aaa gct Ile Leu Ser Ser Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala 240 245 250	772
45	gga gca gta gct gaa gaa gtc tta gca gca atc aga act gtg att gcc Gly Ala Val Ala Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala 255 260 265	820
50	ttt gga gga caa aag aaa gaa ctt gaa agg tac aac aaa aat tta gaa Phe Gly Gly Gln Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu 270 275 280	868
55	gaa gct aaa gga att ggg ata aag aaa gct atc acg gcc aac att tct Glu Ala Lys Gly Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser 285 290 295 300	916
60	att ggt gcc gct ttc tta ttg atc tat gca tca tat gct ctg gct ttc Ile Gly Ala Ala Phe Leu Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe 305 310 315	964
65	tgg tat ggg acc tcc ttg gtc ctc tcc agt gaa tat act att gga caa Trp Tyr Gly Thr Ser Leu Val Leu Ser Ser Glu Tyr Thr Ile Gly Gln 320 325 330	1012
70	gta ctc act gtc ttc ttt tct gta tta att ggg gct ttt agt att gga Val Leu Thr Val Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly 335 340 345	1060

00000-00000-00000

	cag Gln	gca Ala	tcc Ser	cca Pro	agc Ser	att Ile	gaa Glu	gca Ala	ttt Phe	gca Ala	aac Asn	gca Ala	aga Arg	gga Gly	gca Ala	gct Ala	1108
	350						355				360						
5	tat Tyr	gaa Glu	atc Ile	ttc Phe	aag Lys	ata Ile	att Ile	gac Asp	aat Asn	aaa Lys	cca Ser	agc Ser	att Ile	gac Asp	agc Ser	tat Tyr	1156
	365					370					375					380	
10	tcg Ser	aag Lys	agt Ser	gga Gly	cat His	aaa Lys	cca Pro	gat Asp	aat Asn	att Ile	aag Lys	gga Gly	aat Asn	ttg Leu	gaa Glu	ttc Phe	1204
					385					390					395		
15	aaa Lys	aat Asn	gtt Val	cac His	ttc Phe	agt Ser	tac Tyr	cct Pro	tct Pro	cga Arg	aaa Lys	gaa Glu	gtt Val	aag Lys	atc Ile	tta Leu	1252
				400					405					410			
20	aag Lys	ggc Gly	ctc Leu	aac Asn	ctg Leu	aag Lys	gtt Val	cag Gln	agt Ser	ggg Gly	cag Gln	aca Thr	gtg Val	gcg Ala	ctg Leu	gtt Val	1300
			415					420					425				
25	ggg Gly	aac Asn	agt Ser	ggc Gly	tgc Cys	ggg Gly	aag Lys	agc Ser	acc Thr	gtg Val	cag Gln	ctg Leu	atg Met	cag Gln	agg Arg		1348
		430					435					440					
30	ctc Leu	tat Tyr	gac Asp	ccc Pro	aca Thr	gat Asp	ggc Gly	atg Met	gtc Val	tgt Cys	att Ile	gat Asp	gga Gly	cag Gln	gac Asp	att Ile	1396
	445					450					455					460	
35	agg Arg	acc Thr	ata Ile	aat Asn	gta Val	agg Arg	cat His	ctt Leu	cgg Arg	gaa Glu	att Ile	act Thr	ggt Gly	gtg Val	gtg Val	agt Ser	1444
					465				470					475			
40	cag Gln	gag Glu	cct Pro	gtg Val	ttg Leu	ttt Phe	gcc Ala	acc Thr	acg Thr	ata Ile	gct Pro	gaa Glu	aac Asn	att Ile	cgc Arg	tat Tyr	1492
				480					485					490			
45	ggc Gly	cgc Arg	gaa Glu	aat Asn	gtc Val	acc Thr	atg Met	gat Asp	gag Glu	att Ile	gag Glu	aaa Lys	gct Ala	gtt Val	aag Lys	gaa Glu	1540
			495					500					505				
50	gcc Ala	aat Ala	gcc Ala	tat Tyr	gat Asp	ttt Phe	atc Met	atg Lys	aaa Leu	cta Leu	cct Pro	aat Asn	aaa Lys	ttt Phe	gac Asp	act Thr	1588
	510						515					520					
55	ctg Leu	gtt Val	gga Gly	gag Glu	aga Arg	ggg Gly	gcc Ala	cag Gln	ctg Leu	agt Ser	ggt Gly	gga Gly	cag Gln	aaa Lys	cag Gln	aga Arg	1636
	525					530					535					540	
60	atc Ile	gcc Ala	att Ile	gct Ala	cgg Arg	gcc Ala	ctg Leu	gtt Val	cgc Arg	aac Asn	ccc Pro	aag Lys	att Ile	ctt Leu	ctg Val	ctg Leu	1684
				545						550				555			
65	gat Asp	gag Glu	gca Ala	acg Thr	tca Ser	got Ala	ctg Leu	gac Asp	act Thr	gaa Glu	agt Ser	gaa Glu	gca Ala	gtg Val	gtt Val	cag Gln	1732
				560					565					570			
70	gtg Val	gcc Ala	ctg Leu	gat Asp	aag Lys	gcc Ala	aga Arg	aaa Lys	ggc Gly	cgg Arg	act Thr	acc Thr	att Thr	gtg Val	ata Ile	gct Ala	1780
				575				580						585			

	cat cgt ttg tct aca gtt cgt aat gcc gat gtc att gct ggt ttt gat His Arg Leu Ser Thr Val Arg Asn Ala Asp Val Ile Ala Gly Phe Asp 590 595 600	1828
5	gat gga gtc att gtg gag aaa gga aat cat gat gaa ctc atg aaa gag Asp Gly Val Ile Val Glu Lys Gly Asn His Asp Glu Leu Met Lys Glu 605 610 615 620	1876
10	aag ggc att tac ttc aaa ctt gtc aca atg cag aca aga gga aat gaa Lys Gly Ile Tyr Phe Lys Leu Val Thr Met Gln Thr Arg Gly Asn Glu 625 630 635	1924
15	att gag tta gaa aat gcc act ggt gaa tcc aaa agt gaa agt gat gcc Ile Glu Leu Glu Asn Ala Thr Gly Glu Ser Lys Ser Glu Ser Asp Ala 640 645 650	1972
20	ttg gaa atg tct cca aaa gat tca ggg tcc agt tta ata aaa aga aga Leu Glu Met Ser Pro Lys Asp Ser Gly Ser Ser Leu Ile Lys Arg Arg 655 660 665	2020
25	tca act cgc agg agt ata cat gca cca caa ggc caa gac aga aag ctt Ser Thr Arg Arg Ser Ile His Ala Pro Gln Gly Gln Asp Arg Lys Leu 670 675 680	2068
30	ggt aca aaa gag gac ttg aat gag aat gta cct cca gtt tcc ttc tgg Gly Thr Lys Glu Asp Glu Asn Glu Asn Val Pro Pro Val Ser Phe Trp 685 690 695 700	2116
35	agg att ctg aag ctg aac tca act gaa tgg cct tat ttt gtg gtt ggt Arg Ile Leu Lys Leu Asn Ser Thr Glu Trp Pro Tyr Phe Val Val Gly 705 710 715	2164
40	ata ttt tgt gct att ata aac gga ggc ctg caa cca gca ttt tca ata Ile Phe Cys Ala Ile Ile Asn Gly Gly Leu Gln Pro Ala Phe Ser Ile 720 725 730	2212
45	ata ttt tca agg att ata ggg atc ttt acc cga gat gag gat cct gaa Ile Phe Ser Arg Ile Ile Gly Ile Phe Thr Arg Asp Glu Asp Pro Glu 735 740 745	2260
50	aca aaa cga cag aat agt aac atg ttt tct gta ttg ttt cta gtc ctt Thr Lys Arg Gln Asn Ser Asn Met Phe Ser Val Leu Phe Leu Val Leu 750 755 760	2308
55	gga att att tct ttt att aca ttt ttc ctc cag ggc ttc aca ttt ggc Gly Ile Ile Ser Phe Ile Thr Phe Phe Leu Gln Gly Phe Thr Phe Gly 765 770 775 780	2356
60	aaa gct ggg gag atc ctc act aag cgg ctt cga tac atg gtt ttc aga Lys Ala Gly Glu Ile Leu Thr Lys Arg Leu Arg Tyr Met Val Phe Arg 785 790 795	2404
	tcc atg ctg aga cag gat gtc agc tgg ttt gat gac cct aaa aac acc Ser Met Leu Arg Gln Asp Val Ser Trp Phe Asp Asp Pro Lys Asn Thr 800 805 810	2452
	act gga gca ttg aca acc agg ctt gcc aat gat gcg gct caa gtt aaa Thr Gly Ala Leu Thr Thr Arg Leu Ala Asn Asp Ala Ala Gln Val Lys 815 820 825	2500

00672725 \* 000000

	ggg gct ata ggt tcc agg ctt gct gtc att acc cag aat ata gca aat Gly Ala Ile Gly Ser Arg Leu Ala Val Ile Thr Gln Asn Ile Ala Asn 830 835 840	2548
5	ctt ggg aca ggc att att ata tcc tta atc tat ggt tgg caa tta aca Leu Gly Thr Gly Ile Ile Ile Ser Leu Ile Tyr Gly Trp Gln Leu Thr 845 850 855 860	2596
10	ctt tta ctc tta gca att gta ccc atc att gca ata gca gga gtt gtt Leu Leu Leu Leu Ala Ile Val Pro Ile Ile Ala Ile Ala Gly Val Val 865 870 875	2644
15	gaa atg aaa atg ttg tct gga caa gca ctg aaa gat aag aaa gag cta Glu Met Lys Met Leu Ser Gly Gln Ala Leu Lys Asp Lys Lys Glu Leu 880 885 890	2692
20	gaa gga gct ggg aag att gct aca gaa gcc atc gaa aac ttc cga act Glu Gly Ala Gly Lys Ile Ala Thr Glu Ala Ile Glu Asn Phe Arg Thr 895 900 905	2740
	gtt gtt tct ttg act cgg gag cag aag ttt gaa tac atg tat gca cag Val Val Ser Leu Thr Arg Glu Gln Lys Phe Glu Tyr Met Tyr Ala Gln 910 915 920	2788
25	agt ttg caa gta cca tac aga aac tct ttg agg aaa gca cac atc ttc Ser Leu Gln Val Pro Tyr Arg Asn Ser Leu Arg Lys Ala His Ile Phe 925 930 935 940	2836
30	ggg gtc tca ttt tct atc acc cag gca atg atg tat ttt tcc tat gct Gly Val Ser Phe Ser Ile Thr Gln Ala Met Met Tyr Phe Ser Tyr Ala 945 950 955	2884
35	ggc tgt ttc cgg ttt ggt gcc tac ttg gtg gca aat gag ttc atg aac Gly Cys Phe Arg Phe Gly Ala Tyr Leu Val Ala Asn Glu Phe Met Asn 960 965 970	2932
40	ttt cag gat gtt ctt ttg gta ttc tca gct att gtc ttt ggt gcc atg Phe Gln Asp Val Leu Leu Val Phe Ser Ala Ile Val Phe Gly Ala Met 975 980 985	2980
	gca gtg ggg cag gtc agt tca ttt gct cct gac tat gcc aaa gcc aaa Ala Val Gly Gln Val Ser Ser Phe Ala Pro Asp Tyr Ala Lys Ala Lys 990 995 1000	3028
45	gta tca gca gcc cac gtc atc atg atc att gaa aaa agc cct ctg att Val Ser Ala Ala His Val Ile Met Ile Ile Glu Lys Ser Pro Leu Ile 1005 1010 1015 1020	3076
50	gac agc tac agc cct cac ggc ctc aag cca aat acg ttg gaa gga aat Asp Ser Tyr Ser Pro His Gly Leu Lys Pro Asn Thr Leu Gly Gly Asn 1025 1030 1035	3124
55	gtg aca ttt aat gag gtc gtg ttc aac tat ccc act cga cca gac atc Val Thr Phe Asn Glu Val Val Phe Asn Tyr Pro Thr Arg Pro Asp Ile 1040 1045 1050	3172
60	ccc gtg ctc cag ggg ctg agc ctc gag gtg aag aag ggc cag acg ctg Pro Val Leu Gln Gly Leu Ser Leu Glu Val Lys Lys Gly Gln Thr Leu 1055 1060 1065	3220

00672725-092000

	gcc ctc gta ggt agc agt ggc tgt ggg aag agc aca gtt gtt cag ctc Ala Leu Val Gly Ser Ser Gly Cys Gly Lys Ser Thr Val Val Gln Leu	3268
5	cta gag cgc ttc tat gac ccc ttg gct ggt tca gtg cta att gat ggc Leu Glu Arg Phe Tyr Asp Pro Leu Ala Gly Lys Val Leu Ile Asp Gly	3316
10	aaa gag ata aag cac ctg aat gtc cag tgg ctc cga gca cac ctg ggc Lys Glu Ile Lys His Leu Asn Val Gln Trp Leu Arg Ala His Leu Gly	3364
15	atc gtg tct cag gag ccc atc ctg ttt gac tgc agc att gcc gag aac Ile Val Ser Gln Glu Pro Ile Leu Phe Asp Cys Ser Ile Ala Glu Asn	3412
20	att gcc tat gga gac aac agc cgg gtc gta tca cat gaa gag att gtg Ile Ala Tyr Gly Asp Asn Ser Arg Val Val Ser His Glu Glu Ile Val	3460
25	cag gca gcc aag gag gcc aac ata cac cac ttc atc gag aca ctc cct Gln Ala Ala Lys Glu Ala Asn Ile His His Phe Ile Glu Thr Leu Pro	3508
30	gag aaa tac aac acc aga gta gga gac aaa gga acc cag ctc tct ggt Glu Lys Tyr Asn Thr Arg Val Gly Asp Lys Gly Thr Gln Leu Ser Gly	3556
35	ggc cag aaa cag cgc att gcc ata gct cgc gct ctt gtt aga cag cct Gly Gln Lys Gln Arg Ile Ala Ile Ala Arg Ala Leu Val Arg Gln Pro	3604
40	cat att ttg ctt ttg gat gaa gct aca tca gct ctg gat aca gaa agt His Ile Leu Leu Leu Asp Glu Ala Thr Ser Ala Thr Asp Thr Glu Ser	3652
45	gaa aag gtt gtc caa gaa gcc ctg gac aaa gcc aga gaa ggc cgc acc Glu Lys Val Val Gln Glu Ala Leu Asp Lys Ala Arg Glu Gly Arg Thr	3700
50	tgc att gtg atc gcc cac cgc ttg tcc acc atc cag aat gca gat tta Cys Ile Val Ile Ala His Arg Leu Ser Thr Ile Gln Asn Ala Asp Leu	3748
55	ata gtg gtg ttt cag aat ggc aaa gtc aag gag cat ggc aca cat caa Ile Val Val Phe Gln Asn Gly Lys Val Lys Glu His Gly Thr His Gln	3796
60	cag ctg ctg gcc cag aaa ggc atc tat ttt tcc atg gtc agt gtc cag Gln Leu Leu Ala Gln Lys Gly Ile Tyr Phe Ser Met Val Ser Val Gln	3844
65	gct gga gca aag cgc tagtgaactg tggccatatg agctgttaaa tattttttaa Ala Gly Ala Lys Arg	3892
70	tatttgtgtt aaaacatggc atttaaatcaa agttaaagg tgagcactta ctggaaaaac tatgtagaac tacttgttta acatttcttg ctgcaactga agatcaattcc accaagttca	3959
75	gagtcttoag attttataat taaaggaaac aaagaagaaca ttatctgatg gaataaataa ctggatgttaa ttgacattata aaattataga gtaattcaaa gtatgatttg ttaataaatt	4019
80		4079
85		4139

gtataatttt tgtttatatt ttatttgtaa cttactgctt tgcgtgaaaga ttatagaagt 4199  
 ggtaaaaaagt actgaatggt tgaataaagt gctagctata ataaaactaa acttttatat 4259  
 caaaaaaaaa aaaaaaaaaa

5 <210> 27  
 <211> 1281  
 <212> PRT  
 <213> Canis familiaris

10 <400> 27  
 Met Asp Pro Glu Gly Gly Arg Lys Gly Ser Ala Glu Lys Asn Phe Trp  
 1 5 10 15  
 Lys Met Gly Lys Lys Ser Lys Lys Lys Glu Lys Glu Lys Pro  
 20 25 30

15 Thr Val Ser Thr Phe Ala Met Phe Arg Tyr Ser Asn Trp Leu Asp Arg  
 35 40 45  
 Leu Tyr Met Leu Val Gly Thr Met Ala Ala Ile Ile His Gly Ala Ala  
 50 55 60

20 Leu Pro Leu Met Met Leu Val Phe Gly Asn Met Thr Asp Ser Phe Ala  
 65 70 75 80  
 Asn Ala Gly Ile Ser Arg Asn Lys Thr Phe Pro Val Ile Ile Asn Glu  
 85 90 95  
 Ser Ile Thr Asn Asn Thr Gln His Phe Ile Asn His Leu Glu Glu Glu  
 100 105 110

25 Met Thr Thr Tyr Ala Tyr Tyr Tyr Ser Gly Ile Gly Ala Gly Val Leu  
 115 120 125  
 Val Ala Ala Tyr Ile Gln Val Ser Phe Trp Cys Leu Ala Ala Gly Arg  
 130 135 140  
 Gln Ile Leu Lys Ile Arg Lys Gln Phe Phe His Ala Ile Met Arg Gln  
 145 150 155 160

30 Glu Ile Gly Trp Phe Asp Val His Asp Val Gly Glu Leu Asn Thr Arg  
 165 170 175  
 Leu Thr Asp Asp Val Ser Lys Ile Asn Glu Gly Ile Gly Asp Lys Ile  
 180 185 190

35 Gly Met Phe Phe Gln Ser Ile Ala Thr Phe Phe Thr Gly Phe Ile Val  
 195 200 205  
 Gly Phe Thr Arg Gly Trp Lys Leu Thr Leu Val Ile Leu Ala Ile Ser  
 210 215 220  
 Pro Val Leu Gly Leu Ser Ala Ala Ile Trp Ala Lys Ile Leu Ser Ser  
 225 230 235 240

40 Phe Thr Asp Lys Glu Leu Leu Ala Tyr Ala Lys Ala Gly Ala Val Ala  
 245 250 255  
 Glu Glu Val Leu Ala Ala Ile Arg Thr Val Ile Ala Phe Gly Gly Gln  
 260 265 270

45 Lys Lys Glu Leu Glu Arg Tyr Asn Lys Asn Leu Glu Glu Ala Lys Gly  
 275 280 285  
 Ile Gly Ile Lys Lys Ala Ile Thr Ala Asn Ile Ser Ile Gly Ala Ala  
 290 295 300  
 Phe Leu Leu Ile Tyr Ala Ser Tyr Ala Leu Ala Phe Trp Tyr Gly Thr  
 305 310 315 320

50 Ser Leu Val Leu Ser Ser Glu Tyr Thr Ile Gly Gln Val Leu Thr Val  
 325 330 335  
 Phe Phe Ser Val Leu Ile Gly Ala Phe Ser Ile Gly Gln Ala Ser Pro  
 340 345 350

55 Ser Ile Glu Ala Phe Ala Asn Ala Arg Gly Ala Ala Tyr Glu Ile Phe  
 355 360 365  
 Lys Ile Ile Asp Asn Lys Pro Ser Ile Asp Ser Tyr Ser Lys Ser Gly  
 370 375 380  
 His Lys Pro Asp Asn Ile Lys Gly Asn Leu Glu Phe Lys Asn Val His  
 385 390 395 400

0672735-06000

	Phe	Ser	Tyr	Pro	Ser	Arg	Lys	Glu	Val	Lys	Ile	Leu	Lys	Gly	Leu	Asn	
				405						410						415	
	Leu	Lys	Val	Gln	Ser	Gly	Gln	Thr	Val	Ala	Leu	Val	Gly	Asn	Ser	Gly	
				420					425					430			
5	Cys	Gly	Lys	Ser	Thr	Thr	Val	Gln	Leu	Met	Gln	Arg	Leu	Tyr	Asp	Pro	
			435					440					445				
	Thr	Asp	Gly	Met	Val	Cys	Ile	Asp	Gly	Gln	Asp	Ile	Arg	Thr	Ile	Asn	
			450					455				460					
10	Val	Arg	His	Leu	Arg	Glu	Ile	Thr	Gly	Val	Val	Ser	Gln	Glu	Pro	Val	
						470					475					480	
	Leu	Phe	Ala	Thr	Thr	Ile	Ala	Glu	Asn	Ile	Arg	Tyr	Gly	Arg	Glu	Asn	
						485				490					495		
	Val	Thr	Met	Asp	Glu	Ile	Glu	Lys	Ala	Val	Lys	Glu	Ala	Asn	Ala	Tyr	
				500					505					510			
15	Asp	Phe	Ile	Met	Lys	Leu	Pro	Asn	Lys	Phe	Asp	Thr	Leu	Val	Gly	Glu	
				515				520					525				
	Arg	Gly	Ala	Gln	Leu	Ser	Gly	Gly	Gln	Lys	Gln	Arg	Ile	Ala	Ile	Ala	
							535					540					
20	Arg	Ala	Leu	Val	Arg	Asn	Pro	Lys	Ile	Leu	Leu	Asp	Glu	Ala	Thr		
						550				555					560		
	Ser	Ala	Leu	Asp	Thr	Glu	Ser	Glu	Ala	Val	Val	Gln	Val	Ala	Leu	Asp	
						565				570					575		
	Lys	Ala	Arg	Lys	Gly	Arg	Thr	Thr	Ile	Val	Ile	Ala	His	Arg	Leu	Ser	
				580					585					590			
25	Thr	Val	Arg	Asn	Ala	Asp	Val	Ile	Ala	Gly	Phe	Asp	Asp	Gly	Val	Ile	
				595				600					605				
	Val	Glu	Lys	Gly	Asn	His	Asp	Glu	Leu	Met	Lys	Glu	Lys	Gly	Ile	Tyr	
							615					620					
30	Phe	Lys	Leu	Val	Thr	Met	Gln	Thr	Arg	Gly	Asn	Glu	Ile	Glu	Leu	Glu	
						630					635					640	
	Asn	Ala	Thr	Gly	Glu	Ser	Lys	Ser	Glu	Ser	Asp	Ala	Leu	Glu	Met	Ser	
						645				650					655		
	Pro	Lys	Asp	Ser	Gly	Ser	Ser	Leu	Ile	Lys	Arg	Arg	Ser	Thr	Arg	Arg	
						660			665					670			
35	Ser	Ile	His	Ala	Pro	Gln	Gly	Gln	Asp	Arg	Lys	Leu	Gly	Thr	Lys	Glu	
				675				680					685				
	Asp	Leu	Asn	Glu	Asn	Val	Pro	Pro	Val	Ser	Phe	Trp	Arg	Ile	Leu	Lys	
				690			695					700					
40	Leu	Asn	Ser	Thr	Glu	Trp	Pro	Tyr	Phe	Val	Val	Gly	Ile	Phe	Cys	Ala	
						710				715						720	
	Ile	Ile	Asn	Gly	Gly	Leu	Gln	Pro	Ala	Phe	Ser	Ile	Ile	Phe	Ser	Arg	
						725				730					735		
	Ile	Ile	Gly	Ile	Phe	Thr	Arg	Asp	Glu	Asp	Pro	Glu	Thr	Lys	Arg	Gln	
				740				745						750			
45	Asn	Ser	Asn	Met	Phe	Ser	Val	Leu	Phe	Leu	Val	Leu	Gly	Ile	Ile	Ser	
				755				760					765				
	Phe	Ile	Thr	Phe	Phe	Leu	Gln	Gly	Phe	Thr	Phe	Gly	Lys	Ala	Gly	Glu	
				770			775					780					
50	Ile	Leu	Thr	Lys	Arg	Leu	Arg	Tyr	Met	Val	Phe	Arg	Ser	Met	Leu	Arg	
						790				795						800	
	Gln	Asp	Val	Ser	Trp	Phe	Asp	Asp	Pro	Lys	Asn	Thr	Thr	Gly	Ala	Leu	
						805				810					815		
	Thr	Thr	Arg	Leu	Ala	Asn	Asp	Ala	Ala	Gln	Val	Lys	Gly	Ala	Ile	Gly	
				820				825							830		
55	Ser	Arg	Leu	Ala	Val	Ile	Thr	Gln	Asn	Ile	Ala	Asn	Leu	Gly	Thr	Gly	
						835			840				845				
	Ile	Ile	Ile	Ser	Leu	Ile	Tyr	Gly	Trp	Gln	Leu	Thr	Leu	Leu	Leu	Leu	
						850		855				860					
60	Ala	Ile	Val	Pro	Ile	Ile	Ala	Ile	Ala	Gly	Val	Glu	Met	Lys	Met		
						870					875				880		

00000-00000

60



